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ABSTRACT
ENGINEERING STIMULI-RESPONSIVE POLYMERIC NANOASSEMBLIES:
RATIONAL DESIGNS FOR INTRACELLULAR DELIVERY OF BIOLOGICS
SEPTEMBER 2020
KINGSHUK DUTTA
B.Sc., JADAVPUR UNIVERSITY
M.Sc., JADAVPUR UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Sankaran Thayumanavan
Biologic drugs have gained enormous research attention in recent years as reflected
by the development of multiple candidates to the clinical pipelines and an increased
percentage of FDA approval. This is reasoned by the fact that biologics have been proven
to deliver more predictive and promising benefits for many hard-to-cure diseases by
‘drugging the undruggable’ targets. However, the challenges associated with biologic drug
development are multi-fold, viz, poor encapsulation efficacy, systemic instability, low
cellular internalization and endosomal escape capability. Thus, it is essential to develop
new molecular strategies that can not only address the associated drug delivery challenges,
but also help strengthen the fundamental chemical understanding to meet the future need
of this rapidly evolving field.
Designing a supramolecular container that is capable of stably holding sensitive
active and releasing them at target site upon environmental changes is a promising solution
to tackle many complex challenges associated with functional delivery of therapeutics.
vii

Addressing this requires a basic understanding of the structural and functional factors to be
engineered into the delivery vehicle. To this end, we have explored the interactions
between synthetic polymers with various biologics to form well-defined self-assembled
structures, wherein the function of the encapsulated active is only revealed upon specific
structural modulation of the polymer surrounding it. In this dissertation, we have discussed
the development of three distinct self-assembly strategies to reversibly capture sensitive
biologics, viz. protein, nucleic acid and antibody. A covalent self-assembly strategy is
employed for proteins irrespective of their isoelectric points (chapter 2). Our second
strategy utilizes non-covalent interactions (electrostatic and hydrophobic) for
complexation with negatively charged nucleic acids (chapter 3). Finally, we studied a
combination of covalent and non-covalent interactions for encapsulating large proteins and
antibodies (chapter 4 and 5). This dissertation will focus on the inherent challenges
associated with functional delivery of proteins and nucleic acids. It will highlight the
advantages of rational designs to control the complex interplay between the structural
features of the polymers and their biological outcomes.

viii
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CHAPTER 1
INTRODUCTION
Adapted in parts from the manuscript: Dutta, K; Das, R.; Medeiros, J.; Thayumanavan, S.
Charge-Conversion Strategies for Nucleic Acid Encapsulation and Delivery, 2020.

1.1 Biologics as potential therapeutic agents
In the post-genomic era, development of bio-therapeutics has gained an enormous
momentum due to their potential in controlling the human disease portfolio. Since the
approval of first recombinant human insulin by FDA in 1982, research interests have
surged to utilize bio-therapeutics for clinical applications.1 A tremendous growth in the
biotechnology sector have placed over 7000 biopharmaceuticals in the development
pipeline, 74% of which are first-in-class medicines.2 Although small molecule drugs are
still dominating the pharmaceutical sector, Biologics License Approval (BLA) rates are
rapidly increasing, with 21-22 approved drugs each year between 2017 and 2019.3 Based
on a recent analysis, biotherapeutics are expected to capture more than one fourth of the
pharmaceutical industry by 2020.4
Protein, peptide, antibody, and nucleic acids (siRNA, micro-RNA, mRNA and
DNA) are classical examples of biomacromolecules studied under the class of biologics
(Figure 1.1). The recent success of biologic drug products can be attributed to their higher
specificity and potency compared to small molecule therapeutics. Biologics can lead to
more predictive and promising therapeutic benefits in case of many hard-to-cure complex
diseases, with potential to drug the undruggable scenarios. The origin of such selectivity
comes from the macromolecular architecture of biologics with multivalent binding sites
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that dictate precise target recognition leading to exclusive binding events. However, owing
to the dynamic structural features, biologics are ultra-sensitive to external environment and
inherently unstable. Consequently, it is hard to keep these molecules stabilized in
pharmaceutical formulations and deliver into the target tissues in biologically active forms.
The loss of structural integrity and denaturation during systemic circulation presents some
of the major hurdles in functional delivery of biologics. Apart from this, high molecular
mass and polar surfaces of biologics contribute to their poor cellular permeability.1
Moreover, characterization, manufacturing and handling of biologic drugs are rather
stringent and complicated compared to the traditional small molecule medicines. All these
challenges cumulatively prolong the drug discovery timeline leading to an increased
burden for successful development of bio-therapeutics. Thus, it is essential to develop
strategies guided by simple design rules to address the fundamental challenges in nondestructive encapsulation and on-demand targeted release for these complex
biomacromolecules.
This chapter aims to provide an overview of the challenges associated with the
successful delivery of biologic drugs and the current state-of-the-art technologies
developed to address these challenges. The first part of this chapter will specifically focus
on the hurdles related to systemic stability, cellular uptake, endosomal escape, cytotoxicity
and immunogenicity issues of the biologics. The second part will discuss engineered
delivery platforms to address these challenges with a particular focus on three key classes
of biologics, e.g., protein, antibody and nucleic acid therapeutics.
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Figure 1.1 Comparison between small molecule and different forms of biologic drugs
(reprinted with permission from reference 5 and Amgen).
1.2 Salient features and key determinants for efficient delivery of biologic drugs
Developing effective strategies for biopharmaceuticals requires understanding the
key constraints associated with the delivery of biologic drugs. The following sections will
discuss the major challenges associated in dealing with delicate biologics.
1.2.1

Stability of biomacromolecules under in vitro and in vivo conditions
Most biologics suffer from poor stability owing to several modes of degradation

pathways. Proteins are prone to denaturation, aggregation, chemical and proteolytic
degradation when exposed to normal in vitro and in vivo environmental conditions.6
Nucleic acids considered to be relatively stable, can also undergo chemical and proteolytic
degradation in presence of certain enzymes and low pH, respectively.7 Owing to these
stability challenges, different routes of administrations were investigated, e.g., oral,
transdermal, mucosal, pulmonary, nanoparticle-based, and depot injections.1 Amongst
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Figure 1.2 (a) Physicochemical properties of nanoparticles relevant for cytotoxicity; (b)
Inducing cytotoxicity through various cellular interactions with nanoparticles (reproduced
with permission from reference 8).
these, oral delivery is the most favored one for the ease of administration and high patient
compliance. However, proteolytic and enzymatic degradation of the biopharmaceuticals in
stomach and liver, along with low bioavailability due to the hydrophilic macromolecular
structures, have plagued the scope of oral administration. Moreover, pre-systemic
metabolism or ‘first-pass effect’ in liver greatly diminishes the bioavailability of the drug
released into systemic circulation. Finally, rapid clearance through kidney shortens the
biological half-life of the drug reducing the possibility to reach its target site to impart
desired therapeutic action.
1.2.2

Cytotoxicity mediated by nanoparticle-based systems
To address the stability concerns and intracellular trafficking, various delivery

vectors are proposed consisting polymer, lipid, peptide and inorganic nanoparticle based
systems.9 However, a relatively low number of nanoparticle based drug delivery
formulations are actually considered for clinical development and finally get cleared by
U.S. Food and Drug Administration (FDA). A recent analysis shows that the technology
translational efficacy is 5% between global clinical trials to publication numbers and, only
10% of the clinical trials give rise to successful products in market.10 One of the major
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reasons associated with such limited number of clearance is the cytotoxicity issues of the
designed delivery agents.
For nanoparticle-based drug delivery systems, cytotoxicity is majorly governed by
four prime factors: (a) material composition; (b) morphological parameters, e.g., size and
shape; (c) surface charge; and (d) hydrophobicity (Figure 1.2).11 Nanoparticles with diverse
chemical functionalities can bind to extracellular regions like plasma membrane, ionchannels, cell surface receptors, and either damage or block the machineries from
functioning normally.11 Upon penetration into the cells, nanoparticles can even interfere
with the intracellular organelles like mitochondria, lysosome, cytoskeleton and nucleus via
changing metabolic pathways, generating reactive oxygen species and inhibiting protein
functions. The effect of nanoparticle size on toxicity is dependent on several other factors
like the choice of materials, physicochemical properties, and cell types. A consensus in this
aspect is to utilize 50-200 nm particle to be able to minimize cytotoxic effect exerted by
the delivery system.11-12 Shape of nanoparticles also has profound effect on toxicity
induced by increased reactivity and exposure in circulation. Generally, spherical particles
were reported to be less-toxic compared to non-spherical ones.12 Hydrophobic particles,
with identical surface charges, were found to be more cytotoxic when compared to the
hydrophilic particles due to the increased interaction with hydrophobic cellular
membrane.13
The most influential parameter might be the nanoparticle surface charge mediated
cytotoxicity. Several reports had suggested that cationic nanoparticles can change the
plasma membrane and mitochondrial membrane potential (MMP),14-16 thereby creating
punch-holes, increasing the production of ROS and activating caspases and cytochrome C
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to induce apoptosis.14 Whereas anionic and neutral nanoparticles are considered to
relatively non-toxic owing to the diminished interaction with the negatively charged lipid
bilayer of the plasma membrane.17-18
1.2.3

Immunological effects of designed nanoparticulate drug delivery vehicles
A growing concern in therapeutic biologics development is the induced

immunogenicity mediated by particulate material in the delivery formulation or drug
aggregates due to instability under in vivo conditions.19 Recognition of nanoparticles as
foreign objects by immune system could be deleterious, initiating immunosuppression or
immunostimulation leading to inflammatory responses, acute toxicity and loss of
therapeutic efficacy of the biologic drug.20-21 Immunostimulatory responses can be derived
by antigenicity of the biopharmaceuticles, causing the production of neutralizing antibody
that is capable of dually recognizing endogenous target and exogenous delivery vector.
Also, nanoparticulate systems can invoke inflammatory responses upon recognition as
foreign substances and release of cytokines by immune cells to trigger destruction of the
substance.21 Note that, in vaccine development applications nanoparticulate materials can
act as adjuvants which are taken up by dendritic cells and macrophages, leading to
favorable immune response.22 However, downregulation of immune responses
(immunosuppression) can alter the therapeutic effect and promote infection as harmful
foreign substances are undetected by the immune system.21
1.2.4

Challenges involving endosomal escape
One of the major bottlenecks in biologics delivery is entrapment of the cargo into

a vesicle like structure, endosome or early endosome, upon internalization into the cell
through various endocytosis mechanisms. While early endosome matures into late
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endosome and lysosome, the pH of the vesicles decreases to ~6.5, ~6.0 and finally to ~5.0,
respectively.23 Interestingly, the biologics encapsulated in the nanoparticle cargo should be
able to evade from the early or late endosome stage. Entrapped cargo eventually gets
degraded inside lysosome losing the therapeutic efficacy.24 As endosomal escape is often
considered as the rate-limiting step for the delivery of biologics, several studies have
elucidated probable escape pathways with the help of specific molecular designs.23 The
key to endosomal escape is dictated by the interaction of the nanoparticle with the
endosomal membrane, leading to four reported pathways: (i) membrane fusion; (ii) osmotic
rupture, (iii) swelling of nanoparticle; (iv) membrane destabilization (Figure 1.3).23 Fusion

Figure 1.3 Various proposed pathways for endosomal escape (reproduced with permission
from reference 23).
of nanoparticles with the endosomal membrane can be guided by hydrophobic
compatibility, fusogenicity and pH.15, 25-26 Whereas osmotic pressure effect, also known as
‘proton sponge’ effect, is executed by the influx of protons, counter anions and water
molecules into the endosomal vesicle due to buffering effect exerted by the nanoparticle
leading to enlargement and lysis of the endosomal membrane.27-29 Crosslinked polymeric
7

nanoparticles were also reported to have tunable swelling property introducing mechanical
strain beneficial for evading endosome.30-31 Similarly, pH sensitive polymers with specific
architectures (hyperbranched and dendritic polymers) showed efficient destabilization of
endosomal membranes.32-33 Although the endosomal escape process is grossly classified
into the four mechanisms mentioned above, it is likely that more than one mechanism might
be acting simultaneously to impart the overall fate of the endocytosis process.
1.3 Responsive polymers as suitable candidates for therapeutics delivery
To address the above-mentioned critical issues involved in the delivery of
biologics, several drug delivery strategies have been proposed. As the primary goal of this
thesis is to address the delivery issues with three key biologics, viz., protein, nucleic acid
(siRNA) and antibody therapeutics, the following sections are devoted to discuss the state
of the art technologies in each specific case.
1.3.1

Protein: non-covalent vs. covalent encapsulation strategies
Protein therapeutics is considered to be one of the most promising areas of recent

times in the field of pharmaceutical drug development.34-35 Being directly involved in
various biochemical pathways, proteins perform the pivotal role to dictate the overall fate
of major cellular processes.36 Thus, regulating specific protein expressions, by either
attenuation or enhancement, should furnish significant control over such cellular signaling
mechanisms. Being more specific and possessing less cytotoxicity risks compared to nontargeted small molecule drugs, direct delivery of functional proteins into cells is expected
to provide exquisite benefit towards many challenging diseases.
To this end, a wide array of brilliant approaches has been attempted to design
delivery agents based on liposome, hydrogels, inorganics like silica, carbon nanotubes and
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Figure 1.4 (a) Liposomal drug delivery systems; (b) Lysine head-group containing cationic
liposomes for intracellular protein delivery (c) Biocompatible hydrogels for oral delivery
of proteins (reproduced with permission from references 37-39).
quantum dots.6, 40-43 Here, we will majorly focus on examples of liposome and polymer
based approaches relying on non-covalent and covalent interactions.
Liposome is considered to be an excellent biocompatible nanocarrier for the
delivery of both hydrophobic drugs (in bilayer) and hydrophilic protein (inside aqueous
lumen) therapeutics (Figure 1.4).37 β-galactosidase (β-gal, ~465 kDa, with four subunits of
116.3 kDa) enzyme has been efficiently encapsulated with the help of a cationic
guanidinium-cholesterol lipid (bis (guanidinium)-tren-cholesterol, BGTC) and helper
dioleoyl phosphatidylethanolamine (DOPE) lipid, and found to be active after intracellular
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Figure 1.5 (a) Protein PEGylation and subsequent formation of nanoparticles; (b) Recent
approaches for modified PEGylation methods (reproduced with permission from references 44-47).

delivery.40 In another study (Figure 1.4b), a lysine headgroup containing cationic liposome
was utilized to deliver bovine serum albumin (BSA, 66 kDa).38 Several apoptotic mediator
enzymes (caspase 3, caspase 8 and granzyme B ) were encapsulated in a cationic lipid
based formulation consisting trifluoroacetylated lipopolyamine (TFA-DODAPL) and
DOPE. Upon intracellular delivery, the enzymes remained functional and induced
apoptosis.48 However, these systems generally suffer from poor encapsulation efficacy due
to the lack of driving force for hydrophilic proteins to preferentially encapsulate from bulk
media to the interior aqueous pool of liposome. This issue can be partly addressed by
hydrogels based on natural (polysaccharides, protein and DNA based) and synthetic
(polyesters, polyamides, poly(ethylene oxide), polyorthoester and polyphosphazene)
polymers for protein encapsulation.6 Nonetheless, application of hydrogel based systems
are limited by the localized delivery of therapeutic biologics.
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Figure 1.6 (a) A covalent self-assembly strategy for encapsulation of an apoptosis inducing
protein, caspase 3; (b) A traceless reversible thioester chemistry for protein PEGylation
(reproduced with permission from references 49-50).
In this context, covalent protein delivery strategies with polymers would be
beneficial for rendering high encapsulation efficacy owing to the covalently attached
proteins with the delivery vehicle and for imparting structural and in vivo stability from
the polymer backbone. PEGylation is one of the FDA approved techniques heavily used in
biopharmaceutics development (Figure 1.5).51 Attachment of PEG chain shows prolonged
circulation half-life, reduced immunogenicity and cytotoxicity.52-53 In other scenarios,
covalent ligation techniques have been employed via polymeric nanocarriers to effectively
improve encapsulation efficacy and in vivo stability (Figure 1.5). However, many of these
methods require organic solvents and harsh synthetic conditions that tend to irreversibly
modify the protein cargo, resulting in denaturation the sensitive cargo and diminished
activity.54-55
To address these issues, reversible covalent strategies (Figure 1.6) are being
explored that can not only provide high fidelity protein encapsulation, but also help
preserve structure and activity through ‘traceless’ release of protein in native form.50, 55-56
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1.3.2

Nucleic acid: state of the art approaches in RNAi
Nucleic acid based gene silencing, specifically RNA interference (RNAi), has

created an enormous opportunity in therapeutics development.57 Despite many promising
advantages, RNAi technology possesses several limitations that have hindered its
applicability and therapeutic potential.7 Poor cellular internalization and systemic
instability of naked siRNA in presence of serum nucleases followed by fast renal clearance
are two major biological barriers for efficient intracellular delivery of siRNA.58 In addition,
undesirable toxicity from chemical modifications of siRNA or transfection agents increases
the barrier for its successful implementation.59 Ever since its inception, these hurdles are
reflected in the commercial development of RNAi based therapeutics with only one recent
FDA approval in this drug category.60 Thus, designing an efficient and safe siRNA delivery
strategy still remains a grand challenge to realize the fullest potential of such powerful
technology.
To address the critical pitfalls of siRNA-based therapeutics, several approaches
have been proposed which can be classified into two major categories: (a) chemical
modification of siRNAs and (b) siRNA carriers.58,

61

In the first case, siRNAs are

chemically modified to enhance its systemic stability by providing nuclease resistance (e.g.
phosphorothioate, boranophosphate, 2’OMe modifications; see Figure 1.7 for a general
overview of oligonucleotide modifications) and to increase the biological half-life
(PEGylation, hydrophobic modifications with cholesterol, bile or fatty acid).58 These
approaches bring in complexity within siRNA molecules typically resulting in increased
toxicity and reduced silencing ability of the delivered siRNA.62 On the other hand, potent

12

siRNA carriers like viral vectors impart high transfection efficacy; albeit introduces
elevated risk of immunogenicity and undesired mutagenesis.7 In this scenario, non-viral

Figure 1.7 Chemical modifications on oligonucleotides along with their operating
mechanisms (reproduced with permission from reference 61).
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delivery vehicles63-66 like cationic lipids, peptides and polymers provide rather clean and
straight-forward but efficient choices, wherein electrostatic forces between cationic
delivery agents and negatively charged siRNA molecules result in a condensed complex
(Figure 1.8a). The stability of such complexes in biological milieu is essentially
proportional to the electrostatic attractions between the siRNA and the siRNA-binder,
which is dictated by (i) the amount of cationic charge in play and also by (ii) the ability of
these molecular systems to optimize the interactions (e.g. controlled by factors such as

Figure 1.8 (a) Non-viral vectors for nucleic acid delivery (reproduced with permission
from reference 67); (b) Molecular design strategy of guanidinium ion appended telechelic
dithiol monomers for siRNA delivery (reproduced with permission from reference 68).
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molecular flexibility, etc.). Typically, a high positive charge, dictated by the high N/P ratio
(molar ratio of cationic nitrogen in delivery agent to phosphate groups in siRNA), is found
to be critical for complete complexation and protection of siRNA (Figure 1.8b).68
Interestingly, complexes with high cationic charge, under in vivo conditions, poses
increased toxicity and adverse side effects (plasma membrane damage, release of
cytochrome C from mitochondria and alteration in membrane potential).14 As a remedy,
reduction of positive charge at lower N/P ratio in the complex was investigated to attenuate
toxicity.69 However, this approach might compromise the complex stability under in vivo
conditions and does not address the inherent problem of cationic charge driven toxicity.
Moreover, competitive binding with negatively charged serum proteins becomes an
important parameter at lower N/P ratio which can even result in the leakage of siRNA
impeding the therapeutic efficacy. PEGylation of cationic vectors, another promising
strategic solution to this problem, enhances steric crowding in the system diminishing the
binding efficacy with cationic vectors and retards efficient cellular uptake of siRNA
carriers.70 In essence, the paradox with cationic charge vs. toxicity vs. binding affinity and
stability of siRNA delivery vectors demands a new potent self-assembly strategy for
efficient complexation and delivery of siRNA cargo.
1.3.3

Antibody: emerging opportunity to target intracellular proteins
Probing various cellular processes by specific targeting of proteins is immensely

important in developing therapeutic candidates.71 Antibodies, being the key
biomacromolecule utilized for targeting purposes, have so far served the diagnostic need
via targeting extracellular proteins. On the other hand, intracellular targeting of specific
proteins has only been possible with techniques like microinjection and electroporation,
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owing to the membrane impermeable nature of large hydrophilic antibody.71-72 However,
given the concerns regarding cell membrane damage, cytotoxicity and low throughput
methods, those process are limited to in vitro applications.71

Figure 1.9 (a) Molecular design strategy for the endosomolytic peptide based delivery of
antibody; a peptide based fast intracellular delivery strategy for (b) fluorescent IgG
antibody; and (b) anti-nuclear pore complex antibody (reproduced with permission from
references 73-74).
To expand the enormous opportunity associated with intracellular targeting,
molecular designs for encapsulation of antibodies have been proposed.71,

75-79

An

endosomolytic peptide is developed by substituting leucine with glutamic acid of a
cationic-lytic peptide, M-lycotoxin (Figure 1.9a).73 Cytosolic localization of IgG is
observed after rupture of endosomal membrane. On the other hand, liposome made with a
combination of aminoglycoside lipid dioleyl succinyl paromomycin (DOSP) and
imidazole-based helper lipid MM27 has been identified as superior for the intracellular
delivery of anti-cytokeratin8 antibody (anti-K8).40 Harnessing the strengths of lipid and
peptide based systems, a high-speed antibody delivery strategy has been reported with
liposomes modified with cell penetrating peptide, octaarginine (R8) and pH-sensitive
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fusogenic peptide, GALA.74 Within 30 min of incubation, ~98% of cells are transfected by
IgG containing liposomes with endosomal escape and predominant cytosolic localization
(Figure 1.9b).

Figure 1.10 Formation of PIC micelles and intracellular delivery of antibody (reproduced
with permission from reference 80).

Further, delivery of nuclear pore complex (anti-NPC) antibody proved the retention
of structural and functional features of the delivery antibody (Figure 1.9c). In another
elegant approach, anionic polypeptide fused IgG is encapsulated within cationic liposome
to inhibit two intracellular targets - multidrug resistance-associated protein 1 (MRP1) and
the transcription factor NF-κB.72 Polymeric nanoparticles based on polyethyleneimine
(PEI), poly(lactic-co-glycolic acid) (PLGA), poly(ethylene glycol)-block-poly[N-(N′-(2aminoethyl)-2-aminoethyl)aspartamide])

(PEG-b-PAsp(DET))
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and

MePh13-b-dG5

polyoxanorbornene diester copolymer (dG: dense guanidinium functionality) have also
been explored for intracellular trafficking of antibodies.80-83 Polyion complex (PIC)
comprising copolymers (PAsp: poly[N-(N′-(2-aminoethyl)-2-aminoethyl)aspartamide])
have been shown to successfully deliver IgG and anti-NPC antibody (Figure 1.10).80, 84
However, given the enormous possibility of antibody therapeutics, there is still a dearth of
design strategies for intracellular targeting of disease relevant proteins.
1.4 Summary & dissertation overview
In this chapter, the importance of biologic drugs and the challenges associated with
the delivery via biopharmaceutical products are discussed. Along this line, recent state of
the art drug delivery strategies for three key important biologic candidates, viz., protein,
nucleic acid (siRNA) and antibody therapeutics, are discussed. For protein therapeutics,
non-covalent and covalent approaches comprising lipid and polymeric delivery vehicles
have been discussed describing the advantages and pitfalls. Being negatively charged,
nucleic acids like siRNAs have been encapsulated via cationic nanoparticles, which in turn,
raises toxicity issues in proportion with gene silencing. Recent state of the art techniques
and existing issues have been discussed have been discussed. Delivery of antibody drugs
for intracellular targets is gaining recent attention and has been discussed. However, a
dearth of strategies reveals significant challenges associated with the antibody delivery and
a dire need of novel drug delivery vehicles.
Targeting the need for advanced molecular designs of delivery vehicles, this
dissertation will discuss the design principles of developed strategies that target the existing
challenges in the delivery of protein, siRNA (nucleic acid) and antibody therapeutics.
Chapter 2 describes a templated self-assembly strategy with a self-immolative polymer to
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shrink-wrap protein cargoes and their intracellular trafficking. For siRNA delivery, a
tricomponent symbiotic self-assembly strategy has been described in chapter 3 comprising
siRNA, polymer and lipids, that address the toxicity challenges from cationic particles. In
chapter 4, a rigorous structure-activity study has been reported to improve the conjugation
efficacy of protein with the designed activated ester containing self-immolative polymer.
Chapter 5 describes engineering of the developed polymer platform to incorporate an
electrostatic handle for boosting conjugation efficacy of larger proteins and antibody
therapeutics. Summary is described in chapter 6 along with future directions focusing on
some ongoing research efforts and prospective ideas as a corollary of the developed drug
delivery strategies.
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CHAPTER 2
TEMPLATED SELF-ASSEMBLY OF A COVALENT POLYMER NETWORK
FOR INTRA-CELLULAR PROTEIN DELIVERY AND TRACELESS RELEASE
Adapted with permission from: Dutta, K; Hu, D.; Zhao, B.; Ribbe, A. E.; Zhuang, J.;
Thayumanavan, S. “Templated Self-Assembly of a Covalent Polymer Network for Intracellular Protein Delivery and Traceless Release” J. Am. Chem. Soc. 2017, 139 (16), 5676–
5679. Copyright © 2017 American Chemical Society.

2.1 Introduction
Using proteins as a therapeutic is attractive, as this promises to directly address
genetic deficiencies and there-fore mitigates side-effects that plague many small molecule
drugs.1 Potential side-effects from small molecule binders are understandable, as these
molecules must be designed to target a specific protein in our complex biological system,
highlighted by the nearly 20,000 protein-encoding genes. On the other hand, proteins can
directly compensate for a specific deficiency and therefore the drug development is less
heuristic. However, realizing the full potential of protein-based therapeutics has been
difficult, mainly due to their in vivo instability and immunogenicity. To overcome these
issues, approaches to modify protein surfaces have been taken, starting with PEGylation
that has been shown to enhance protein circulation lifetimes.2-4 More recently, strategies
that allow for attaching other polymers to proteins have been developed in order to endow
these conjugates with stimulus-responsive characteristics or to realize new self-assembled
structures.5-8 These reports provide examples of innovative strategies that allow for
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enhanced circulation lifetimes and thus have impacted the utility of proteins that function
in the extracellular environment.9
The next level of challenge involves the ability to develop systems that can handle
intracellular proteins, where trafficking the cargo across a cellular membrane is a major
hurdle. Two limiting approaches have been taken to address this need, both of which
involve non-covalent self-assembly. First involves electrostatic binding of proteins to
complementarily charged polymers and nanoparticles.10-12 The second approach includes
encapsulating proteins in water-filled compartments, such as liposomes.13 A limitation of
the former approach comprises non-specific fouling of the complex surfaces due to
electrostatic interactions and the associated toxicities.14 The latter approach has the
potential to address the fouling issues, but is fraught with low loading capacities, especially
when charge-neutral lipids are used.

Figure 2.1 Schematic representation of the formation of a covalent polymer network using
the protein as the template and its traceless and triggered release in a reducing environment.
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We envisaged that a covalent self-assembly approach, where the protein cargo
itself acts as the template for the polymer to self-assemble around it, has the potential to
encapsulate proteins with high fidelity and present charge-neutral surface functionalities
(Figure 2.1). The key design hypothesis here is that an initial reaction between the side
chain functionalities of a random copolymer and multiple surface-exposed functional
groups of a target protein would cause a few polymer chains to organize around the protein.
This covalent capture then can act as a template to form a polymer sheath around the protein
through a polymer side-chain crosslinking step, as schematically illustrated in Figure 2.1.
We envisaged that the high-fidelity protein encapsulation within this sheath would be aided
by: (a) convex sur-face of globular proteins on which the reactive functional groups are
presented, and (b) high-yielding and multivalent reactions are presented; and (b) highyielding and multivalent reactions between the protein and polymer side chains.
2.2
2.2.1

Results and discussion
Design and synthesis of a self-immolative polymer for lysine conjugation
Cysteine and lysine are two popular handles for conjugating polymers with

proteins, because of their nucleophilicity.15-22 Because of the surface availability in larger
number of proteins, lysines are generally preferred. However, this amino acid presents a
challenge in that it is more difficult to functionalize them in a form, whereby they can be
tracelessly liberated in the intracellular environment. We hypothesized that placing reactive
side-chain functionalities in a polymer, with responsive self-immolation characteristics,23
would result in a novel and general system that is capable of encapsulating proteins with
high fidelity and tracelessly releasing them upon encountering a target microenvironment.
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The structure of the target polymer P1 (Scheme 2.1), which satisfies all the design
requirements, was synthesized by RAFT polymerization. Reaction of an amine with the pnitrophenylcarbonate (NPC) moiety in P1 will produce the corresponding carbamate, as

Scheme 2.1 Chemical structures of polymers and the reaction scheme for protein
conjugation, crosslinking to generate the nano-assembly and its release in the presence of
a reducing agent.

shown in P2. The polymer is first treated with the protein, where multiple lysine moieties
are reacted with the NPC groups in the polymer chains. The remaining NPCs are reacted
with a diamine crosslinker to complete the sheath formation around the protein (Figure 2.1
and Scheme 2.1). Note that a disulfide moiety is placed at the β-position, relative to the
carbamate oxygen, which serves to render the polymer responsive to the more reductive
intracellular environment, compared to the extracellular space.18 Reductive cleavage of the
disulfide will result in carbamate cleavage to release the original amine. This reaction will
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cause both the polymer being uncrosslinked and the protein being tracelessly liberated from
the polymer.

Figure 2.2 (a) Top: Bright Field Cryo-TEM image of NA-CytCPEG showing both
individual and small clustered particles. Inset shows a cluster of 3 protein nanoassemblies,
Bottom: HAADF image of a NA-CytCPEG nanoassembly. The bright spots with diameters
of 2-3 nm are caused by the Fe-content of Cyt C, inset is NA-EmptyPEG particle with no
detectable Fe from EDS (~50 nm); (b) MALDI-MS analysis of the trypsin digest from
encapsulated and naked Cyt C; (c, d) SDS-PAGE of the NA-CytCPEG under non-reducing
and reducing conditions (10 mM DTT, 37 °C for 4 h).
2.2.2

Conjugation studies and characterization of protein-polymer nanoassemblies
To test our design strategy, we chose cytochrome C (CytC, pI 9.6) as a model

protein, because of its distinct cellular readout in the form of apoptotic cell death. After
initially reacting CytC with P1, the polymer-protein conjugate was further secured by
crosslinking with ethylenediamine (ED) or tetraethyleneoxide-bis-amine (PEG) to afford
nano-assemblies NA-CytCED and NA-CytCPEG, respectively. Note that the reaction
between the NPC moiety and an amine produces p-nitrophenol as a by-product, the distinct
absorption of which is conveniently monitored. Therefore, the protein conjugation step was
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quantified using the evolution of the absorption spectrum. Encapsulation efficiency and
loading capacity were found to be 64-67% and 5-7%, respectively. Dynamic light
scattering (DLS) measurements revealed the hydrodynamic diameters of native CytC and
the protein-containing nanoassembly to be ~4 nm and ~8-10 nm, respectively. Moreover,
zeta potential measurements revealed that the surface of the complex is charge-neutral,
suggesting that the complex surface is dominated by the PEG moieties from P1. Figure
2.2a (top) shows a Cryo-EM image of NA-CytCPEG. The average individual particle size is
in the 10-30 nm range which is in agreement with DLS data. To obtain a more detailed
insight into the protein distribution within the nano-assemblies we employed High Angle
Annular Dark Field Microscopy (HAADF) and Energy Dispersive X-Ray Spectroscopy
(EDS) at cryo temperatures. Figure 2.2a (bottom) shows a HAADF image of an individual
nano-assembly. The whole assembly has a diameter of about 20 nm and the bright spots in
the 2-3 nm range are caused by the Fe-content of discrete Cyt C molecules (compare with
the empty assemblies in the inset) and EDS analysis con-firmed the presence of Fe.
An important objective of this work is to use the polymer sheath to protect the
protein from protease degradation. To rigorously test for this, we subjected the polymerprotein conjugate to protease digest with trypsin and analyzed the products using MALDI
mass spectrometry. While the unprotected Cyt C afforded characteristic peptide frag-ment
peaks, the conjugate at the same protein concentration did not afford any discernible
fragments (Figure 2.2). These results show that assemblies do indeed protect the protein.
The conjugates also seem to be generally stable in serum.
Next, we were interested in testing whether the encapsulated protein can be released
in a reducing environment. We first tested this possibility using gel electrophoresis (SDS-
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PAGE). As anticipated, when the protein is conjugated to the protein, no bands
corresponding to the protein was found (Figure 2.2). When the same SDS-PAGE gel was
run under reducing conditions, appearance of protein bands clearly indicated that the
encapsulated protein can be re-leased. This is the first indicator, suggesting that the protein
release using the reductive self-immolative linker is feasible. We utilized SDS-PAGE
experiments to quantify the amount of proteins inside our nanoassemblies. After treating
the nanoassemblies with excess dithiothreitol (DTT), the intensity of the protein band in
the gel is compared with native proteins of different concentrations to estimate the amount
of proteins present inside the nanoassembly (Figure 2.2).

Figure 2.3 Structure and function of released Cyt C from the NA-Cyt CPEG, evaluated by
(a) CD spectroscopy; and (b-c) ABTS activity assay: b- assay kinetics, c- % activity of
samples treated with DTT.
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2.2.3

Structure and activity studies of released protein
The protein encapsulation and release process would be a futile exercise, if the

methodology does not preserve the structure and function of the protein upon release. To
this end, the secondary structure of the released protein was examined by circular
dichroism (CD) spectroscopy, the spectrum of which was found to be identical to that of
the native Cyt C (Figure 2.3). This suggests that the conjugation and release processes did
not alter the secondary structure of the protein. We also claim that the strategy leads to a
traceless release of the protein in reductive environment. To test this hypothesis, the
released protein was analyzed by mass spectrometry. The m/z for the released protein
matched the native Cyt C, suggesting that there are no remnants of the polymer after the
protein’s reductive release.
Next, we investigated whether the function of the protein is maintained by
quantifying the released protein’s activity using an ABTS assay (based on 2,2’-azino-bis(3ethylbenz-thiazoline-6-sulfonic acid) (Figure 2.3b-c).2410a While the nanoassembly did
not exhibit any enzymatic activity, the activity recovery was nearly quantitative when the
assembly was treated with 10 mM DTT (compare the activities of native Cyt C and released
Cyt C in the presence of 10 mM DTT in Figure 2.3). This activity recovery was also found
to be dependent on the concentration of DTT and thus the extent of protein release. These
results show that the polymer shell can act to ‘turn-off’ the protein function, until it is
released in its target environment. Both structure and function recoveries were found to be
independent of the crosslinker length in ED and PEG linkers, as shown in Figure 2.3.
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2.2.4

Intracellular delivery and cellular activity studies
The ultimate goal of the proposed research is to utilize this polymer coating to

traffic the protein across the cellular membrane and release it in the cytosol. It is the higher
redox potential of the cytosol that is being targeted for selective release. To track the
location of the protein under con-focal laser scanning microscopy (CLSM), Cyt C was
labeled with rhodamine B and the cell nucleus was stained with hoechst 33342. After 4 h

Figure 2.4 HeLa cells treated with NA-Cyt CPEG conjugates to study cellular uptake: (a) 4
h post-incubation; (b-c) endosomal co-localization and escape at 4 h and 24 h, respectively;
(green: lysotracker; red: rhodamine B; blue: hoechst); (d) cell viability after 72 h (dosage
represents amount of NA-Protein conjugate); (e) detection of activated caspase-3/7 after
72 h using the Cy5-tagged assay reagent; scale bar: (a) 50 µm, (b, c, e) 10 µm.

incubation, well-distributed red fluorescence from labeled proteins was observed (Figure
2.4a), while negligible fluorescence was observed from cells that were treated with an
identical concentration of naked proteins. These results suggest that the polymer conjugate
has better access to the cells, compared to the native protein itself. The time course of
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cellular internalization process was also monitored under CLSM for this conjugate. Since
the most likely pathway for uptake is endocytosis, we were next interested in evaluating
whether the proteins are stuck in the endo-some or they escaped the endosome to get into
the cytosol. For a cytosolic delivery, the latter is desired. Accordingly, the endosomes were
labeled with lysotracker green. The data clearly indicate that the nanoassemblies enter the
cells through the endosomes (see co-localization of lysotracker green and rhodamine-B
label after 4 h incubation (Figure 2.4b)), but the proteins escape the endosomes over time
as seen by the dominant red color in the cell in the 24 h image (Figure 2.4c).
To evaluate whether the delivered Cyt C is active, we evaluated the apoptotic cell
death in response to the protein delivery. Cyt C is known to induce apoptosis through interaction with apoptotic protease activating factor 1 (Apaf-1) in cytosol and activation of procaspase-9, which in turn initiates pro-caspase-3 leading to activation of caspase dependent
apoptotic pathways.25-26 The dose-dependent decrease in cell viability of the nanoassembly
(Figure 2.4d), combined with the lack of toxicity for the corresponding concentration of
the free nanoassembly or naked Cyt C, indicate that the cytosolically delivered Cyt C is
causing apoptosis. Further-more, the mechanism of action of Cyt C allows the direct
interrogation whether the caspase-dependent pathway is activated in the cytosol. A
fluorimetric immunoassay that causes a caspase product to be intercalated the DNA in the
nucleus was utilized to assess this possibility. The co-localization of the caspase-processes,
cy5-tagged reagent (red) and the nuclear stain (blue) confirmed the apoptotic nuclei in the
cells (Figure 2.4e). Control experiments show that the nanoassembly without the Cyt C
does not cause the activation of the cy5-tagged reagent.
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2.2.5

Versatility of the protein encapsulation approach
The true testament to the versatility of this strategy is the applicability to a broad

range of proteins. To test this, we used two other proteins, viz. lysozyme (Lys) and
ribonuclease A (RNase A). Both proteins were found to be success-fully conjugated with
the polymer P1. SDS-PAGE, CD, and activity studies also show that the encapsulated
protein can be released with high fidelity under reducing conditions with high retention in
both structure and function (Figure 2.5a-b). It is interesting to note that the overall kinetics

Figure 2.5 SDS-PAGE showing protein release (reducing conditions), cellular uptake (4
h) and viability (72 h) in HeLa cells for (a) NA-Lys and (b) NA-RNase A conjugates, scale
bar: 50 µm.

of proteins release was observed to have the order: Cyt C<RNase A<Lys. The release
kinetics seems to correlate with the number of sur-face exposed lysines in each protein
(Cyt C: 19, RNase A: 10, Lys: 6).27-28 This is understandable, since the higher number of
anchoring points requires more sites for the reducing agent to process during release.
Finally, the intracellular delivery and activity of these proteins were also evaluated (see
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Figure 2.5). While lysozyme is expected to be innocuous to cells, RNase A with access to
cytosolic RNA can initiate cell death.29-30 Although both proteins were taken up by the
cells as assessed by CLSM studies, the lysosome-containing nanoassembly did not induce
any cell death, whereas the RNase A-bearing nanoassembly had a profound effect on cell
viability (Figure 2.5). The proteins studied so far are basic (pI >8.5) with a MW of 12-15
kDa. To further test this system, we also investigated the encapsulation and release
properties of eGFP with higher MW and lower pI (MW ~27 kDa, pI 5.5). SDS-PAGE and
cellular uptake studies show that this protein, too, can be successfully encapsulated and
delivered.
2.3

Summary
In summary, we have developed a versatile strategy for the encapsulation of

proteins and their traceless release in response to a specific trigger. The encapsulation is
templated by the lysine handles in the protein itself, which are then used to wrap the protein
with a polymer sheath in a secondary crosslinking step. The versatility of the approach is
high-lighted by the fact that: (i) it utilizes a functional handle that is abundantly available
on the surface of >85% the globular proteins, which renders the strategy broadly applicable; (ii) the target protein is encapsulated with high fidelity, i.e. high loading capacity;
(iii) the cargo is protected from degradation by proteases; (iv) the protein activity is masked
in the encapsulated state; (iv) the polymer sheath is re-moved tracelessly with high
efficiency in response to a tar-get intracellular environment; (v) the native structure and
function are retained upon release; (vi) the protein can be delivered with high fidelity into
the cytosol; and (vii) activity of the protein is regained in the cytosol. Thus, we believe that

42

this simple and general strategy will serve to produce a potent protein therapeutic delivery
platform for a broad range of proteins.
2.4
2.4.1

Experimental
Materials
All chemicals, polyethylene glycol monomethyl ether methacrylate (PEGMA; MW

500), 2,2′-dithiodipyridine, 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (chain
transfer agent), D,L-dithiothreitol (DTT), lysozyme, RNase A, cytochrome C and
rhodamine B isothiocyanate were obtained from Sigma-Aldrich and were used without
further purification unless otherwise mentioned. 2,2′-azobis-(2-methylpropionitrile)
(AIBN) was procured from Sigma-Aldrich and purified by recrystallization before usage.
Pyridyl disulfide ethyl methacrylate (PDSMA) was synthesized using previously reported
procedure.31
2.4.2

Synthesis of p(PEGMA-co-PDSMA), PPcP
PDSMA (0.511 g, 2 mmol), PEGMA (1 g, 2 mmol) and 4-cyano-4-

(phenylcarbonothioylthio) pentanoic acid (55.7 mg, 0.2 mmol) were weighed and
dissolved with 2 mL THF in a 25 mL Schlenk flask. To the reaction mixture, 1 mL AIBN
(6.7 mg, 0.0408 mmol) solution in THF was added and mixed for 5 min. The flask was
purged with argon and performed three freeze-pump-thaw cycles. After that the reaction
vessel was sealed and transferred to an oil bath preheated at 70 °C. The polymerization was
quenched after 24 h by cooling down the reaction flask with cold water and the solvent was
evaporated. The viscous reaction product was purified by repeated washing with cold
diethyl ether and finally dried in high vacuum at room temperature for 24 h. Yield: 96%,
GPC (THF) Mn: 27 K. Đ: 1.1. 1H NMR (400 MHz, CDCl3): δ 8.47, 7.70, 7.13, 4.21−4.07,
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3.64−3.37, 3.03, 1.93-1.82, 1.03−0.87. From 1H NMR, integration of the methoxy proton
(in PEG unit) and the aromatic proton (in pyridine unit) provided the molar ratio of two
monomers to be 1:1 (PEG/PDS).
2.4.3

Modification of synthesized p(PEGMA-co-EDSMA) polymer, PPcE
PDS polymer (1 g, 1.32 mmol PDS repeat unit) was weighed in a 20 mL glass vial

and dissolved in 8 mL DCM. Catalytic amount (100 µL) of glacial AcOH was added to it
and stirred for 5 min. Afterwards, 2-mercaptoethanol (0.9 mL, 13 mmol) was added
dropwise to the reaction mixture and the solution was stirred for 24 h at room temperature.
After that, the modified polymer was purified by dialyzing against methanol using a
membrane of MWCO: 3.5 kDa. After dialysis, the solvent was evaporated and the polymer
was dried under vacuum for 24 h. Yield: 90%, GPC (THF) Mn: 26 K. Đ: 1.2. 1H NMR (400
MHz, CDCl3): δ 4.24−4.09, 3.87, 3.65−3.53, 3.37, 2.95-2.90, 1.93-1.84, 1.04-0.89.
2.4.4

Synthesis of p(PEGMA-co-NPC) (NPC: p-nitrophenylcarbonate), P1
Modified polymer P2 (1 g, 1.39 mmol) and 4-Nitrophenyl chloroformate (325 mg,

1.61 mmol) were dissolved in 5 mL DCM taken in a 20 mL glass vial. The reaction mixture
was cooled in ice bath for 10 min. To the cold mixture, pyridine (130 µL, 1.61 mmol) was
added dropwise under vigorous stirring. Finally, the reaction mixture was stirred at room
temperature for 24 h and the self-immolative polymer was purified by dialyzing against
DCM/MeOH 1:1 mixture using a MWCO 3.5 kDa membrane. Yield: 98%, GPC (THF)
Mn: 32 K. Đ: 1.2. 1H NMR (400 MHz, CDCl3): δ 8.29-8.27, 7.41-7.42, 4.54, 4.23-4.08,
3.63-3.37, 3.04-2.94, 1.89-1.80, 1.03−0.88.
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2.4.5

1

H-NMR spectra for polymer samples PPcP, PPcE and P1

1

H-NMR spectra of the samples were recorded on a 400 MHz Bruker NMR

spectrometer using residual proton resonance of the solvent as the internal standard and
chemical shifts were reported in parts per million (ppm).
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2.4.6

Gel permeation chromatography (GPC) for PPcP, PPcE and P1
Molecular weights of all synthesized polymers were estimated by GPC in THF

using poly(methyl methacrylate) (PMMA) standards with a refractive index detector.
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Figure 2.9 GPC(THF) for polymers PPcP, PPcE and P1
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2.4.7

Preparation of polymer-protein nanoassemblies

2.4.7.1 NA-EmptyED and NA-EmptyPEG
The self-immolative polymer P1 (10 mg) was dissolved in 2.5 mL phosphate buffer
(adjusted to pH 8.5) at 20 ºC. A calculated amount (~0.005 mmol) of ethylenediamine (for
NA-EmptyED) or (PEO)4-bis-amine (for NA-EmptyPEG) was added to the solution and kept
stirring for 24 h for cross-linking. The resulting nanoassembly was purified by repeated
washing (five times) with phosphate buffer pH 7.4 Amicon Ultra Centrifugal Filters
MWCO 30 kDa. The final volume of empty nanoassembly was adjusted to 500 µL with
phosphate buffer of pH 7.4.
2.4.7.2 NA-LysED, NA-LysPEG, NA-RNaseAED, NA-RNaseAPEG, NA-CytCED and NACytCPEG
Initially, polymer P1 (10 mg) was dissolved in 1.5 mL phosphate buffer (adjusted
to pH 8.5). To this solution, 1 mL solution of a specific protein (1 mg lysozyme or RNase
A or cytochrome C in phosphate buffer, pH 8.5) was added dropwise and stirred for 24 h
at 20 ºC to generate P2. Then, calculated amount (~0.005 mmol) of ethylenediamine (for
NA-ProteinED) or (PEO)4-bis-amine (for NA-ProteinPEG) was added to each solution for
cross-linking and mixed for another 24 h at 20 ºC. Finally, the reaction mixture was washed
(five times) with phosphate buffer (pH 7.4) using Amicon Ultra Centrifugal Filters MWCO
30 kDa to get purified nanoassemblies (NA) encapsulated with proteins. The final volume
of all conjugates was adjusted to 500 µL with phosphate buffer of pH 7.4.
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2.4.8

Monitoring protein-polymer conjugation, degree of NPC group modification

by protein and crosslinking density
The conjugation process and cross-linking density for the protein-polymer
conjugates can be evaluated by UV-Vis spectroscopy. The amount of released 4nitrophenol was monitored at its λmax 400 nm (measured molar extinction co-efficient
≈12.14*103 LM-1cm-1 at 400 nm). Absorbance of each solution was measured after the
conjugation and cross-linking processes. For each absorbance measurement, 25 µL of
sample was withdrawn and diluted to 1 mL with distilled water. Cross-linking density was
calculated by assuming that the formation of a single chain crosslinking bond would
require cleavage of two NPC units and produce two 4-nitrophenol molecules.
The molar ratio of NPC:PEG in the polymer, P1= 50:50 (x mol : y mol, from NMR)
NPC molecular weight = 387 g/mol, PEG molecular weight = 500 g/mol
So, x mol * 387 g/mol + y mol * 500 g/mol= 0.1 mg
x mol = 50/50 y mol
Amount of polymer used = 0.1 mg/mL for each absorbance measurement
Moles of NPC-unit (x mol) in the solution= (0.1/887)/1000= 1.13 * 10-7 mol
Example for NA-LysED:
From Beer-lamber’s law: A = ε.c.l and path-length=1 cm
So, concentration of 4-nitrophenol, [c]= 0.3692/ (12.14 * 103) = 3.04 * 10-5 M
Thus, moles of 4-nitrophenol in 1 mL solution= 3.04 * 10-8 mol
This represents 27 mol% of total NPC unit. As we assume that two 4-nitro phenol are
released per crosslinking bond formation and NPC unit is 50 mol% of total polymer.
Therefore, crosslinking density =27/2 *0.5 = 6.7 %.
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Table 2.1 NPC modification and crosslinking density of nanoassemblies

3
* Amount of reacted NPC group, calculated based on amount of 4-nitrophenol released
and original content of the same in the reactant polymer.
# moles of lysine/moles of NPC * 100; calculated based on initial polymer dosage (10
mg) and encapsulated proteins (see encapsulation efficiency)
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Figure 2.10 (a) Time-course of absorbance profile for released 4-nitrophenol as a fate of
conjugation of lysozyme with polymer P1; Absorbance spectra of polymer-protein
conjugates- before and after crosslinking for (b) lysozyme; (c) RNase A and (d)
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cytochrome C. UV−visible absorption spectra were recorded on a PerkinElmer Lambda 35
spectrophotometer.
2.4.9

Encapsulation efficacy and loading capacity

All nanoassemblies were evaluated for amount of protein encapsulation after conjugation
and cross-linking process. Protein concentration in each sample was measured from the
filtrate after crosslinking reaction and the amount of protein was back-calculated in the
conjugate. An absorbance based assay (with PierceTM 660 nm Protein Assay Reagent) was
utilized to quantify the protein amount. The encapsulation efficiency (EE) and loading
capacity (LC) were calculated based on the following formulas:
EE, % ൌ 

initial protein loaded െ free “unencapsulated” protein
൨ ൈ 100
initial protein loaded
LC, % ൌ 

amount of “encapsulated” protein
൨ ൈ 100
amount of polymer

Table 2.2 Encapsulation efficiency and loading capacity of nanoassemblies
Sample

Amount of protein

Encapsulation

Loading capacity

encapsulated, µg

efficiency (EE), %

(LC), %

(Initial dose= 1mg)
NA-Lys ED

550

55

5.5

NA-Lys PEG

560

56

5.6

NA-RNaseAED

558

56

5.6

NA-RNaseAPEG

553

55

5.5

NA-CytCED

637

64

6.4

NA-CytCPEG

673

67

6.7

2.4.10 DLS and zeta potential plots:
Dynamic light scattering (DLS) and zeta potential measurements were performed using a
Malvern Nanozetasizer-ZS. All samples were diluted with phosphate buffer pH 7.4 to
adjust final concentration to 1 mg/mL.
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Figure 2.11 Particle size analysis of protein-polymer nanoassemblies from DLS
measurements
Table 2.3 Particle size values for the nanoassemblies
Sample

Size, nm

Lysozyme

3.6 ± 0.4

RNase A

3.3 ± 0.2

Cytochrome C

4.3 ± 0.1

NA-EmptyED

9.7 ± 0.1

NA-EmptyPEG

9.5 ± 0.1

NA-Lys ED

9.7 ± 0.2

NA-Lys PEG

9.4 ± 0.3

NA-RNaseAED

9.1 ± 0.1

NA-RNaseAPEG

9.5 ± 0.1

NA-CytCED

9.2 ± 0.2

NA-CytCPEG

8.6 ± 0.1
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Figure 2.12 Zeta potential plots for protein-polymer nanoassemblies

Table 2.4 Zeta potential values for the nanoassemblies
Sample

Zeta potential, mV

NA-EmptyED

-7.3 ± 1.3

NA-EmptyPEG

-9.2 ± 1.5

NA-Lys ED

-7.6 ± 0.7

NA-Lys PEG

-7.1 ± 0.4

NA-RNaseAED

-8.2 ± 0.7

NA-RNaseAPEG

-8.7 ± 0.7

NA-CytCED

-6.4 ± 0.5

NA-CytCPEG

-2.1 ± 0.5
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2.4.11 Cryo-TEM sample preparation and instrumentation
(a top) Cryo-EM sample preparation was done using a FEI Vitrobot MKII applying
purified NA-Protein sample solution (20-21 mg/ml) to a c-flat holey carbon grid (hole size
2 µm) after washing the grid in chloroform. The samples were then transferred using a
Gatan cryo-transfer holder to a FEI TecnaiT12 TEM operating at 120 kV acceleration
voltage. Images were acquired using standard low dose methods at 5 µm under focus. (a
bottom) Sample preparation and HAADF imaging conditions are described under Figure
2.15.

Figure 2.13 Cryo TEM images: (a) Bright Field image of NA-CytCPEG was obtained after
allowing a drop of sample solution to dry on a carbon coated grid and subsequent transfer
into the TEM at room temperature mounted on a cryo-TEM holder. The sample was then
cooled to -182 °C for observation. The bright field image shows particles in the size of 2030 nm, which corresponds well to the size observed after cryo-transfer sample preparation.
The contrast is naturally not as good as after the cryo-EM sample preparation (see main
text Figure 2a) due to the carbon support film and most likely particles have undergone
some deformation due to drying. This sample was also used for the HAADF and EDS
measurements at cryo-temperature (main Text Figure 2.22a bottom and Figure 2.15). Due
to relatively high beam currents and long acquisition times necessary for EDS
measurements it was only possible to perform these measurements on these samples since
samples prepared through cryo-transfer are quickly destroyed during the measurements.
The bright field image here, all HAADF images (Main text and SI) and all EDS
measurement (SI) were done using a JEOL FEM-2200FS field emission TEM equipped
with an Oxford 80mm2 X-Max EDS-Spectrometer. Acceleration Voltage was 200 kV and
camera length for HAADF was 100 cm. Samples were mounted on a Gatan 636 Double
Tilt Cryo-Holder with Beryllium cradle to avoid Fe signal typical for standard stainless53

steel holders. (b) Bright Field image of NA-CytCPEG obtained after allowing a drop of
sample solution to dry on a carbon coated grid and subsequently observed in a TEM at RT.
No additional staining was performed. Compared to the sample in part (a) observed at cryo
temperatures the sample quickly degrades under electron beam exposure and forms ring
like structures where the average diameter of the inner dark ring is in the range of 10-30
nm. Interestingly, individual NA-CytCPEG particles in aggregates each form a single ring
allowing to identify the number of NA-CytCPEG particles within an aggregate (see
calculation and Figure 2.16 for # of proteins per particle). The imaging was done using a
JEOL JEM-2000FX TEM operating at 200kV acceleration voltage.

Figure 2.14 Room temperature TEM images: for NA-Protein samples (samples were dropcasted on a carbon coated grid and dried at room temperature before subjecting room
temperature TEM study. For all samples, a mixture of individual as well as clustered
particles were observed because of drying on TEM grids. This is also in agreement with
the cryo-EM images provided in Figure 2a in manuscript and Figure 2.13.
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Figure 2.15 Energy Dispersive X-Ray Spectroscopy (EDS) analyses and High Angle
Annular Dark Field Microscopy (HAADF, inset) images at cryo temperature (-178 °C) for
NA-CytCPEG. Figure 2.15 insets shows HAADF images of individual nano-assemblies. For
HAADF and EDS analysis, samples were transferred using a Gatan 636 Double Tilt CryoHolder with Beryllium cradle to avoid any contamination from external matal sources. The
whole assembly has a diameter of ~20 nm and the bright spots in the range of ~2-3 nm is
caused by the Fe-content of discrete CytC protein molecules.32 EDS analysis confirmed the
presence of Fe inside (a, c) the nanoassemblies and none in the outer space (c). As expected,
we did not observe any bright spots of Fe in NA-EmptyPEG particle (d, inset) and EDS
confirms the absence of Fe in it(d).

2.4.12 Estimation of approximate number of proteins per particle:
Example for NA-LysED:
Diameter of nanoassembly, D = 9.7 nm, radius, R = 4.85 nm
Volume of each particle, VPPC = (4/3)πR3 = (4/3) π(4.85)3 nm3 = 477.6 × 10-21 cm3
Again, for lysozyme, diameter of protein, d = 3.6 nm, radius, r = 1.8 nm
Volume of each protein, VLy = (4/3)πr3 = (4/3) π(1.8)3 nm3 = 24.4 × 10-21 cm3
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Assuming that maximum sphere packing efficiency to be ~74%, number of lysozyme per
nanoassembly to be = (477.6 × 10-21/ 24.4 × 10-21) × (0.74) = 14
Based on Carl Friedrich Gauss theory on close packing of sphere in space: highest average
packing density is given by π/3√ 2 ≈ 0.74
The results for all other nanoassemblies are summarized below:

Table 2.5 Theoretically calculated number of proteins per nanoassembly based on size
Sample

# of Protein per PPC particle

NA-Lys ED

14

NA-Lys PEG

14

NA-RNaseAED

16

NA-RNaseAPEG

18

NA-CytCED

7

NA-CytCPEG

6

Figure 2.16 HAADF images of different NA-CytCPEG particles. The bright spots with a
diameter of 2-3 nm are caused by the Fe-content of the Cyt C. This allows to identify and
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approximately count number of CytC proteins per particle through Image J software (see
discussions in Figure 2.13b), approx. # of proteins are reported in the inset, scale bar: 20
nm.
2.4.13 Enzymatic degradation (trypsin digest) study
Polymer-protein conjugate solutions and native proteins (lysozyme, RNase A and
cytochrome C) were subjected to enzymatic degradation study to evaluate the stealth power
of polymeric nanoassemblies to encapsulate and protect the sensitive cargos from protease
mediated cleavage. Sample solutions were prepared with polymer-protein complexes (with
final protein concentration of 0.39 mg/mL based on previous protein analysis) in NaHCO3
buffer (pH=8.0). The concentrations of native proteins in each control sample were also
kept identical for comparison purpose. After that 10% acetonitrile was added to each
sample to denature the protein and incubated at 50 ºC for 45 minutes. For RNase A, samples
were treated with 15% AcOH and incubated at 90 ºC for 4 h. After hydrolysis, samples
were freeze-dried and finally added 10% acetonitrile and 90% NaHCO3 buffer of pH 8.0.
Finally, all samples were digested with trypsin from porcine pancreas at a ratio of 1:25
(trypsin:protein) at 37 ºC for 17 h. After digestion samples were collected by centrifugation
and subjected to MALDI-MS analysis. The matrix was prepared with a solvent mixture of
acetonitrile, water and trifluoroacetic acid (with a ratio 50:47.5:2.5) containing 10 mg/mL
α-cyano-hydroxycinnamic acid. The matrix and digested samples were mixed at 1:1 ratio
and spotted on the MALDI target for fragmental analysis.
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Figure 2.17 Trypsin digest for ED and PEG-crosslinked polymer-protein nanoassemblies

Cytochrome C
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Table 2.6 Major MS-Digest fragments for Lysozyme, RNase A and Cytochrome C from
MALDI-MS analysis
m/z

Start

End

Sequence

1045

135

143

(K)GTDVQAWIR(G)

1428

52

63

(K)FESNFNTQATNR(N)

1676

116

130

(K)IVSDGNGMNAW VAWR(N)

1753

64

79

(R)NTDGSTDYGILQINSR(W)

m/z

Start

End

Sequence

1151

1

10

(-)MPAPATTYER(I)

1547

85

98

(K)LWSSLTLLGSYKGK(N)

1662

1

14

(-)MPAPATTYERIVYK(N)

1685

26

41

(R)LEFQDGGVGLTAAQFK(Q)

m/z

Start

End

Sequence

1168

29

39

(K)TGPNLHGLFGR(K)

1478

89

100

(K)KTEREDLIAYLK(K)

1478

90

101

(K)TEREDLIAYLKK(A)

1598

40

54

(R)KTGQAPGFTYTDANK(N)

1633

10

23

(K)IFVQKCAQCHTVEK(G)

58

2.4.14 Assessment of serum stability of NA-LysPEG, NA-RNaseAPEG and NA-CytCPEG
nanoassemblies
To the stability of nanoassemblies in serum is considered to be an important criterion to
perform as an efficient delivery vehicle. The serum stability of the PPCs were performed
by monitoring the changes in particle size through DLS.33 All samples were incubated with
differential amounts of serum (0%, 10%, 25% and 50%) for 6 h at 37 ºC before subjecting
to DLS measurements. Conjugates were found to quite stable with negligible shifts in the
particle sizes confirming no protein adsorption leading to aggregation and biofouling.
15

Particle size, nm
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nm

nm

nm

nm
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7.4 ± 0.4
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9.5 ± 0.1

8.4 ± 0.6

7.5 ± 0.2
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Figure 2.18 Particle size analysis of nanoassemblies in presence of serum

2.4.15 Lysine residues in proteins

Figure 2.19 Lysine residues in Lysozyme (#6), RNase A (#10) and Cytochrome C (#19)
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2.4.16 SDS-PAGE for protein-polymer conjugation and release studies:
30 µL of different samples containing NA-EmptyED, NA-EmptyPEG, NA-LysED,
NA-LysPEG, NA-RNaseAED, NA-RNaseAPEG, NA-CytCED and NA-CytCPEG were mixed
with 10 µL of loading buffer (DTT free) and 25 µL of each sample was loaded on
acrylamide gel. For release experiment, identical protein-polymer conjugate samples were
treated with 10 mM DTT and incubated at 37 ºC for 4 h before subjecting to acrylamide
gel electrophoresis. To calculate the amount of released protein from each sample, standard
curves were generated from the known concentrations of pure protein samples loaded into
the gel lanes. The gel image analysis and quantification were performed with Bio-Rad
Image LabTM software.

Figure 2.20 SDS-PAGE for encapsulation analysis with nanoassemblies containing Lys
and RNaseA
2.4.17 Release kinetics of proteins from the protein-polymer nanoassemblies:
To monitor the release kinetics of proteins (lysozyme, RNase A and cytochrome
C), 30 µL of NA-LysED, NA-LysPEG, NA-RNaseAED, NA-RNaseAPEG, NA-CytCED and
NA-CytCPEG samples were incubated at 37 ºC with requisite amounts of 10 mM DTT for
different time intervals. After each incubation time, samples were collected and
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immediately frozen at -20 ºC. Finally, all samples were subjected to SDS-PAGE analysis
to quantify the amount of released proteins.

Figure 2.21 Release kinetics of proteins from the nanoassemblies by SDS-PAGE at
disulfide of polymer to DTT ratio 1:1.

Figure 2.22 Release kinetics of proteins from the PPCs by SDS-PAGE at disulfide of
polymer to DTT ratio 1:10, quantification data provided in the 3D bar graph after 6 h of
release.
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Figure 2.23 Release kinetics of proteins from the nanoassemblies: (a, b) Plot of
concentration of protein released (µM) vs. time; (c, d) Normalized plot of
released/encapsulated protein vs. time. Although the concentration/amount of released
proteins are approximately same for both RNase A and Cyt C, the normalized plots (moles
of released/encapsulated protein vs. time) differentiates the protein release behavior more
clearly and the released protein amounts for each can be correlated with their lysine
content.
2.4.18 Activity assays:
To measure the activity of released proteins from different polymer-protein
conjugates, first samples were treated with 10 mM DTT and incubated at 37 °C for 4 h.
Identical samples were subjected to 50 µM DTT mimicking extra-cellular reducing
environment and incubated under similar condition. SpectraMax® M5 spectrophotometer
(Molecular Devices) was utilized for evaluating all activities through absorbance and
fluorescence measurements.
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a. For lysozyme:
The EnzChek® Lysozyme Assay Kit (Thermo-Fisher Scientific) was used to check
the lysozyme activity on a substrate based on Micrococcus lysodeikticus cell walls which
was labeled with fluorescein to such an extent that the fluorescence is quenched. Due to
lysozyme’s enzymatic activity, the mucopolysaccharide cell walls of the labelled
microorganism containing β-(1-4)-glucosidic linkages between N-acetylmuramic acid and
N-acetyl-D-glucosamine residues were hydrolysed releasing proportional amount of
fluorescein. To perform the assay, 20 µL sample was mixed with 20 µL prepared substrate
solution and subjected to fluorescence measurement (Ex/Em: 494/518 nm) over 1h with
SpectraMax® M5 spectrophotometer.
b. For RNase A:
RNaseAlert® activity kit (Thermo-Fisher Scientific) was used to check the activity
of released RNase A for all samples. RNase A cleaves the oligonucleotide substrate of the
assay consisting a fluorophore and a quencher present at two extreme ends, thus releasing
the fluorophore which can be detected and quantified with a fluorometer. For a typical
kinetic experiment, the substrate was mixed with 5 µL test buffer, 35 µL nuclease free
water and 10 µL sample (diluted X10,000 from DTT experiment). 40 µL of the prepared
sample mixture was transferred to a black 96-well plate and immediately measured for
fluorescence (Ex/Em: 490/520 nm) with SpectraMax® M5 spectrophotometer over a 30
min time course.
c. For cytochrome C:
The peroxidase activity of cytochrome C was determined by examining the
catalytic conversion of 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS).
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Cytochrome C catalyzes the reduction of H2O2 to water which is coupled with one-electron
oxidation of chromogenic ABTS forming a brilliant blue-green ABTS radical cation. The
assay kinetics can be monitored by observing the changes in absorbance spectra of the
radical cation at 418 nm. Before subjecting to activity measurement, DTT treated samples
were washed thoroughly with PBS buffer of pH 7.4 to remove DTT and other byproducts.
The test solution was prepared by mixing 100 µL sample solution with 400 µL H2O2 (25
mM) and 500 µL ABTS (1 mg/mL). Absorbance spectra were recorded for all samples at
418 nm for a time course of 5 min using SpectraMax® M5 spectrophotometer.

Table 2.7 Abbreviations used in activity assay plots
Sample

Details

Sample

Protein_DTT 0.05 mM

Native protein treated with
0.05 mM DTT

NA-ProteinPEG 0.05 mM

Protein_DTT 10 mM

Native protein treated with
10 mM DTT

NA-ProteinED 10 mM

NA-EmptyED

Empty ED-crosslinked
NA-ProteinPEG 10 mM
nanoassemblies treated
with 10 mM DTT
Empty PEG-crosslinked
Blank
nanoassemblies treated
with 10 mM DTT
Protein encapsulated EDcrosslinked nanoassemblies
treated with 0.05 mM DTT

NA-EmptyPEG
NA-ProteinED 0.05 mM
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Details
Protein encapsulated PEGcrosslinked nanoassemblies
treated with 0.05 mM DTT
Protein encapsulated EDcrosslinked nanoassemblies
treated with 10 mM DTT
Protein encapsulated PEGcrosslinked nanoassemblies
treated with 10 mM DTT
Only phosphate buffer, pH
7.4

Figure 2.24 Activity of released proteins from nanoassemblies containing (a-b) Lysozyme;
(c-d) RNase A.
2.4.19 Circular dichroism (CD) spectra:
CD spectra of the released and native protein samples were recorded on JASCO J1500 spectrophotometer. In a typical experiment, NA-protein sample was incubated with
requisite amount of DTT for 24 h. After that, the sample was dialyzed against PBS buffer
pH 7.4 with a membrane MWCO 20 kDa for 2 days to separate the polymer. Finally, the
purified sample was concentrated with Amicon Ultra Centrifugal Filters MWCO 3K and
the concentration was measured with Pierce 660 nm Protein Assay Reagent. For recording
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the spectra, 200 µL protein solution was injected into a quartz cuvette of 1-mm path length,
equilibrated at 25 ºC for 10 min and scanned from 190 to 250 nm (scan rate: 20 nm/min,
interval: 0.2 nm, average of three spectra).
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Figure 2.25 CD spectra of native proteins and polymer-protein nanoassemblies.

2.4.20 MALDI-MS spectra for the released proteins:
MALDI-MS analyses were performed with Bruker Autoflex III time-of-flight mass
spectrometer. All mass spectra were acquired in the reflectron mode with an average of
500 laser shots at ~60% optimized power.
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Figure 2.26 Comparison of MALDI-MS spectra of the native proteins and released
proteins from nanoassemblies.
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Figure 2.27 MALDI-MS spectra of the NA-ProteinPEG nanoassemblies.

2.4.21 Labeling of proteins with Rhodamine B:
To perform the cell-uptake studies, fluorescence-labelled proteins (lysozyme,
RNase A and cytochrome C) were prepared with Rhodamine B isothiocyanate (RB). In a
typical labelling procedure, proteins (4 mg) were dissolved separately in 2 mL of 0.1 M
NaHCO3 buffer (pH 8.5) and stirred for 15 min at 4 ºC. RB (5 eq. of each protein, 10
mg/mL in DMSO) was added dropwise to each protein solution and stirred at 4 ºC for 2 h
protected from light. The RB-labelled-proteins were purified by extensive dialysis with 50
mM Tris pH 7.4 and 50 mM NaCl mixture to remove excess RB and concentrated using 3
kDa Amicon Ultra Centrifugal Filters. Protein concentrations in each labelled conjugate
were calculated using UV-Vis spectroscopy. The molar ratio of RB and labelled lysozyme,
RNase A and cytochrome C were estimated to be 0.62, 0.43 and 0.63, respectively. All
labelled polymer-protein conjugates were prepared with the RB-labelled proteins
following the method described under ‘Synthesis of polymer−protein nanoassemblies’.
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2.4.22 Cell culture:
Human cervical carcinoma (HeLa) cells were cultured in T75 cell culture flask
containing Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) in a
humidified incubator with 5% CO2 at 37 °C. Culture media was supplemented with 10%
fetal bovine serum (FBS), 1% L-glutamine and 1% antibiotic-antimycotic (100 units/mL
of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL of Amphotericin B).
2.4.22.1 Cellular uptake studies for protein delivery and endosomal escape:
Cell internalization studies were performed with HeLa cells seeded at 100,000
cells/mL in glass-bottomed petri-dishes and cultured for 1 day at 37°C in a 5% CO2
incubator. Prior to delivery cells were washed three times with PBS buffer and incubated
with 1 mL media containing 6 µL polymer-Rhodamine B-protein conjugate or Rhodamine
B-protein conjugate (protein concentration 1 mg/mL) at 37 °C for 4 h. After that, cell
nucleus was stained with Hoechst 33342 (8 µM) and finally the media was replaced with
fresh stock and incubated for another 1 h before subjecting to CLSM analysis. In addition,
to study the endosomal escape of the labelled proteins, HeLa cells were incubated with
labelled nanoassemblies for 4 and 24 h. After that it was stained with LysoTracker® Green
to label endosomes/lysosomes and studied the co-localization of red and green fluorescence
channels. Live cell imaging was performed using Nikon Spectral A1+ confocal microscope.
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Figure 2.28 Negligible uptake for HeLa cells incubated with only proteins, cell nucleus
was stained with Hoechst 33342, scale bar: 50 µm.

Figure 2.29 Cellular internalization with ED-crosslinked nanoassemblies, cell nucleus was
stained with Hoechst 33342, scale bar: 50 µm.
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Figure 2.30 (a) Depth profiling for NA-CytCPEG dosed nanoassemblies: pseudo-colored
consecutive slices through z-axis and (b) z-stack orthogonal projection from CLSM
experiment showing localization of cytochrome C inside HeLa cells.

Figure 2.31 (a) Time course of uptake for NA-CytCPEG, (b) Fluorescence intensity
measurement from the red channel by Image J software at different time points of uptake
experiment, expressed as Corrected total cell fluorescence, CTCF = Integrated Density (Area of selected cell × Mean fluorescence of background).34
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Figure 2.32 Endosomal escape studies by co-localization of LysoTracker Green and
Rhodamine B tagged protein; co-localization of dyes after 4 h incubation confirms
existence in the endosomes and after 24 h distinct red fluorescence confirms release of
proteins into the cytosol from endosomes. Scale bar: 10 µm.
2.4.22.2 Cell viability with alamarBlue® assay:
HeLa cells were seeded into 96-well tissue culture plates at a density of 5000
cells/well/100 µL sample and incubated at 37 °C. After 24 h, culture media was replaced
and cells were treated with different concentrations of protein-polymer conjugates and
control protein samples (0.1 mg/mL to 2 mg/mL NA-ProteinPEG concentration; for naked
protein concentration is matched with the encapsulated one in the NA-Protein sample and
can be calculated from encapsulation efficacies, 2 mg/mL of NA-CytCPEG refers to 126
µg/mL of cytochrome C) in 100 µL media. All samples were incubated for 6 h at 37 °C,
then the media was replaced and incubated for another 66 h at 37 °C. Afterwards media
was replaced, washed with PBS buffer for three times and each well was treated with 100
µL 10% alamarBlue in media with serum. Finally, samples were incubated for 1 h and
subjected to fluorescence measurement with SpectraMax® M5 at 560 nm excitation/590
nm emission wavelength in a black 96-well flat-bottomed plate.
2.4.22.3 Study of apoptosis with NA-CytCPEG nanoassembly:
HeLa cells were seeded at 40,000 cells/mL density in glass-bottomed petri-dishes
and cultured for 1 day at 37°C in a 5% CO2 incubator. Cells were washed three times with
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PBS buffer and incubated with 1 mL media containing NA-CytCPEG conjugate (2 mg/mL)
at 37 °C for 4 h. After that, the media was replaced and cells were incubated for another
68 h. To detect the apoptotic cells, each sample was treated with CellEvent™ Caspase-3/7
Red Detection Reagent (10 µM) and hoechst 33342 (8 µM) to stain the nucleus by
incubating for 30 min before subjecting to CLSM analysis. The apoptosis assay reagent
consists of a DEVD peptide attached to a nucleic acid-binding cy5-dye. When bound with
the peptide, the dye becomes intrinsically non-fluorescent as the DEVD peptide retards the
DNA-binding ability of the dye. Once caspase-3/7 enzymes are activated in apoptotic cells
by the delivery of cytochrome C, the DEVD peptide is cleaved by those and enable the dye
to bind to DNA to produce a bright, fluorogenic response. Co-localization of blue (hoechst)
and red (cy5) channels was studied to check the nuclei of the apoptotic cells.

Figure 2.33 Detection of activated caspase-3/7 after 72 h in control HeLa cells treated with
NA-EmptyPEG sample; scale bar: 10 µm, no co-localization of hoechst and cy5-tagged
assay reagent was observed in the nucleus.
2.4.22.4 Encapsulation, release and cellular internalization studies with eGFP
To check the robustness of the polymeric delivery system, we investigated the
encapsulation and release properties of eGFP that has higher MW and lower pI (MW ~27
kDa, pI 5.5) compared to lysozyme, RNase A and cytochrome C (MW between 12-15 kDa
and pI >8.5). eGFP was encapsulated within polymer matrix by the reactive coupling
method described in “synthesis of polymer-protein nanoassemblies” section, and was
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subsequently released with the aid of redox-stimuli DTT (see section ‘SDS-PAGE for
protein-polymer conjugation and release studies’, Figure 2.31). NA-eGFPPEG assemblies
were subjected to cellular uptake studies with HeLa cells (dosage 2 mg/mL, see previous
‘cellular uptake studies for protein delivery’ section) and imaged using confocal
microscope. Evenly distributed green fluorescence of delivered eGFP (Figure 2.35)
demonstrates successful delivery of the protein into HeLa cells.35

Figure 2.34 SDS-PAGE for encapsulation and release analysis with nanoassembly
containing eGFP.

Figure 2.35 Cellular internalization with NA-eGFPPEG nanoassemblies, cell nucleus was
stained with Hoechst 33342, scale bar: 20 µm.
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CHAPTER 3
A

SYMBIOTIC

SELF-ASSEMBLY

STRATEGY

TOWARDS

LIPID-ENCASED

CROSSLINKED POLYMER NANOPARTICLE FOR EFFICIENT GENE SILENCING
Adapted with permission from: Dutta, K.; Davide, B.; Ribbe, A. E.; Dominique, A.; Mager, J.;
Giovanni, P. M.; Thayumanavan, S. “Symbiotic Self-Assembly Strategy toward Lipid-Encased
Cross-Linked Polymer Nanoparticles for Efficient Gene Silencing” ACS Appl. Mater. Interfaces
2019, 11, 24971−24983. Copyright © 2019 American Chemical Society

3.1

Introduction
Self-assembly that relies on non-covalent intermolecular interactions, comprising single or

multi-component molecular building blocks, plays a fundamentally important role in many
biological processes and in the development of novel functional materials.1-2 However, designing
and assembling multiple molecular entities to generate a predictable and controlled supramolecular
assembly have considerable challenges; but if achieved, this can propel the design of materials
with functional capabilities that are currently not attainable. With this in mind, we have designed
a new three-component self-assembling system, where the parts are interdependent in the
formation of the nanoassembly. In addition to demonstrating the formation and the characterization
of such an assembly, the utility of such a nanostructure in addressing current toxicity and cellular
delivery challenges involving small interfering RNA (siRNA) molecules has been investigated.
Although discovery of siRNA, a potential gene silencing agent, has created attractive
opportunities targeting a wide array of diseases,3-5 RNAi technology has produced only one drug
approved for clinical use.6 Poor cellular internalization, serum instability, rapid clearance, severe
cytotoxicity and potential immunological flare-ups have been identified as the critical barriers for
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such promising technology.7-12 Potential solutions like, chemically modified siRNAs and viral
vectors have yet to overcome issues owing to cytotoxicity, stability, immunogenicity and reduced
silencing ability upon structural modifications.7, 13-14 Interestingly, non-viral approaches, based on
electrostatic complexation of nucleic acids using cationic lipids, peptides, nanoparticles, or
polymers, have the potential to resolve the major reported issues.15-20 However, the key obstacle
in these carrier-based delivery systems is the adverse side effects originated from the cationic
charge mediated alteration in membrane potentials of cellular organelles and non-specific
interactions with negatively charged serum proteins.13, 21-22
To address this, two interesting approaches, viz. charge-masking strategies23-24 and
spherical nucleic acids25 have been reported wherein cationic charges are masked and negatively
charged nucleic acids are decorated on surfaces, respectively. In addition to the non-cationic
surface display, the degradable cationic blocks offer opportunities to mitigate toxicity issues
associated with cationic polymers as well.26-29 Mimicking viral mechanism of cellular entry,
another polymeric delivery agent, virus-inspired polymer for endosomal release, is developed with
a hydrophilic cationic block and an endosomolytic peptide displayed only under acidic pH.30 In a
significant departure from the conventional approaches, direct decoration of a high density of
nucleic acids themselves as surface functionalities on nanoparticles and polymers have produced
negatively charged nanostructures with good cellular internalization and gene silencing
capabilities.25, 31 Natural green tea catechin condensed siRNA-cationic polymer nanoparticles and
fluorinated oligoethylenimine nanocomplexes have also shown encouraging outcomes for siRNA
delivery.32-33 Despite these advances, there still exists a need for RNAi-based therapeutic
approaches that would retain the key advantages of non-viral carriers, while mitigating their
shortcomings.
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Inspired by this, we envisaged that a possible solution to all these delicate and
overwhelming challenges would be a noncationic approach wherein the cationic charge is
irreversibly removed after encapsulation of siRNA without compromising stability and activity of
the nucleic acid. To this end, we designed a unique and well-defined ‘symbiotic self-assembly’
approach to efficiently self-assemble a polymer, lipids, and the nucleic acid to form stable lipid
decorated siRNA-polymer (L-siP) nanoassemblies (Scheme 3.1). We term this as symbiotic self-

Scheme 3.1 Symbiotic self-assembly strategy to construct L-siP nanoassembly and its key
molecular components.

assembly, because none of these three components would form the nanostructures by themselves
under the required conditions, but they produce well-defined assemblies when brought together in
a sequence. We outline the design hypothesis, self-assembly, and their utility in effectively
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delivering siRNA molecules inside cells, using four different siRNAs in different cell lines. The
system has been designed such that: (i) the high binding affinity results in efficient capture of
siRNAs inside the assemblies; (ii) although electrostatics is utilized to capture the siRNAs, the
residual assembly is non-cationic due to an in situ crosslinking protocol that removes the cationic
charge on the polymer, yet incarcerates the siRNA; (iii) the surface charge of the assemblies is
non-cationic; and (iv) the siRNA can be released using a trigger that corresponds to the operational
environment of the cargo.
3.2

Results and discussion
The self-assembly process was envisioned in three key steps. First, a cationic amphiphilic

polymer would be utilized to electrostatically capture the siRNA (Scheme 3.1, Figure 3.1a-b). Note
that electrostatic interaction energy is governed by Coulomb’s law (E=q1.q2/4πor), where
represents the dielectric constant of the medium. In this case, the ionic interaction between the
polymer and the siRNA can be significantly enhanced in low dielectric media. The hydrophobic
alkyl chain in the amphiphilic random copolymer facilitates the complexation between the polymer
and the siRNA in an organic-rich solvent medium, where the electrostatic interactions are expected
to be strong. However, the medium is not completely non-aqueous, as polyelectrolyte interactions
are entropically driven34 and it is important to accommodate the critical counterion dissociation
that facilitates the interaction between these two macromolecules. Second, while we utilize the
cationic charge to bind the siRNA with high affinity, we are interested in eliminating the cationic
charge in the system since this has been implicated in many complications in non-viral carriers.13,
21-22

Therefore, we utilize a cationic functional group that can be triggered to concurrently self-

crosslink and release the cationic functionality (Scheme 3.1, Figure 3.1b-c). Such a process
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switches the driving force for retaining the siRNA within the assembly, from an electrostatic one
to a combination of physical incarceration (due to crosslinking) and solvophobic forces (due to the

Figure 3.1 (a) Synthesis of p(PDSMA-co-DodecylMA) polymer (PPDS/DD) and postpolymerization modification to install cationic charge yielding ⊕PPDS/DD polymer; (b) Reaction
scheme for preparation of non-cationic L-siP nanoparticles via disulfide based crosslinking; (c)
Schematic representation of differentially crosslinked polymer-siRNA assemblies; (d) 1H NMR
spectra of ⊕PPDS/DD polymer treated with different amounts of DTT for crosslinking in
acetone:water (deuterated)= 70:30.
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unfavorable organic-rich medium for the highly charged siRNA). Finally, the resultant complex
from this process is relatively apolar with lipophilic alkyl chains on their surface; this complex
therefore is not amenable for distribution in aqueous media. We utilize this incompatibility to
achieve a hydrophobic force driven coating of charge-neutral lipids in aqueous medium. The
concentration of the lipids in this step is such that it does not exhibit self-assembly by itself, but
does so on the surface of the existing hydrophobic exterior of the polymer-siRNA complex. This
symbiotic self-assembly, where the organization of each of these components into the assembly is
dependent on the presence of other components in the system, is thus achieved in three convenient
steps.
3.2.1

Synthesis, characterization and crosslinking study of cationic PDS-Dodecyl polymer

(⊕PPDS/DD)
To achieve the desired self-assembly, a cationic random co-polymer PDS-Dodecyl
polymer (⊕PPDS/DD) was targeted (Figure 3.1a). This copolymer was synthesized via RAFT
polymerization of pyridyl disulfide methacrylate and dodecyl methacrylate monomers (molar ratio
9:1, Figure 3.1) to obtain p(PDSMA-co-DodecylMA) polymer (PPDS/DD; MW =14.5 kDa; Đ: 1.3).
The nitrogens in the PDSMA side-chain were quantitatively methylated using methyl triflate to
achieve the ⊕PPDS/DD polymer (Figure 3.1). All polymers were characterized with 1H, 13C & 1H15

N NMR, GPC and FT-IR spectroscopy. Methylation of the PPDS/DD polymer was confirmed from

the chemical shift and integration of pyridinium ring protons in the final ⊕PPDS/DD polymer. To
further confirm the synthesis of the ⊕PPDS/DD polymer, two-dimensional heteronuclear correlation
NMR experiments (1H-15N HMBC) were performed with the synthesized polymers and 1methylpyridine-2-thione molecule, released after crosslinking with 1,4-dithiothreitol (DTT,
reported in equivalents). A clear shift of

15

N NMR band for ⊕PPDS/DD polymer, in addition to
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appearance of a new correlation band corresponding to methylated nitrogen, confirms successful
installation of cationic charge in the ⊕PPDS/DD polymer. Further, 1H NMR spectra for differentially
crosslinked samples in presence of different amounts of DTT showed the disappearance of the
methylated-PDS units with the concurrent appearance of the peaks that correspond to the small
molecule byproduct of the crosslinking reaction, N-methylpyridothione (Figure 3.1d). These
experiments were carried with the polymer by itself without self-assembling the polymer through
electrostatic complexation with siRNA, for characterization purposes. Note that complete
crosslinking was achieved at 1 equiv DTT (2 times excess than required) which could be attributed
to suppressed reactivity owing to steric barriers.
3.2.2

‘Symbiotic self-assembly’ to create L-siP nanoassemblies
The first step of proposed self-assembly (Scheme 3.1) involves electrostatic complexation

between ⊕PPDS/DD polymer with naked siRNA in acetone:water mixture (70:30 v/v). In addition
to reducing the dielectric constant of the media35 to facilitate greater Coulombic interaction, the
choice of solvent mixture is also optimized for the solubility of both ⊕PPDS/DD polymer & siRNA.
The amphiphilicity of ⊕PPDS/DD polymer, governed by the ratio of cationic PDS and dodecyl
moieties, was also found to affect the solubility of such complexes. We found that 90:10 ratio
polymer exhibited better solubility and complexation capability, compared to that of the initially
attempted 70:30 ratio polymer. All subsequent complexation experiments were conducted with the
90:10 ratio polymer in the acetone:water co-solvent system. To further analyze whether the
observed interaction between the polymer and the siRNA is indeed based on electrostatics, we
conducted molecular dynamics (MD) simulations of a coarse-grained (CG) molecular model of
this system (see experimental for details about the model) in the acetone:water 70:30 mixture.
Simulations show that while the cationic polymers and the oligonucleotides are held together,
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removal of cationic charge in the polymer detaches the oligonucleotides from the polymer chain.
This supports the idea that the self-assembly process is controlled by electrostatic interactions (see
experimental).
The next step in our self-assembly involves structurally reinforcing the complex through a
chemical crosslinking reaction, which concurrently also releases the cationic charge from the
polymer. This crosslinking step was executed using DTT, where the rapid thiol-disulfide exchange
reaction between DTT and the methylated-PDS unit affords a thiol moiety on the polymer side
chain, along with a stable small molecule byproduct, viz. N-methylpyridine-2-thione. The thiol
moiety on the polymer chain can subsequently react with other methylated-PDS units within the
complex to generate crosslinks. Note that this crosslinking step helps to shed positive charge, while
also stitching the polymer chains to cage siRNA, thus preventing the loss of siRNA that is
electrostatically encapsulated in the first step. More details on the effect of crosslinking density is
provided in the next section.
Note that the complexation and crosslinking steps were conducted in an organic rich
(acetone-water) media. In order for using this complex to deliver the siRNA molecule to cells, this
complex must be in an aqueous media. To achieve this, the complex was coated with lipids in
aqueous phase. Since the crosslinked polymer-siRNA complex was achieved in an organic solvent,
we envisaged that the surface of the complex is apolar and would therefore be viable for coating
with lipid molecules. Accordingly, we used a combination of a zwitterionic lipid (DOPE) and a
PEGylated lipid (DSPE PEG-2000), because of their fusogenic and solubilization abilities
respectively.9,36-37 Briefly, a mixture of DOPE and DSPE PEG-2000 lipids was initially dissolved
in water at a concentration much below their critical aggregation concentrations.38 The crosslinked
polymer-siRNA nanoassembly was then added to the aqueous lipid mixture (water/organic=20,
87

Figure 3.2 Effect of N/P ratio & cross-linking on encapsulation stability & siRNA release: (a)
Variation of N/P for uncrosslinked particles; (b) Effect of variation of cross-linking measured by
the DTT feed amount at higher N/P ratio on encapsulation & siRNA release; (c) DLS size
distribution and (d) correlation diagram for N/P 15 nanoassemblies at different cross-linking; (e)
Lipid coated nanoassembly constructed with CG-MD simulation: snapshot of the equilibrated LsiP15/1 (cut in half on the major diameter to clearly see the interior). Polymer is shown in transparent
green, the dsDNA in yellow and the polymer outer layer is transparent grey (inset: exterior of the
NA, where lipids are shown in grey); (f) Radial distribution functions g(r) providing the relative
probability to find polymer, dsDNA and lipids at various distances from the center of the
nanoassembly.
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v/v) for the self-assembly of lipids on its surface (see experimental for details) to produce the final
lipid-polymer-siRNA (L-siP) nanoassembly (Scheme 3.1). Interestingly, the overall self-assembly
process is considered symbiotic, because the lipids are used at concentrations well below their
CACs and yet it self-assembles on the surface of the polymer-siRNA complex, which in itself
required functional complementarity for its formation.
3.2.3

Effect of N/P and crosslinking on complexation and triggered release of siRNA from

L-siP
The relative ratio of complementary charges (N/P) is often used, with number of positively
charged nitrogens (N) in the polymer to the number of negatively charged phosphate moieties (P)
in the nucleic acid as the measure, to evaluate the complexation efficiency. To understand the
effect of this ratio on complexation, we systematically varied the amount of polymer to investigate
the construction of L-siP assemblies at different N/P ratios (Figure 3.2). All particles were coated
with DOPE and PEG-lipids to make them hydrophilic and stable in aqueous medium. The siRNA
encapsulation was evaluated with agarose gel retardation assay (Figure 3.2a-b). First,
complexation was studied at different N/P ratios without any crosslinking. At low polymer
concentrations (N/P of 2.5 and 5), the complexation was found to be inefficient as noted from the
significant presence of free siRNA in the gel. At N/P 7.5 and above, the siRNA encapsulation was
found to be efficient (Figure 3.2a). In addition to the encapsulation efficiency, it is also necessary
that we release the encapsulated siRNA molecules in the presence of a biologically relevant
intracellular trigger.39-40 Therefore, the release of siRNA from these assemblies were assessed in
the presence of a redox-stimulus at a concentration that is similar to that found in the cytosol (10
mM glutathione, GSH). In the presence of this stimulus, the siRNA release was found to be
significant in the N/P 7.5 complex, but was significantly lower at higher N/P ratios (Figure 3.2a).
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However, dynamic light scattering (DLS) measurements revealed non-uniform, bimodal and broad
particle size distributions with poor correlation coefficients for all uncrosslinked nanoassemblies
(see experimental) suggesting unstable nanoparticle formations.
The study of uncrosslinked complexes above provides an initial insight into the optimal
N/P ratios. Note however that in our final complex, the positive charges will be removed through
crosslinking. Therefore, the efficiency of siRNA encapsulation in this scenario might be very
different as the balance between weakening of the complexation due to charge removal and
strengthening the incarceration due to crosslinking would play an important role. To evaluate this
balance, we studied the effect of crosslinking towards the formation of L-siP particles at different
N/P ratios (Figure 3.2b). Upon increasing crosslinking degree, leakage of siRNA was evident from
the assemblies formed at N/P 7.5 and 10. At higher N/P ratios (starting from N/P 15), in
combination with higher crosslinking (0.25 equiv DTT onwards), the siRNA encapsulation was
found to be stable (Figure 3.2b), as evident from narrow particle size distributions with excellent
correlation coefficients. However, the release of siRNA was found to be crosslinking dependent,
where the maximum release was obtained between 0.25-1 equiv of DTT crosslinking. This can be
attributed to the critical balance of positive charge and crosslinking degree in L-siP
nanoassemblies. At lower crosslinking degree (0-0.1 equiv DTT), residual cationic charge left after
DTT treatment becomes the dominating factor and is able to hold back the siRNA tightly in the
nanoassemblies. While at higher crosslinking degree (2 equiv DTT), siRNAs might be deeply
buried and shielded inside the nanoassembly preventing adequate exposure to external reducing
release environment. Evidently, at even higher N/P 25, where the polymeric burden was more,
negligible release of siRNA was observed for similar reasons (Figure 3.2b). Based on these
observations, a threshold of N/P 15 was thus considered as an efficient L-siP system for both
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siRNA encapsulation and release (also see later for quantification). As L-siP nanoassemblies
contain lipids, the zeta potential values were found to be negative (-30 to -40 mV, see
experimental) as an effect of efficient coating of DOPE and PEG- lipids.41-42
To further understand the complexation and release process, we also carried out CG-MD
simulations (see experimental). In our models, to mimic the crosslinking process, we introduced SS- groups in the polymer assembly, while cleaving the positively charged functionalities,
assuming that crosslinking has occurred. When we introduced the crosslinking in the equilibrated
N/P 7.5 model system, we could clearly observe leakage of the oligos from the polymer (see
experimental). Next, we built a molecular model for the more promising N/P 15 L-siP system
(Figure 3.2d and 3.2e). We started from an N/P 15 polymer-oligo network that was spontaneously
formed in 70:30 acetone:water (v/v) via CG-MD simulation (details are available in the
Computational Methods in experimental). Then, we introduced a 100% crosslinking by adding a
suitable number of DTT molecules in the system. To be sure to form a single aggregate in the
center of the simulation box (useful for successful steps) following compaction due to crosslinking,
we used a recently optimized simulation technique that push the system toward a single
aggregation center.43 The DTT molecules selectively and strongly interacted with the -SS- groups
in the polymer during this CG-MD simulation, while after coordination the cationic groups of the
polymer involved in the process have been cleaved. Next, we added DOPE lipid molecules and
replaced the solvent consistently with the experiments (water/organic=20, v/v). We then
equilibrated the L-siP model nanoparticle via CG-MD simulation, which provided us with an
insight into the structure of this assembly at a resolution <5 Å (Figure 3.2d). The lipid layer
(transparent grey) covers the interior of the assembly, where the oligos (yellow) appear as trapped
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Figure 3.3 (a) CG-MD simulation snapshots (taken after 4 µs) showing how the oligo release
proceeds at different degrees of de-crosslinking: no decrosslinking, 90% of crosslinking removed
and complete de-crosslinking; (b) Quantification of the different release behaviors as the number
of contacts between oligo and polymer as a function of simulation time (initial number of contacts
normalized to 1); (c) Ribogreen assay to quantify encapsulated & released siRNA from L-siP15/1;
Summary of encapsulation (d) and release profiles (e) at different N/P & crosslinking ratios
showing the most promising composition to be N/P 15 at 1 equiv DTT crosslinking.
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in the polymer matrix (green). From the equilibrated phase CG-MD trajectory we computed the
radial distribution functions of the polymer, lipid and oligonucleotides (g(r): relative probability
to find these in space) as a function of the distance from the center of the nanoparticle (Figure
3.2e). The superposition of the cyan and purple curves in Figure 3.2e indicates that the polymer
and the oligos are uniformly mixed in the core of the assembly while the lipids cover it and
constitute the shell of the nanoassembly, which resulted well stable L-siP in such experimental
conditions.
Starting from this equilibrated crosslinked L-siP model, we further probed the
nanoassembly to understand the effect of crosslinking on stabilization and release of
oligonucleotides. Upon deleting the lipid shell, we explored the release of encapsulated
oligonucleotides as a function of the de-crosslinking ratio. The polymer-oligo complex remains
stable in 100% DTT, i.e., fully crosslinked condition (Figure 3.3a). However, at 90% decrosslinking (90% of DTT molecules eliminated from the model) we observed partial release of
oligoes from the assembly, which completely disassembled under complete removal of DTT (0%
DTT). Figure 3.3b quantifies these observations, showing the number of contacts between the
polymer and the guest oligos over time calculated with respect to the initially equilibrated
nanoassembly.
We further experimentally confirmed the encapsulation and release of siRNA from the LsiP nanoparticle via RiboGreen assay for the promising N/P 15 case (Figure 3.3c, see
experimental).44 Under the encapsulated state, siRNA is significantly inaccessible to the assay
reagent showing no apparent fluorescence signal generation. However, the amount of siRNA, once
released from the assembly under reducing conditions, the fluorescent signal generation was found
to be dependent on the crosslink density. These observations further support the results obtained
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from the agarose gel retardation study above (Figure 3.2a-b). The degree of siRNA encapsulation
and release obtained from agarose gel studies is summarized in Figure 3.3d and 3.3e.
To further understand the fate of siRNA during encapsulation and release steps, we also
performed

31

P NMR experiments to monitor the processes (see experimental). A

phosphorothioate-modified siRNA (PTsi, δ ~53 ppm) is utilized to distinguish it from the

Figure 3.4 Cryo-TEM images of L-siP particles at N/P 15 (a) without crosslinking & (b) with
cross-linking (DTT-1 equiv), scale: 50 nm; (c) N-STORM confocal microscopy images of single
L-siP15/1 particle, red: cy3-siRNA, green: carboxyfluorescein labelled DSPE-PEG lipid that coats
the polymer-siRNA nanoassembly, scale: 100 nm.
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phosphorus in phosphate groups of DOPE and DSPE-PEG lipids (δ ~0 ppm).45-46 Once
encapsulated the mobility of the siRNA inside the polymer cage will be significantly impaired
compared to its situation in bulk solvent. As a result, the

31

P band at δ ~54 ppm (for PTsi) is

completely eliminated after the formation of L-siP nanoassembly, whereas it reappears upon
subjecting it with the release condition (with 10 mM GSH & Triton X-100, see experimental).45
This evidence further supports the results obtained from agarose gel retardation and RiboGreen
assay studies (Figure 3.2a-b, 3.3c). Evidently, to reduce the quantity of polymer in the L-siP
assembly construction with suitable high crosslinking degree (in context of reducing cytotoxicity
by shedding cationic charge), we chose the L-siP assembly (L-siP15/1) constructed under N/P 15
with crosslinking using 1 equiv of DTT (we choose excess DTT to ensure complete removal of
cationic charge as discussed in Figure 3.1d) as the desired candidate for further cellular
experiments.
3.2.4

Cryo-TEM and N-STORM confocal imaging of L-siP nanoassembly
Prior to evaluating the intracellular delivery of siRNA using these nanoassemblies, we

further characterized the nanoassemblies via cryo-TEM and N-STORM confocal fluorescence
microscopy (Figure 3.4). Cryo-TEM studies were performed for both the N/P 15 uncrosslinked
and crosslinked samples. Images of the uncrosslinked assembly (Figure 3.4a) clearly show a fractal
morphology consisting loose aggregates, whereas crosslinked L-siP15/1 nanoassembly (Figure
3.4b) showed uniform spherical assemblies with an average size of ~100 nm. These results are in
accordance with our earlier DLS observations (Figure 3.2b-c). To further characterize the particle
construction, we prepared L-siP15/1 nanoassembly utilizing carboxy-fluorescein labelled DSPE
PEG-2000 lipid and cy3-labelled siRNA. As per our symbiotic self-assembly hypothesis, polymer
complexed siRNA would dwell in the inner core while the shell would comprise lipid mixture
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Figure 3.5 siRNA delivery in MDA-MB-231 cell line: (a) Cellular uptake of cy3-labelled siRNA
(4 h incubation), scale: 20 µm; (b) Quantification of uptake with flow cytometry (4 h incubation);
(c) Mechanism of siRNA transfection in presence and absence of endocytic inhibitors; (d)
Endosomal colocalization of red cy3-siRNA and Lysotracker blue (pseudo-colored as green) after
4 h and escape after 24 h incubation, scale: 20 µm; (e) Calcein assay showing efficient escape of
calcein from endosome and localization in cytosol in presence of L-siP15/1 NA, scale: 10 µm; (f)
Cellular viability and (g) LDH cytotoxicity assay for empty L-siP, L-siP nanoassemblies with
different siRNA concentrations (25, 50, 100, 200 & 500 nM) at N/P 15 and Lipofectamine (LF)siRNA complexes (with fixed 100 nM siRNA) at 2, 5 and 10 µg/mL LF concentrations; Student’s
t-test (compared L-siP/siNC sample bearing 100 nM siRNA with L-siP/Empty and LF samples):
***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05.

surrounding the electrostatic polymer-siRNA complex. The N-STORM images in Figure 3.4c
clearly demonstrate the L-siP nanoassembly design with red cy3-siRNA comprising the inner part
and green lipid layer encapsulating it externally. Interestingly, color-coded intensity profile
defined by the electron scattering cross-section across the particles also matches the N-STORM
measurements (Figure 3.4c & see experimental).
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3.2.5

Cellular uptake and intracellular distribution
To test the ability of L-siP15/1 towards intracellular delivery of siRNA, we prepared these

nanoassemblies using cy3-labelled siRNA and investigated their cellular distribution in three
different cancer cell lines, viz. mammary gland/breast cancer cell line MDA-MB-231, cervical
cancer cell line HeLa and a prostate cancer cell line DU-145 (Figure 3.5, for MDA-MB-231 and
see experimental for HeLa & DU-145). As shown in Figure 3.5a, a clear distribution of red
fluorescence in the cytosolic region confirms efficient transfection of cy3-siRNA nanoassembly
(Figure 3.5b for flow cytometry quantification). The transfection efficacy was also evaluated in
HeLa and DU-145 cells though confocal laser scanning microscopy (CLSM) (see experimental)
and flow cytometry (see experimental). A quantitative comparison reveals the following order of
uptake potency in different cell lines: MDA-MB-231>HeLa>DU-145.
Next, we probed the cellular uptake mechanism via utilizing different inhibitors for
endocytic pathways in the above-mentioned cell lines through flow cytometry with cy3-siRNA
containing L-siP15/1 nanoassembly (Figure 3.5c & see experimental). EIPA and hyperosmolar
sucrose, inhibitors for macropinocytosis and clathrin-dependent endocytosis, respectively were
found to have a striking effect on uptake in MDA-MB-231 and HeLa cells, whereas the effect of
nystatin, an inhibitor for caveolae-mediated endocytosis, was found to be comparatively
reduced.47-49 These results show that the major cellular internalization proceed through
macropinocytosis and clathrin-dependent pathways for MDA-MB-231 and HeLa cell lines. In
contrary, DU-145 cells only showed a significant decrease in fluorescence intensity when
incubated in presence of EIPA suggesting macropinocytosis being the exclusive choice of uptake
pathway (see experimental).
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To evaluate the intracellular distribution of delivered cy3-siRNA through L-siP15/1
assembly over time, we performed CLSM of MDA-MB-231 cells in presence of endo/lysosomal
stain, lysotracker blue (pseudo-colored in green in Figure 3.5d). After 4 hours of incubation, the
red fluorescence from cy3-siRNA was observed to be co-localized with lysotracker blue (Figure
3.5d), indicating that the nanoassemblies are located in endo/lysosomal compartments.
Interestingly, this co-localization diminishes significantly after 24 h incubation, as indicated by
clear separation of red (cy3-siRNA) and blue (pseudo-colored in green for lysotracker stain)
channels suggesting endosomal disruption and release of siRNA into the cytosol. A quantitative
comparison is reflected in the decrease in co-localization ratio from 0.65 (4 h) to a lower value
0.34 (24 h). The probable reason for such facile intracellular release of siRNA cargo could be
explained from the fusogenicity of DOPE lipid, employed in decorating the L-siP nanoassembly,
through attachment and fusion with anionic endosomal membrane.7
To further investigate whether endosomal disruption is indeed facilitated by L-siP
nanoassemblies, we performed calcein green assay (Figure 3.5e and see experimental). Calcein, a
membrane-impermeable dye, shows punctate green fluorescence above its self-quenching
concentration when entrapped in endo-lysosomal compartments.50 However, the green
fluorescence changes to a bright diffused pattern (dequenched state), if calcein can be released in
cytosol after successful escape from endosomes mediated by delivery agents. As shown in Figure
3.5e & see experimental, the punctate green fluorescence of calcein in control cells confirms the
endosomal entrapment, whereas a diffused fluorescence is observed for L-siP15/1 nanoassembly
treated cells, suggesting efficient endosomolytic activity of the L-siP assemblies.
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3.2.6

Evaluation of cytotoxicity and nuclease stability for L-siP15/1
Stability of the siRNA-polyion based electrostatic complex is mostly guided by the overall

high cationic charge which eventually compromises the safety of the delivery agent increasing
cytotoxicity. To evaluate the safety feature of L-siP15/1 nanoassembly, we evaluated cellular
viability and plasma membrane integrity in MDA-MB-231 (Figure 3.5f-g), HeLa and DU-145 (see
experimental) cell lines. L-siP/siNC nanoassembly (siNC: negative control siRNA) showed ~86%
cellular viability even at 200 nM siRNA concentration (with comparable polymer amount for N/P
15), whereas viability reduces to ~42% for lipofectamine-siRNA sample (LF-siNC) at an identical
concentration (Figure 3.5e). Cytotoxicity study in HeLa and DU-145 cells also demonstrate a high
cellular viability compared to lipofectamine (see experimental).
Next, we were interested in checking the integrity of the plasma membrane through lactate
dehydrogenase (LDH) assay.51-52 The compromised cell membrane would release cytosolic LDH
enzyme into cell culture media which, in turn, can be quantified through an absorbance-based
assay.51-52 Figure 3.5g shows a minimal to no membrane damage mediated by L-siP assemblies
even at a significantly high dosage (200 or 500 nM siRNA). In comparison, LF-siNC samples
showed ~3 to 7-fold increase in membrane damage compared to untreated cells (Figure 3.5g, see
experimental). These results demonstrate significantly less cytotoxicity of the designed L-siP
nanoassembly desirable for a safe delivery agent. As L-siP nanoassembly comprises biocompatible
DOPE/PEG-based lipids and methacrylate-derived polymers, it will be prone to slow hydrolytic
and enzymatic degradation under in vivo conditions with significantly less probability of systemic
accumulation.53-54
One of the bottlenecks of RNAi based technology is the limited stability of naked siRNA
with a plasma half-life of <10 min due to the degradation mediated by serum endonucleases.55
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Figure 3.6 eGFP silencing with L-siP15/1: Confocal microscopy images (a) for eGFP silencing and
flow cytometry data (b) for quantification of eGFP fluorescence in HeLaeGFP cells; scale: 20 µm;
Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05.
Thus, a critical requirement for an efficient delivery agent is to provide end-to-end protection till
the cargo is delivered in the intracellular space. To this goal, we investigated the stability of the
encapsulated siRNA in the presence of RNase A and 10% fetal bovine serum.56-57 After incubation
at different time interval with RNase A and serum, the L-siP/siNC nanoassemblies were subjected
to redox-triggered release condition (10 mM GSH) and evaluated in agarose gel retardation assay.
L-siP nanoassembly is efficient in protecting siRNA even after 24 h of incubation, whereas the
unprotected naked siRNA is completely degraded within 4 h of incubation in presence of RNase
A and serum (see experimental).
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3.2.7

Gene silencing efficacy and retrieval of cytotoxicity mediated through PLK1 & MDR1

siRNAs
Finally, we were interested in checking the efficacy of the L-siP15/1 assembly in silencing
specific gene activity. To this end, HeLaeGFP and DU-145eGFP cells, stably expressing eGFP, were
treated with L-siP15/1 nanoassembly containing 50, 100 and 200 nM GFP-siRNA. The reduction of
green fluorescent intensity was evaluated through CLSM and flow cytometry (Figure 3.6, see
experimental). CLSM images, shown in Figure 3.6a (see experimental), reveals a clear decrease
in green fluorescence intensity for both HeLaeGFP and DU-145eGFP cells upon treatment of L-siP15/1
nanoassembly. Further, the GFP expression (quantified through flow cytometry, Figure 3.6b & see
experimental) was decreased to 43% at 200 nM siRNA concentration (L-siP/siGFP) in HeLaeGFP
cells in comparison to ~84% for negative control siRNA (L-siP/siNC) treated cells. A similar trend
was also observed in DU-145eGFP cells where L-siP/siGFP and L-siP/siNC treated cells showed
50% and 110% eGFP expression, respectively. Lipofectamine RNAiMAX-eGFP siRNA complex
(LF-siGFP), evaluated as positive controls, exhibited reduction of eGFP expression up to 61% and
33% for HeLaeGFP and DU-145eGFP cells, respectively at similar siRNA concentrations.
Encouraged by these results, we further tested the gene knock-down efficacy of the LsiP15/1 nanoassemblies towards two other gene types, PLK1 and MDR1, through evaluation of
mRNA transcription levels by quantitative real-time polymerase chain reaction (qRT-PCR) and
protein expressions by western blot analysis (Figure 3.7). PLK1, a critical controller of mitosis, is
found to be overexpressed in many cancer cells, leading to faster tumor progression.58 On the other
hand, MDR1 gene in multi-drug resistant cells upregulates the expression of drug transporter
proteins, like P-glycoprotein (P-gp).59 Although various small molecule inhibitors for PLK1 and
MDR1 are reported in literature, siRNA-based silencing is considered to be advantageous due to
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Figure 3.7 Gene silencing studies: qRT-PCR (a, b) and western blot (c, d) analysis for (a, c) PLK1
and (b, d) MDR1; Cellular viability mediated by knock-down of (e) PLK1 gene and (f) MDR1
gene (after treatment of doxorubicin for MDR1). Uptake comparison of doxorubicin via confocal
microscopy (g) in untreated and L-siP/siMDR1 treated cells; orthogonal view is for L-siP+Dox
sample; scale: 10 µm; Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05.

its specificity, much reduced toxicity and wide applicability in multiple cancer cells. We separately
constructed L-siP assemblies based on PLK1- & MDR1-siRNA and evaluated the gene knockdown efficacy in MDA-MB-231 and NCI-ADR/RES cell lines, respectively. qRT-PCR studies
showed efficient silencing of both PLK1 and MDR1 genes as evident by the reduced relative gene
expression levels of ~12-18% in cells treated with L-siP nanoassemblies containing PLK1 and
MDR1 siRNAs (Figure 3.7a and 3.7b, at 50 or 100 nM siRNA concentrations). Moreover, western
blot analyses (Figure 3.7c, 3.7d and see experimental) revealed that PLK1 and P-gp protein
expressions were reduced to ~25% and ~31% (~24% and 51% for lipofectamine), respectively
compared to untreated cells.
To further demonstrate the consequence of L-siP nanoassembly mediated siRNA delivery
and gene silencing, cellular viability studies were conducted on both PLK1 and MDR1 transfected
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MDA-MB-231 and NCI-ADR/RES cell lines, respectively. For PLK1 compromised cells (Figure
3.7e), viability was reduced to ~47% for L-siP nanoassembly (~51% for lipofectamine positive
control). Similarly, when treated with anti-cancer drug -doxorubicin (Dox), MDR1 depleted NCIADR/RES cells showed mere ~31% viability compared to ~73% and ~35% for free Dox and
lipofectamine transfected positive control cells, respectively (Figure 3.7f).60 Moreover, CLSM
images (Figure 3.7g) confirm significantly higher red fluorescence intensity in cells from Dox
suggesting efficient penetration of the drug in L-siP nanoassembly (MDR1-siRNA) treated cells,
whereas a rather subdued red fluorescence is observed for only free drug-treated cells.
3.3

Summary
In summary, we report a unique siRNA encapsulation and intracellular delivery approach

by developing a new symbiotic self-assembly strategy of a polymer, siRNA and lipid molecules.
In this approach, the initial complexation with the siRNA is made possible through classical
electrostatic interactions. The key feature here is that this interaction was carried out in a relatively
apolar media that not only enhances the binding affinity between the polymer and the siRNA, but
also facilitates the retention of siRNA within the in situ generated polymer ‘cage’. Note that the
electrostatic complex is converted to a physically incarcerating capsule through a crosslinking
reaction, which concurrently removes the positive charge in the polymer. As the positive charges
are being removed, but before the crosslinking reinforcement is fully in place, the siRNA
molecules could escape the complex. However, the siRNA remains stably encapsulated, because
the bulk environment of this in situ crosslinking reaction is apolar and incompatible. This structure
is then finally camouflaged by the coating of a zwitterionic lipid that also imparts biocompatibility
and endosomolytic ability. We call this process symbiotic, because each of these components
require the other components in the solution in order to provide the final self-assembled structure.
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We have rigorously characterized each of the steps in the self-assembly process, nanoassembly
formation, lipid coverage, cellular internalization and cytosolic release using both experimental
and computational modeling approaches. Efficient gene-silencing mediated by the designed
nanoassembly provides evidence for successful integration and leverage of the built-in molecular
features. We have shown that this self-assembly strategy offers several advantages: (i) reduction
of cytotoxicity from cationic charge-based delivery vectors; (ii) tunability in crosslinking degree
affecting siRNA binding and release efficacy; (iii) a biologically relevant trigger for siRNA
release; (iv) efficient cargo protection from degradation by nucleases; and (v) integrated utility of
the useful features of lipids (biocompatible surface & tuning endosomal escape) and designer
polymers (structural integrity, multivalent interaction & protection). We anticipate that the strategy
reported herein could potentially serve as a safe platform and aid in the development of RNAi
based therapeutics.
3.4
3.4.1

Experimental
Materials & characterizations
Dodecyl

methacrylate,

2,2′-

dithiodipyridine,

4-cyano-4-

(phenylcarbonothioylthio)pentanoic acid, D, L-dithiothreitol (DTT), Glutathione were obtained
from Sigma-Aldrich, USA and were used without further purification unless otherwise mentioned.
2,2′-azobis-(2-methylpropionitrile) (AIBN) was procured from Sigma-Aldrich, USA and purified
by recrystallization before usage. Methyl trifluoromethanesulfonate was procured from Matrix
Scientific, USA. 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (18:1 (Δ9-Cis) PE: DOPE) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene

glycol)-2000]

(ammonium salt, DSPE-PEG2000) lipids were procured from Avanti Polar Lipids. Silencer™
Negative Control No. 1 siRNA (Catalog #: AM4611, proprietary sequence not provided),
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Silencer™ Cy™3-labeled Negative Control No. 1 siRNA (Catalog #: AM4621, proprietary
sequence not provided), Silencer™ GFP (eGFP) siRNA (Catalog #: AM4626, proprietary
sequence not provided) and MDR1/ABCB1-siRNA (sense: 5’-GCUUAACACCCGACUUACAtt3’, antisense: 5’-UGUAAGUCGGGUGUUAAGCtc-3’) were procured from Thermo-Fisher
Scientific.

PLK1-siRNA

was

obtained

from

Qiagen,

USA

(sense:

5’-

CGGGCAAGAUUGUGCCUAATT-3’, antisense: 5’-UUAGGCACAAUCUUGCCCGCG-3’).
Lipofectamine RNAiMAX, LysoTracker™ Blue DND-22, were obtained from Thermo-Fisher
Scientific.

Phosphorothioate

siRNA

(PTsi)

was

obtained

from

Dharmacon

(sense:

A*U*G*U*A*U*U*G*G*C*C*U*G*U*A*U*U*A*G, antisense: C*U*A*A*U*A*C*A*G*G
*C*C*A*A*U*A*C*A*U; * denotes phosphorothioate modifications).
3.4.2

Synthesis of random co-polymer for complexation with siRNA

3.4.2.1 Synthesis of p(PDSMA-co-DodecylMA) polymer (PPDS/DD)
Pyridyl disulfide ethyl methacrylate (PDSMA) was synthesized using previously reported
procedure. Reversible Addition-Fragmentation chain Transfer (RAFT) polymerization was
utilized to synthesize p(PDSMA-co-DodecylMA) Polymer. In a typical procedure, PDSMA (0.903
g,

3.5

mmol),

dodecyl

methacrylate

and

chain

transfer

agent

4-cyano-4-

(phenylcarbonothioylthio)pentanoic acid were taken in a 25 mL Schlenk flask and dissolved in 2
mL dry THF. To this mixture, 1.1 mg (0.007 mmol) AIBN, dissolved in 1 mL dry THF, was added.
The solution was mixed for 5 min, the flask was subjected to three freeze-pump-thaw cycles and
purged with argon. Finally, the sealed flask was transferred to a preheated oil-bath and the
polymerization was carried out at 70 °C for 24 h. After that, the Schlenk flask was cooled down to
quench the reaction and THF was evaporated. The reaction mixture was purified by precipitating
in diethyl ether for three times and finally dried in vacuo for overnight at room temperature. Yield:
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78%, GPC (THF) Mn: 14.5 kDa, Đ: 1.3; 1H NMR (400 MHz, CDCl3): δ ppm 4.24−4.09, 3.87,
3.65−3.53, 3.37, 2.95-2.90, 1.93-1.84, 1.04-0.89; 13C NMR (100 MHz, CDCl3): δ ppm 177.4,
177.07, 176.34, 159.69, 159.56, 159.5, 149.87, 137.31, 121.07, 120.01, 119.96, 62.84, 54.47,
45.34, 45.28, 45.00, 32.06, 31.71, 29.80, 29.50, 29.18, 25.41, 22.83, 14.25, 11.56.
3.4.2.2

Synthesis of cationic-PDS-dodecyl polymer (⊕PPDS/DD)

In a 20 mL glass vial, 0.75 g of PPDS/DD polymer was weighed and dissolved in 5 mL DCM. The
solution was cooled in ice for 10 min and after that methyl trifluoromethanesulfonate (0.73 g, 4.4
mmol) was added to it dropwise. The mixture was stirred at 4 °C overnight, the solvent was dried
and precipitated in diethyl ether three times to purify. The polymer was dried overnight in vacuo
at room temperature. Yield: 75%, calculated Mn: ~22 kDa; 1H NMR (400 MHz, CDCl3): δ ppm
4.24−4.09, 3.87, 3.65−3.53, 3.37, 2.95-2.90, 1.93-1.84, 1.04-0.89; 13C NMR (100 MHz, CDCl3):
δ ppm 177.33, 159.3, 159.13, 147.57, 144.35, 125.51, 124.03, 122.05, 115.7, 62.51, 45.7, 45.13,
44.86, 37.1, 36.97, 31.73, 31.35, 29.43, 22.4, 19.08, 16.95, 13.02.
3.4.3

Characterization of polymers

(a) Gel permeation chromatography (GPC)
GPC of PPDS/DD polymer was performed in Agilent 1260 LC instrument with a refractive index
detector using THF as the eluent and molecular weights were calculated against poly(methyl
methacrylate, PMMA) standards.
(b) 1H, 13C, 1H-15N & 31P NMR
1

H, 13C and 31P NMR spectra of the samples were recorded on a Bruker NMR spectrometer (400.13

MHz for 1H, 100.62 MHz for 13C & 161.97 MHz for 31P). 2D NMR (1H-15N Heteronuclear

106

Figure 3.8 1H NMR spectra of (a) PPDS/DD and (b) ⊕PPDS/DD polymers.
Multiple Bond Correlation, HMBC) correlation spectra were acquired on Bruker NMR
spectrometer (500.13 MHz for 1H, 50.68 MHz for 15N).
Molar ratio between the PDSMA and DodecylMA monomers for PPDS/DD polymer was calculated
from the ratio of the integrations of -CH2 protons adjacent to the methacrylate monomers
(PDSMA, δ 4.21 and DocecylMA, δ 3.9 with x:y= 9:1).
(c) FT-IR spectra
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FT-IR spectra of the polymers was recorded on a Bruker Alpha FT-IR (ATR) spectrometer from
3500 cm−1 - 400 cm−1 range.
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Figure 3.9 1H-15N HMBC spectra of 1-methylpyridine-2-thione, PPDS/DD and ⊕PPDS/DD polymers.
The absence of some correlation peaks with ring protons for the ⊕PPDS/DD polymer can be
attributed to the short T2 (spin-spin) relaxation which can be approximately calculated as,
T2≈1/(πδ1/2), where δ is peak width at half height. For macromolecules like polymers, signals
from protons with short T2 often do not survive the 2D pulses that keep magnetization along xy
plane. This also suggests slower molecular reorientation of cationic pyridine ring protons
compared to the N-methyl protons.
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Figure 3.10 Gel permeation chromatography of PPDS/DD polymer.
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Figure 3.11 FT-IR spectra of PPDS/DD and ⊕PPDS/DD polymers. A band at 1617 cm-1 is observed
for N-methylated pyridinium polymer (⊕PPDS/DD) characteristic of C=N vibration related to
quaternary nitrogen atom in the ring. This band is absent in the PPDS/DD polymer. The pyridine ring
low intensity band (PPDS/DD polymer) at 1485 cm-1 due to conjugated C=C and C=N bonds become
stronger in the ⊕PPDS/DD polymer spectra. C=O stretching at 1718/1722 cm-1 is used as calibration
peak for both polymers.

3.4.4

Study of siRNA encapsulation with varying dosages of ⊕PPDS/DD polymer (at different

N/P ratios)
3.4.4.1

Preparation of L-siP nanoassembly without crosslinking
To study the effect of N/P ratio on complexation, two different sets of solutions were

prepared containing siRNA and ⊕PPDS/DD in a mixed solvent system (acetone:water=70:30). In
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first set, a fixed amount of siRNA (2 µg) was dosed in acetone/water solvent mixtures (70:30) to
get 50 µL identical solutions. In another set, different amounts ⊕PPDS/DD polymer solution (2
mg/mL in acetone:water= 70:30) were diluted with same mixed solvent system to achieve another
50 µL solutions. Afterwards, the polymer solutions were added to the fixed amount siRNA
solutions (containing 2 µg siRNA) to finally achieve N/P ratios of 5, 7.5, 10, 15, 20 and 25. All
these mixed solutions were incubated for 2h in an orbital shaker at 20 °C to facilitate complexation.
Meanwhile, mixed lipid solutions were prepared in 2 mL water containing 20% wt./wt. DOPE &
10 mol% DSPE-PEG (based on ⊕PPDS/DD polymer) and stirred for 30 min. Next, each of 100 µL
nanoassembly solutions, after 2 h complexation period, was added to an aqueous pool of lipid
mixture and stirred for 3 h at 20 °C. In this step, the glass vials were kept open to facilitate the
evaporation of organic solvents and maturation/hardening of the nanoassemblies. Finally, the
solutions were filtered through Amicon Ultra Centrifugal Filters MWCO 10 kDa to remove
remaining organic solvents, purify and concentrate the solutions. The final volume of L-siP
nanoassembly solutions was adjusted to 100 μL with nuclease-free deionized water.
3.4.4.2

Preparation of L-siP nanoassembly with crosslinking
Crosslinking of L-siP nanoassemblies were achieved by introducing DTT solutions after

the complexation step. Different amounts of DTT (0.1, 0.25, 0.5, 1 and 2 equivalents with respect
to PDS moiety in ⊕PPDS/DD polymer) dissolved in acetone/water (70:30) mix solvent were added
to the siRNA-polymer mixtures after 2 h complexation step. Each solution was incubated in an
orbital shaker at 20 °C for another 2 h. After that all solutions were subjected to lipid locating step.
3.4.5
3.4.5.1

Agarose-gel retardation assay for proof of complexation & siRNA release
Encapsulation study
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20 µL samples (with different N/P ratios and varying crosslinking) were mixed with 4 µL
of gel loading buffer and loaded into 2% agarose gel made in TAE buffer containing EtBr. Samples
were run in horizontal electrophoresis system at 110 V for 1 h and subjected to imaging analysis
with NuGenius gel imager system (Syngene).
3.4.5.2

Release study
20 µL sample was mixed with 1 µL Triton-x (0.1 g/mL) and sonicated for 5 min. Next, 250

mM glutathione solution was added to it and the pH was adjusted to ~7-8 with 1 N NaOH solution
(final glutathione concentration was 10 mM). The mixture was incubated for 6 h at 37 °C and
subjected to agarose gel electrophoresis and visualization method as described above.
3.4.6

MD-simulations: modelling for encapsulation & release
Construction of coarse-grained (CG) models, simulation parameters, features of N/P 7.5

and 15 systems, DTT crosslinking, Construction of complete L-siP nanoassembly and release
simulations of siRNA are described in detail in Supporting Information. Here, we have decided to
use dsDNA as our CG models are based on the MARTINI force field, for which reliable dsDNA
parameters are already available in literature. However, our choice is justified also by the fact that,
at the level of precision of our CG models, the difference between dsDNA and siRNA is likely to
be negligible, given the electrostatic nature of self-assembly in this system and the fact that the
charges would be the same in molecules of same lengths.
3.4.7

MD-simulation details about modelling for encapsulation & release

CG models – The CG model for the cationic PDS-Dodecyl polymer (⊕PPDS/DD) has been built
based on the popular MARTINI force field. The CG structure has been mapped from an all atom
(AA) structure of the polymer, while the appropriate CG MARTINI beads have been selected to
preserve the different hydrophobicity of the mapped chemical groups. Experiments have been
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conducted using double strand dsRNA fragments, which are rigid charged molecules. For
convenience, the CG simulations have been conducted using rigid 20-bp dsDNA segments of the
same length instead of RNA, given the availability of a reliable MARTINI model for DNA (using
dsDNA instead of dsRNA make little difference in our models, as the aggregation is controlled by
electrostatic interactions and that can be both thought of as rigid charged cylindrical molecules).
DTT has been mapped consistently on an AA model. The DTT CG model is composed of four CG
beads – two central SP2 beads plus two terminal SC5 beads. The interaction between the DTT
terminal SC5 beads and the first SC5 bead of the PDSMA chains has been then artificially strongly
enhanced, to mimic the effect of DTT crosslinking ((i) strong selective spontaneous coordination
and (ii) formation of stable bonds).

Figure 3.12 Coarse grained (CG) representation of the cationic-PDS-Dodecyl polymer
(⊕PPDS/DD). The CG MARTINI beads used in the model are indicated in the figure. SQ0 beads are
charged (+1e). When modelling crosslinking, (i) the interaction of the first SC5 bead of the
PDSMA chain with DTT has been artificially augmented to observe the spontaneous formation of
stable (not breakable) bonds, and (ii) the side groups coordinated to DTT have been then detached
from the rest of the polymer.
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Figure 3.13 CG-MD simulations at N/P 7.5 ratio showing the leakage of oligonuclueotides from
the polymers following to crosslinking (insertion of DTT molecules). (a) The self-assembled
system before DTT insertion appears as a quite loose network, kept together mainly by electrostatic
interactions. When DTT crosslinking happens, polymers undergo compaction and the guest
nucleotides detach form the polymer chains due to the loss of electrostatic interactions. (b)
Quantification of the leakage: number of polymer-polymer and polymer-dsDNA contacts as a
function of the CG-MD simulation time after the insertion of DTT.
Simulation parameters – All simulations have been performed with the GROMACS molecular
dynamics suite, patched with the PLUMED plugin. In production runs, we used the MD integrator
with a time step of 20 fs, the v-rescale thermostat with a time constant of 2 ps and the ParrinelloRahman barostat with a time constant of 8 ps.
Aggregation in N/P 7.5 and N/P 15 systems – We built the two systems by inserting 6 (or 12)
dsDNA chains in a simulation box containing the same amount (58) of cationic polymer chains, a
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70:30 acetone:water mixture and monovalent counterions to ensure charge neutrality of the system.
In both systems, we observed spontaneous aggregation between the dsDNA fragments and the
cationic polymer chains, led by the electrostatic interaction between their oppositely charged
groups. The final aggregates in 70:30 acetone:water appeared as quite loose and not very dense),
consistent with experimental observations of the systems before the insertion of DTT.
DTT crosslinking – The effect of crosslinking has been mimicked in two steps: (i) the insertion of
DTT molecules that selectively bind to the S-S groups of the polymers and (ii) the cleavage of
positively charged groups of the polymers. For (i), we first imposed an artificially strong
interaction between the terminal DTT CG beads and the first SC5 beads in the side charged groups
of the polymer) – this allowed us to model the spontaneous coordination of DTT to those side
groups that are really accessible by DTT molecules. Then (ii), the side charged groups coordinated
to DTT have been detached from the rest of the polymer (deletion of the explicit bonds), and the
SQ0 bead has been turned neutral, consistent with the experimental process.
Creation of the L-siP nanoparticle for the N/P 15 system – To create a model of the L-siP
nanoparticle, we started from the self-assembled polymer-dsDNA system at N/P 15 and introduced
a 100% crosslinking as described above. We replaced the 70:30 acetone:water mixture with a
(more polar) 20:1 water:acetone solvent mixture, coherent with the experiments, and introduced
in the system enough DOPE lipids to cover the assembled aggregate surface. In order to obtain a
single aggregate at the center of the simulation box, we used a recently optimized simulation
technique (involving the use of PLUMED plugin) that drives the spontaneous assembly of selfassembling molecules toward a single aggregation center (instead of forming multiple nuclei,
which slow down the aggregation process). The system has been then equilibrated for 4 µs of CG-
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MD simulation. The radial distribution functions of Figure 3.2f have been calculated with the gmx
rdf tool of the GROMACS suite and normalized to have the same integral.
Release simulations – To model the release of dsDNA fragments at different crosslinking
conditions, we started from the equilibrated L-siP nanoparticle at N/P 15 ratio and 100% of
crosslinking (1 equiv DTT). We removed the DOPE lipid molecules and performed 3 different
simulations: one keeping all coordinated DTT in the system (100% crosslinking), one removing
90% of the DTT molecules (thus, effectively simulating a residual 10% crosslinking condition)
and a last one removing all the DTT (0% residual crosslinking). The dsDNA release has been
quantified by monitoring the number of contacts between the polymer and the guest oligos in time
during the CG-MD run calculated with gmx mindist and normalized dividing by the initial value
(corresponding to the equilibrated L-siP nanoparticle).
3.4.8

Visualization of L-siP nanoassembly with N-STORM confocal microscope
For N-STORM imaging, cy3-labelled siRNA loaded L-siP nanoassemblies were prepared

and the outer lipid layer of the nanoassembly was incorporated with carboxyfluorescein labelled
PEG-lipid (18:0 PEG2000 PE CF). The particles were first deposited on a L-lysine coated 35 mm
glass bottomed petri-dish and incubated at room temperature for 15 min. Next, excess solution was
withdrawn and gently washed with nuclease free water to remove loosely bound particles. Finally,
imaging buffers (5% m/v glucose, 0.1 M MEA, 1 mg/mL glucose oxidase and catalase) were added
to the wet petri-dish and transferred to NIKON confocal/N-STORM set-up for imaging (100X
TIRF objective, excitation at 488 & 561 nm).
3.4.9

Measurement of DLS and Zeta-potentials for L-siP nanoassemblies

Dynamic light scattering (DLS) and zeta potential measurements were performed using a Malvern
Nanozetasizer-ZS. Prepared L-siP nanoassembly and control samples were diluted with Milli-Q
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water (50 µL sample added to 850 µL water) before subjected to particle size and zeta potential
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Figure 3.14 DLS size distribution (a) and correlation diagram (b) of uncrosslinked particles at different
N/P ratios.
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Figure 3.15 Zeta potential measurements for (a) uncrosslinked samples at different N/P ratios; (b)
for L-siP15/1 with varying crosslinking; (c) lipids and mixture of (lipids + ⊕PPDS/DD). At higher
N/P ratio and crosslinking density zeta potential decrease upto ~10 mV. Note that the zeta potential
is not expected to show a significant change as the lipds layers are surrounding the particles in all
cases which shows negative zeta potentials.

3.4.10 Encapsulation efficiency and loading capacity
As in N/P 15 with 1 equiv. DTT crosslinking condition, there was no unencapsulated siRNA
band observed in agarose gel electrophoresis, the encapsulation efficacy for L-siP15/1
nanoassembly was 100%.
The loading capacity for L-siP15/1 nanoassembly is calculated based on the following formula:
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LC, %

amount of encapsulated siRNA
amount of polymer

100

LC for L-siP15/1 nanoassembly was found to be (2 µg*100/27 µg=) 7.4%.
L-siP (with PTsi) + GSH

L-siP (with PTsi & Lipid)

⊕PPDS/DD + PTsi

Phosphorothioate-siRNA (PTsi)

PTsi

Lipids

Figure 3.16 31P NMR spectra indicating peaks from phosphorothioate-siRNA (PTsi, δ 53.5655.97 ppm) and lipids (δ ~0 ppm). For crosslinked ⊕PPDS/DD + PTsi and final L-siP (with PTsi &
Lipid) samples, no 31P peak from siRNA is observed due to complexation, whereas peak from
lipid coating is visible. Once PTsi is released from L-siP nanoassembly, it becomes visible again
in 31P NMR.

Figure 3.17 Color-coded intensity profiling of a single L-siP15/1 nanoassembly showing a dense
crosslinked polymer core with relatively light external lipid coating, scale: 50 nm.
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3.4.11 Cryo-TEM study of L-siP nanoassemblies-N/P 15- crosslinked (1 equiv DTT) &
uncrosslinked
Cryo Transmission Electron Microscopy was performed using FEI (Fisher Scientific) Tecnai
T12 instrument operated at 120 kV using a Gatan 636 cryo-transfer holder. Imaging was done
under low dose conditions. Samples were prepared using a FEI (Fisher Scientific) Vitrobot MKII
using liquid ethane. Lacey Carbon on 200 mesh Copper Grids were glow discharged for 30 s prior
usage.
3.4.12 Quantification of siRNA encapsulation & release for L-siP nanoassembly through
Quant-iT™ RiboGreen assay
To generate a standard curve of free siRNA, different concentrations of negative control siRNA
solutions were prepared in nuclease-free water as per the manufacturer’s protocol. L-siP
nanoassemblies encapsulated with negative control siRNA with differential crosslinking density
were diluted with TE buffer and mixed with RiboGreen reagent in a black 96 well plate. Another
set of L-siP nanoassemblies were subjected to glutathione mediated release condition at first; then
mixed with buffer and RiboGreen reagent. Samples were incubated at room temperature for 5 min
and then subjected to fluorescence measurements in SpectraMax® M5 fluorescence microplate
reader (excitation: 480 nm, emission: 520 nm).
3.4.13 Cell culture
HeLa (cervical cancer), DU 145 (prostate cancer) , MDA-MB-231 (mammary gland/breast
cancer), NCI/ADR-RES (derived from the ovarian cell line OVCAR-8/Adriamycin (Doxorubicin
or Dox) resistant, procured from NCI, Frederick), HeLaeGFP and DU 145eGFP (eGFP transfected)
cell lines were cultured in 100 mm cell culture petri-dish containing Dulbecco’s Modified Eagle
Medium/Nutrient Mixture F-12 (DMEM/F12) in a humidified incubator with 5% CO2 at 37 °C.
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Culture media was supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and 1%
antibiotic-antimycotic (100 units/mL of penicillin, 100 μg/mL of streptomycin, and 0.25 μg/mL of
Amphotericin B).
3.4.14 Cellular internalization, endosomal escape and L-siP nanoassembly stability studies

Figure 3.18 Cellular uptake of cy3-labelled siRNA in HeLa, DU-145 and MDA-MB-231 cell
lines, scale: 20 µm.
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3.4.14.1 Cellular internalization studies
(a)

Confocal microscopy
5

HeLa, DU 145 and MDA-MB-231 cell lines were seeded at 1×10 cells/mL density (1 mL)
in 35 mm glass-bottomed petri-dishes and cultured for 3 days at 37°C and 5% CO2 incubator for
proper adhesion. Afterwards cells were washed three times with PBS buffer and incubated with LsiP nanoassemblies containing 100 nM cy3-siRNA in 1 mL serum-free media at 37 °C for 4 h.
Next, the media was removed, washed three times with PBS and incubated with NucBlue™ Live
ReadyProbes™ reagent in FBS containing media for 1 h to stain cell nucleus. Live cell imaging
was performed using Nikon Spectral A1+ confocal microscope. All images were analyzed with
Nikon NIS-Elements software.
(b) Flow cytometry for uptake quantification
5

HeLa, DU 145 and MDA-MB-231 cell lines were seeded at 1×10 cells/mL density (1 mL)
in 12 well plate and cultured for 1 day at 37°C and 5% CO2 incubator. Next, cells were washed
three times with PBS buffer and incubated with L-siP nanoassemblies containing 100 nM cy3siRNA in 1 mL serum-free media at 37 °C for 4 h. Next, cells were washed with cold PBS and
trypsinized (0.25% trypsin-EDTA solution) for 10 min to remove non-internalized samples from
cell surface and de-touch from well plate. Cells were pelleted by centrifugation, washed two times
with cold PBS and finally re-suspended with 500 µL cold PBS for flow cytometry analysis in BD
LSRFortessa™ instrument. Data analyses was performed with FlowJo software to obtain
fluorescence intensities of cell samples.
(c) Mechanism of cellular uptake
HeLa, DU 145 and MDA-MB-231 cell lines were seeded at 1.2×105 cells/mL density (1 mL) in
12 well plate and cultured for 1 day at 37°C and 5% CO2 incubator. Next, cells were washed
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Figure 3.19 Quantification of cellular uptake and mechanism of siRNA transfection in presence
and absence of endocytic inhibitors for Hela, DU-145 and MDA-MB-231 cell lines through flow
cytometry (a, c: bar graph; b, d: histogram plots).
with PBS and pre-incubated with EIPA (100 µM, macro-pinocytosis pathway), Nystatin (30 µM,
caveolin pathway) and Hyper-osmolar sucrose (45 mM, clathrine pathway) in serum-free media
for 1 h at 37°C. After pre-incubation step, cells were co-incubated for another 1 h with L-siP
nanoassemblies loaded with cy3-siRNA (50 nM, 1 mL serum-free media) and different inhibitors
with final concentrations mentioned above. Untreated and L-siP-cy3-siRNA treated cells without
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any inhibitor were used as negative and positive controls, respectively. Next, cells were harvested
as described before for flow cytometry analysis.
3.4.14.2 Endosomal escape
5

MDA-MB-231 cells were seeded at 1.5×10 cells/mL density (1 mL) in 35 mm glassbottomed petri-dishes and cultured for 1 day at 37°C and 5% CO2 incubator.

Figure 3.20 Calcein assay for MDA-MB-231 cells: z projection (with 2 µm increment) and
orthogonal view, scale: 20 µm.

(a) Colocalization of Lysotracker Blue-cy3 siRNA
To study the endosomal escape, cells were washed with PBS three times and incubated
with 100 nM cy3-siRNA L-siP nanoassemblies for 4 h in serum-free media. Next, one set of
samples was subjected to confocal imaging after endosome staining and the other set was
incubated for 24 h in complete media before subjecting to endosome staining and confocal
microscopy. Lysotracker blue was used to stain endosomes as per manufacturer’s protocol. Live
cell imaging was performed using Nikon Spectral A1+ confocal microscope. To improve visibility,
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Lysotracker Blue stain in the images was pseud-colored with green and colocalization with red
cy3-siRNA was studied. All images were analyzed with Nikon NIS-Elements 4.0 software.
(b) Calcein assay
Cells were transfected with negative control siRNA loaded L-siP nanoassembly (100 nM
siRNA) and 100 µM calcein for 8 h in serum-free media. Next, those were washed three times
with PBS and incubated with complete media for another 2 h. A control set of cells was generated
with only calcein treatment (without L-siP). Before subjecting to CLSM study, cell nucleus was
stained with NucBlue™ Live ReadyProbes™ reagent. Cells were imaged with Nikon Spinning
Disk Confocal Microscope (excitation 488 nm laser) and data was analysed with Nikon NISElements software.
3.4.14.3

Stability of L-siP nanoassembly in presence of RNase A and serum

To test the L-siP nanoassemblies stability in presence of RNase A, 15 µL of L-siP
nanoassembly solution (N/P 15, 1 equiv DTT crosslinked) was mixed with 1 uL RNase A solution
(50 µg/mL) or serum (10% v/v) and incubated at 37 °C for different time intervals. After that, 2
µL of EDTA (0.5 M) and 2 µL SDS (100 mM) were added to it and heated at 60 °C for 5 min.
Afterwards, samples were subjected to glutathione (10 mM) based release conditions and finally
loaded into 2% agarose gel (EtBr stained) to check the band intensity. For control, equal amount
of naked siRNA was subjected to the identical conditions.
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Figure 3.21 Stability assessment of siRNA (Naked or L-siP15/1) in presence of RNase A and 10%
Serum at 37 °C.
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Figure 3.22 Cellular viability of (a) HeLa and (b) DU-145 cells in presence of L-siP nanoassembly
at different loaded concentrations of siRNA; L-siP/Empty: crosslinked nanoassembly without
siRNA (with same polymer concentrations as in L-siP/siNC); siNC: negative control siRNA; LF:
Lipofectamine; Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05.
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Figure 3.23 Cytotoxicity measured by LDH assay in (a) HeLa and (b) DU-145 cells in presence
of L-siP nanoassembly at different loaded concentrations of siRNA; L-siP/Empty: crosslinked
nanoassembly without siRNA (with same polymer concentrations as in L-siP/siNC); siNC:
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negative control siRNA; LF: Lipofectamine; Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns
(non-significant)>0.05.
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Figure 3.24 Comparison of cytotoxicity measured by (a) cellular viability and (b)
LDH assay in MDA-MB-231, HeLa and DU-145 cells in presence of L-siP
nanoassembly (empty, cross-linked nanoassembly without siRNA) and
Lipofectamine RNAiMAX at different concentrations of polymer and lipofectamine
(1, 2, 4, 8 and 10 µg/mL, which corresponds to 25, 50, 100, 200 and 500 nM siRNA
incorporated L-siP in Figure 5.5f-g).
3.4.15 Toxicity studies of L-siP nanoassemblies in HeLa/DU-145/MDA-MB-231 cell lines
3.4.15.1 AlamarBlue assay for cellular viability
3

HeLa, DU 145 and MDA-MB-231 cells were seeded (7.5 ×10 cells in 0.1 mL per well)
into 96-well tissue culture plates and incubated at 37 °C. After 24 h, cell culture media was
replaced with serum-free media containing L-siP nanoassemblies bearing different concentrations
of negative control siRNA (25, 50, 100, 200 and 500 nM). Identical control crosslinked
nanoassemblies devoid of any siRNA, L-siP(empty), were also tested for toxicity. Lipofectamine®
RNAiMAX was complexed at different dosages (2, 5 and 10 µg/mL) with negative control siRNA
(at 100 nM) and compared with other samples. After 24 h incubation, media was replaced with
complete fresh one and incubated for another 2 days (72 h in total). After that cells were washed
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with PBS for three times and each well was treated with 100 μL 10% alamarBlue in complete
media. Finally, cells were incubated for 1 h at 37 °C and solutions were transferred to black 96well flat-bottomed plate for fluorescence measurement with SpectraMax® M5 microplate reader
(excitation: 560 nm, emission: 590 nm).
3.4.15.2 LDH cytotoxicity assay for membrane damage studies
For LDH assay, all cells were incubated with L-siP nanoassembliess for 24 h and then subjected
to Pierce LDH cytotoxicity assay.61 50 µL of media was collected from 96 well cell culture plate
and transferred to another 96 well plate. To that solution 50 µL LDH reaction mixture was added
and incubated at room temperature for 30 min. Next, 50 µL stop solution was added to each well
and subjected to absorbance measurements with SpectraMax® M5 microplate reader at 490 nm
and 680 nm (cytotoxicity was calculated based on absorbance, A= A490-A680).
3.4.16 Gene silencing studies

Figure 3.25 eGFP silencing with L-siP15/1 in DU-145eGFP cells: (a) Confocal microscopy
images and (b) flow cytometry data for quantification of eGFP fluorescence, respectively; scale:
20 µm; Student’s t-test: ***p<0.001, **p<0.01, *p<0.05, ns (non-significant)>0.05.

3.4.16.1 Knockdown of GFP in GFP-transfected HeLa & DU-145 cell lines through flow
cytometry & confocal microscopy
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To study the gene silencing, GFP-transfected HeLa and DU-145 cells were plated in 12
well plate (5× 104 cells in each well) and incubated for 24 h at 37 °C. After that cells were
transfected with GFP-siRNA loaded L-siP nanoassemblies (50, 100 & 200 nM siRNA
concentrations) and incubated for 24 h. Next, media was replaced with fresh one and incubated for
another 24 h at 37 °C. Finally, cells were trypsinized, pelleted by centrifugation and washed two
times with PBS followed by suspension in 500 µL PBS. Flow cytometry was performed with this
cell suspension in a BD LSRFortessa™ instrument (excitation wavelength: 488 nm, FITC channel)
to check the reduction in GFP fluorescence intensity. FlowJo version 10 software was used to
analyze data and obtain fluorescence intensities of the samples.
5

For confocal microscopy analyses for GFP-silencing, 1×10 cells were plated in 35 mm glassbottomed petri-dishes and incubated for 3 days at 37°C and 5% CO2 incubator for proper adhesion.
Afterwards cells were transfected with L-siP-GFP-siRNA nanoassemblies, incubated for 24 h,
washed and subjected to further 24 h incubation before subjecting to washed three times with PBS
buffer and incubated with L-siP nanoassemblies containing 100 nM cy3-siRNA in 1 mL serumfree media at 37 °C for 24 h. Next, the media was removed, washed three times with PBS and
incubated with NucBlue™ Live ReadyProbes™ reagent in FBS containing media for 1 h to stain
cell nucleus. Live cell imaging was performed using Nikon Spinning Disk confocal microscope.
All images were analyzed with Nikon NIS-Elements software.
3.4.16.2 Knockdown of PLK1 in MDA-MB-231 and MDR1 in NCI-ADR/RES cell lines
through qPCR & western blot studies
1.5 × 105 cells were plated in 6 well tissue culture plate, incubated for 24 h at 37 °C- 5%
CO2 atmosphere and then transfected with L-siP nanoassemblies containing PLK1 and MDR1
siRNA (at 50 & 100 nM siRNA concentration) for MDA-MB-231 & NCI-ADR/RES cells,
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respectively. Control samples containing L-siP nanoassemblies without siRNA, untreated cells and
only siRNA treated cells were subjected to similar conditions. After transfection (24 h), media was
changed and incubated at 37 °C- 5% CO2 atmosphere for another 24 h.
qPCR studies
Finally, cells were washed and total RNA was isolated by RNA extraction kit (High Pure RNA
Isolation Kit, Roche) according to manufacturer’s protocol. Isolated RNAs were checked for purity
and concentrations by measuring absorbances at 260/280 nm.
Next, cDNA synthesis was performed with iScript cDNA synthesis kit (Bio-Rad Laboratories)
from the isolated RNA. After that, RT-PCR was performed using the synthesized cDNA, PerfeCTa
MultiPlex qPCR SuperMix (Low ROX) and Taqman probes for PLK1, MDR1 and control β-actin
genes in Mx3005P qPCR System (Stratagene/Agilent). Target gene expression levels were
normalized and reported as fold increase compared to β-actin using the ΔΔCT method.
Western blot analyses
To isolate total proteins, cells were washed with cold PBS buffer once and scraped to de-touch
from the plate and transferred with cold PBS to an eppendorf tube. Afterwards, cells were
pelletized by centrifugation, washed with cold PBS twice to remove proteins from media. Next,
RIPA lysis buffer containing protease/phosphatase inhibitor mix was added to the cell pellet
keeping it in ice and incubated for 15 min, followed by 3×30 s sonication to ensure complete lysis
of cells. Finally, lysed cells were centrifuged at 14000 rpm - 4 °C to collect soluble protein extracts
and quantified with 660 nm protein assay.
Western blot analyses were performed to identify PLK1 and MDR1/P-gp protein levels in cells.
Rabbit monoclonal antibodies (PLK1, MDR1/ABCB1 & β-Actin mAbs, Cell Signaling) were used
to detect target proteins and loading control. HRP-linked anti-rabbit IgG was used as secondary
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antibody and proteins bands were detected by enhanced chemiluminescence (ECL) reagent
(Luminol, coumaric acid and H2O2).
3.4.17

Cellular viability post-PLK1 and MDR1 knockdown
MDA-MB-231 and NCI/ADR-RES cells were seeded at a density of 5×103 cells/well/100

µL in 96-well tissue culture plate. After 24 h incubation, media well removed and treated with LsiP nanoassemblies loaded with PLK1 siRNA (for MDA-MB-231 cells) and MDR1 siRNA (for
NCI/ADR-RES) at final siRNA concentration of 100 nM in serum-free media. Control sets of
samples were also subjected to identical conditions. After 24 h incubation, media was replaced
with fresh complete one and incubated for another 48 h.
For PLK1 siRNA treated samples, cells were subjected to alamarBlue assay (as described in
manuscript). For MDR1-siRNA treated samples, media was removed, treated with 10 µM
doxorubicin in complete media and incubated for another 48 h. After that cells were subjected to
alamarBlue assay (as described in manuscript).
3.4.18

Uptake of doxorubicin in NCI/ADR-RES cells after MDR1 knockdown
5

NCI/ADR-RES cells were seeded at 1×10 cells/mL density (1 mL) in 35 mm glassbottomed petri-dishes and cultured for 3 days at 37°C and 5% CO2 incubator for proper adhesion.
Afterwards, media was removed, treated with L-siP nanoassemblies loaded with MDR1-siRNA
(final siRNA concentration: 100 nM) in serum-free media and incubated for 24 h. Next, media was
replaced with fresh complete one and incubated for another 48 h. After that, cells were treated with
10 µM doxorubicin and incubated for 4 h. Finally, media was removed, cells were washed with
PBS and nucleus was stained with NucBlue™ Live ReadyProbes™ reagent before subjecting to
confocal microscopy by Nikon Spectral A1+ confocal microscope. All images were analyzed with
Nikon NIS-Elements software.
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3.5

Abbreviations

‘L-siP’: ‘Lipid decorated siRNA-Polymer’ nano-assembly; siNC: siRNA-Negative Control; LF:
Lipofectamine; PLK1: polo-like kinase-1; MDR1: multi drug resistant-1; CLSM: Confocal Laser
Scanning Microscopy.
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CHAPTER 4
A STRUCTURE-ACTIVITY STUDY TO MODULATE REACTIVE SIDE CHAINS
OF

A

SELF-IMMOLATIVE

POLYMER

FOR

OPTIMAL

PROTEIN

CONJUGATION
Adapted in parts from the manuscript under review: Dutta, K; Kanjilal, P. Das, R.;
Medeiros, J.; Thayumanavan, S. “Synergistic Interplay of Covalent and Non-Covalent
Interactions in Reactive Polymer Nanoassembly Facilitates Intracellular Delivery of
Antibodies”

4.1 Introduction
Controlled polymerization and post-modification techniques have provided many
impressive examples of creating functional polymers for utilization in catalysis, sensing,
tissue-engineering and controlled drug delivery.1-10 Amongst these, activated ester
polymers have gained significant attention for providing enormous flexibility in
bioconjugation processes to install a desired functionality, which was otherwise impaired
due to the structural instability of sensitive biomolecules under harsh reaction conditions.1,
11-15

Inspired by this, we had designed a self-immolative polymer containing activated

carbonate moieties and reported a covalent self-assembly approach for encapsulation of
functional proteins through the reactive side chains.16 Lysines, an abundant surface
functionality in majority of proteins,16-17 have been utilized as conjugation handles for
reaction with the activated carbonate moieties to form self-assembled nanostructures. Due
to the presence of reactive side-chain functionalities that are responsive to redox stimuli,
the encapsulated proteins could be released in a ‘traceless’ manner with retention of its
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catalytic activity.18-19 Understanding the potential of the newly developed polymer
platform, we envisaged the utilization of such reactive covalent self-assembly approach for
conjugation of functional antibody through the conveniently available lysines present on
the surface of antibodies. However, slow macromolecular reaction kinetics owing to high
pKa of lysine amines,20 incomplete reactivity of activated carbonate groups with lysines,16
and competitive hydrolytic degradation of polymer were found to be major hurdles in the
successful extension of this approach for conjugation of larger biomacromolecules, such
as antibodies (~150 kDa).

Figure 4.1 Schematic representation of activated carbonate containing self-immolative
polymers tested for lysine conjugation

In this chapter, we have synthesized various activated carbonates containing selfimmolative polymers and studied the kinetics of aminolysis vs. hydrolysis in presence of a
small molecule lysine analogue (Figure 4.1). Down-selected activated carbonate polymer
with higher degree of aminolysis and low hydrolysis is utilized to test encapsulation and
stimuli-responsive release of proteins.
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4.2

Results and discussion

4.2.1 Synthesis of activated carbonate-containing monomers and polymers for protein
conjugation
While the reaction between amines and various activated ester moieties are wellestablished, including for bioconjugation, such an understanding does not exist for
activated carbonates.1, 11-12, 21 Note that utilization of an activated carbonate, instead of the
classical activated ester, is critical for reversibility in polymer-protein conjugation through
surface lysines. We also envisaged that the resultant carbamate linker would impart
hydrolytic stability of the covalent connection, and provide potential biocompatibility due
to resemblance to the biologically abundant amide moiety. Stable conjugation with
reversible features is critical for a versatile assembly that can translocate the protein across
a cellular membrane and release the protein cargo in its native form without any remnants
of polymer.13, 22 To address this, we incorporated a disulfide bond for redox-mediated
cleavage at the β-position of the carbonate moiety in the polymer chain. Upon cleavage of
the disulfide owing to the presence of higher intracellular glutathione concentration, the
self-immolative mechanism will kick-in to release the attached protein tracelessly in its
pristine form (Figure 4.2).18 Although we have successfully demonstrated encapsulation of
proteins with p-nitrophenyl-carbonate, this functionality falls short of the ability to
encapsulate larger proteins, such as antibodies, likely due to low reactivity and competitive
hydrolysis issues. We surmised that identifying a reactive functionality that is biased
towards aminolysis over hydrolysis would address these challenges.
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Figure 4.2 (a) Schematic of the designed random copolymers for evaluating protein
conjugation; (b) General reaction scheme for the synthesis of activated ester containing
monomers; (c) General reaction scheme for polymerization to achieve random copolymers
of PEG and activated ester monomers; and (d) Activated carbonate polymer mediated
protein conjugation and ‘traceless’ release.
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To this end, we synthesized a library of random copolymers containing six potential
activated

carbonate

pentafluorophenyl

candidates,
(PFP),

viz.,

nitrophenyl

trichlorophenyl

(TCL),

(NPC,

previously

reported),

hexafluoropropanol

(CF3),

trimethylaminophenyl (NMe3) carbonate moieties (Figure 4.2). The polymers were
synthesized via RAFT polymerization technique using carbonate methacrylate and PEG
methacrylate monomers (Figure 4.2, see experimental section for detailed synthetic
procedures). Post-polymerization modification of a PEG-hydroxyethylene disulfide
polymer was utilized to synthesize NHS carbonate ester polymer (see experimental
section).16 All monomers and polymers were characterized by NMR (1H, 13C and 19F NMR
(as required)) and gel permeation chromatography. The ratio between the carbonate and
PEG groups (~2:8) were evaluated from 1H NMR.
4.2.2

Comparison of aminolysis vs. hydrolysis and efficacy studies
To test the designed polymers for conjugation efficacy and degradation kinetics,

we first investigated the aminolysis reaction in the presence of a protected small molecule
lysine analogue (Figure 4.3). Kinetic studies of the desired aminolysis and the competitive
hydrolytic degradation were performed by reacting polymers with the lysine analog in
phosphate buffer (pH 8.5, previously optimized for protein conjugation).16 For TCL-, CF3, NMe3-, and NPC-polymers, both aminolysis and hydrolysis rates were found to be very
slow. Aminolysis rates for PFP- and NHS-polymers were found to be much faster.
However, with the NHS-polymer, this increase in rate of aminolysis was also accompanied
by an increase in the rate of hydrolysis. Considering that we require fast aminolysis rates,
combined with a significant bias towards aminolysis relative to hydrolysis rates, we
concluded that the PFP-polymer would be the best choice for protein conjugation.
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Figure 4.3 Kinetics studies with synthesized activated ester containing polymers to
examine extent of aminolysis and hydrolysis reactions.
To investigate the translation of our findings with small molecules on to proteinpolymer conjugation, we investigated the reactions of NPC-, PFP-, and NHS-polymers
with a model protein, horseradish peroxidase (HRP). Percentage encapsulation of proteins,
as evident from the SDS-PAGE analysis, was found to follow the following order: PFP
(48%) > NHS (18%) > NPC (11%) (Figure 4.4a). Importantly, to ‘shrink-wrap’ the protein
cargo after conjugation, a crosslinking reaction is employed to better protect it from
degrading environmental conditions. However, residual activated ester group analyses
revealed only ~9% remaining groups for NHS-polymer leaving little room for crosslinking
reaction (54% and 90% for PFP and NPC-polymers, Figure 4.4b). We also found similar
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Figure 4.4 (b) SDS-PAGE analyses for studying HRP encapsulation percentage with the
NPC, PFP and NHS-polymers (PFP:48%, NHS: 18% and NPC:11%); (c) Measurements
of residual activated carbonate ester moieties left after protein conjugation that can be
utilized for crosslinking reaction; (d) SDS-PAGE analyses to show similar encapsulation
percentage with Cyt C for the NPC, PFP and NHS-polymers (PFP:54%, NHS: 22% and
NPC:18%).
bioconjugation efficacy (PFP:54%, NHS: 22% and NPC:18%) for another protein
cytochrome C (Figure 4.4c). These studies further confirm that the PFP-polymer is the
appropriate down-selected candidate for protein conjugation.
4.3 Summary
In summary, we demonstrated a versatile strategy for encapsulation of proteins
using an activated carbonate polymer platform. Towards developing a fundamental
understanding in the activated carbonate chemistry for protein conjugation, we first
developed the structure-reactivity relationship by synthesizing and testing several activated
carbonate-bearing polymers for their reactivity in aminolysis vs. hydrolysis. PFP-polymer
not only provided faster aminolysis rate along with slower hydrolysis, this also enabled to
utilize the left-over reactive carbonate functionalities for enforcing secondary-crosslinking
to secure the nanoparticle formation. Based on the kinetics studies with small molecule
lysine analogue, we chose PFP-carbonate as the preferred functionality for encapsulating
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proteins. We tested the protein conjugation efficacy and redox-mediated release of the
proteins thereafter via SDS-PAGE analyses. This polymer platform is expected to provide
beneficial effect in protein conjugation and would be tested and improved for encapsulation
of larger proteins and antibodies.
4.4
4.4.1

Experimental
Materials
2-Hydroxyethyl disulfide, methacryloyl chloride, bis(trichloromethyl) carbonate

(triphosgene),

4-nitrophenol,

2,4,5-trichlorophenol,

N-hydroxysuccinimide

and

1,1,1,3,3,3-hexafluoro-2-propanol were procured from Sigma-Aldrich and were used
without further purification unless otherwise mentioned. 4-(Dimethylamino)phenol was
purchased from Combi-Blocks, USA. Polyethylene glycol monomethyl ether methacrylate
(PEGMA; MW 500), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid, 4-Cyano-4[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid (chain transfer agents), D,Ldithiothreitol (DTT), bis(pentafluorophenyl) carbonate and N,N′-disuccinimidyl carbonate
were also procured from Sigma-Aldrich. 2,2′-azobis-(2-methylpropionitrile) (AIBN) was
purchased from Sigma-Aldrich, USA and purified by recrystallization in methanol. All
protein samples, e.g., peroxidase from horseradish and cytochrome C were purchased from
Sigma-Aldrich.
4.4.2

Synthesis of activated ester containing monomers and polymers

4.4.2.1 Synthesis of methacrylate monomer of 2-hydroxyethyl disulfide

4 g (26 mmol, 1 equiv) of 2-hydroxyethyl disulfide was weighed in a 250 mL
round-bottom flask and was dissolved in 75 mL dry THF. 5.4 mL (3.9 g, 39 mmol, 1.5
equiv) of triethylamine was added to the solution and stirred for 5 min. The mixture was
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cooled in ice bath for 10 min. 2.5 mL (26 mmol, 1 equiv) of methacryloyl chloride
dissolved in 75 mL DCM was added to the reaction flask through a dropping funnel over
a period of 30 min. After complete addition, the ice bath was removed, and the reaction
was continued for another 12 h under argon. After that the solvent was evaporated in a
rotary evaporator. The reaction mixture was dissolved in ethyl acetate (50 mL), washed
with distilled water (3×50 mL), saturated NaCl solution (1×50 mL) and finally dried over
Na2SO4. The organic layer was collected and purified by flash column chromatography
using hexane/ethyl acetate (75:25 v/v). Yield: 76%. 1H NMR (400 MHz, CDCl3) (δ ppm):
6.13-6.14 (dd, 1H), 5.59-5.6 (t, 1H), 4.41-4.43 (t, 2H), 3.87-3.91 (q, 2H), 2.96-2.99 (t, 2H),
2.87-2.90 (t, 2H), 2.06-2.09 (t, 1H), 1.95 (t, 3H). 13C NMR (100 MHz, CDCl3) (δ ppm):
167.24, 136.02, 126.11, 62.61, 60.20, 41.69, 36.99, 18.29. ESI-MS (m/z) for C8H14O3S2
expected [M]+: 222.04, obtained: [M+Na]+: 245.02.
4.4.2.2 General synthesis of methacrylate activated ester monomers
In a typical procedure, 500 mg (2.25 mmol, 3 equiv) of 2-hydroxylethyl disulfide
methacrylate was taken in a 20 mL glass vial and dissolved in 7.5 mL of dry THF. 275 mg
(2.25 mmol, 3 equiv) of 4-dimethylaminopyridine (DMAP) was added to the solution and
stirred for 10 min to dissolve. The reaction vial was stoppered and purged with argon. 227
mg (0.75 mmol, 1 equiv, purity: 98%) of triphosgene dissolved in 5 mL of dry THF was
added to the vial in a dropwise manner. The reaction was stirred for 5 h. After that
calculated amount of DMAP (see specific examples below) was added to the vial. Finally,
phenols/alcohols for corresponding activated esters were added (dissolved in 2.5 mL dry
THF, see specific examples below) to the reaction mixture dropwise and stirred for 12 h.
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The reaction mixture was filtered to remove the salt, THF was dried in a rotary evaporator
and the mixture was purified with column chromatography (DCM: hexane 90:10).
Nitrophenyl carbonate methacrylate monomer (NPC-monomer):

Amount of chemicals used as par the general synthetic procedure described above:
4-nitrophenol: 344 mg (2.47 mmol) and DMAP: 302 mg (2.47 mmol), Yield: 56%. 1H
NMR (400 MHz, CDCl3) (δ ppm): 8.27-8.30 (m, 2H), 7.26-7.41 (m, 2H), 6.13-6.14 (dd,
1H), 5.59-5.60 (t, 1H), 4.53-4.57 (t, 2H), 4.42-4.45 (t, 2H), 3.00-3.06 (m, 4H), 1.94-1.95
(dd, 3H).

13

C NMR (100 MHz, CDCl3) (δ ppm):167.13, 155.40, 152.32, 145.50, 135.99,

126.10, 125.35, 121.79, 66.79, 62.46, 37.23, 36.81, 18.29. ESI-MS (m/z) for C15H11NO7S2
expected [M]+: 387.04, obtained: [M+Na]+: 410.03.
Pentafluorophenyl carbonate methacrylate monomer (PFP-monomer):

Amount of chemicals used as par the general synthetic procedure described above:
Pentafluorophenol (PFP): 455 mg (2.47 mmol), and DMAP: 302 mg (2.47 mmol), Yield:
49%. 1H NMR (400 MHz, CDCl3) (δ ppm): 6.13-6.14 (d, 1H), 5.59-5.60 (m, 1H), 4.564.60 (td, 2H), 4.41-4.45 (td, 2H), 2.99-3.06 (ddd, 4H), 1.95-1.96 (d, 3H). 13C NMR (100
MHz, CDCl3) (δ ppm): 167.13, 151.14, 142.46, 141.14, 140.12, 138.61, 136.65, 136.00,
126.11, 126.08, 68.03, 62.76, 62.40, 42.20, 40.44, 37.41, 37.33, 37.16, 36.46, 30.94, 30.64,
29.71, 25.48, 24.79,18.30, 18.27. 19F NMR (376 MHz, CDCl3) (δ ppm): -152.84-152.79, 148

156.94-156.83, -161.63-161.51. ESI-MS (m/z) for C15H13F5O5S2 expected [M]+: 432.01,
obtained: [M+Na]+: 455.00.
Trichlorophenyl carbonate methacrylate monomer (TCL-monomer):

Amount of chemicals used as par the general synthetic procedure described above:
2,4,5-trichlorophenol: 488 mg (2.47 mmol) and DMAP: 302 mg (2.47 mmol), Yield: 89%.
1

H NMR (400 MHz, CDCl3) (δ ppm): 7.56 (s, 1H), 7.4 (s, 1H), 6.13-6.14 (dd, 1H), 5.59-

5.60 (t, 1H), 4.53-4.56 (t, 2H), (4.41-4.43 (t, 2H), 2.99-3.05 (dt, 4H), 1.95 (dd, 3H). 13C
NMR (100 MHz, CDCl3) (δ ppm): 167.12, 151.91, 145.78, 135.99, 131.64, 131.21, 131.09,
126.09, 124.91, 67.16, 62.46, 37.28, 36.70, 18.29. ESI-MS (m/z) for C15H15Cl3O5S2
expected [M]+: 445.75, obtained: [M+Na]+: 468.93.
Hexafluoropropanol carbonate methacrylate monomer (CF3-monomer):

Amount of chemicals used as par the general synthetic procedure described above:
1,1,1,3,3,3-hexafluoro-2-propanol: 415 mg (2.47 mmol) and DMAP: 302 mg (2.47 mmol),
Yield: 48%. 1H NMR (400 MHz, CDCl3) (δ ppm): 6.13-6.14 (dq, 1H), 5.60 (q, 1H), 5.535.60 (m, 1H), 4.52-4.56 (t, 2H), 4.40-4.43 (t, 2H), 2.97-3.02 (td, 4H), 1.95-1.96 (dd, 3H).
13

C NMR (100 MHz, CDCl3) (δ ppm): 167.13, 152.70, 136.00, 126.08, 121.57, 118.76,

71.10, 70.75, 70.41, 70.06, 69.71, 67.97, 62.38, 37.31, 36.39, 18.26. 19F NMR (376 MHz,
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CDCl3) (δ ppm): -73.49. ESI-MS (m/z) for C12H14F6Cl3O5S2 expected [M]+: 416.02,
obtained: [M+Na]+: 439.01.
Dimethylamino carbonate methacrylate monomer (NMe2-monomer):

Amount of chemicals used as par the general synthetic procedure described above4-(Dimethylamino)phenol: 429 mg (2.47 mmol) and DMAP: 302 mg (2.47 mmol), Yield:
53%. 1H NMR (400 MHz, DMSO-d6) (δ ppm): 7.01-7.03 (d, 2H), 6.70-6.72 (d, 2H), 6.056.06 (dd, 1H), 5.70-5.71 (t, 1H), 4.32-4.41 (m, 4H), 3.04-3.09 (m, 4H), 2.88 (s, 6H), 1.881.89 (d, 3H). 13C NMR (100 MHz, DMSO-d6) (δ ppm): 166.84, 166.82, 154.03, 149.13,
141.93, 136.13, 126.61, 126.58, 121.84, 113.16, 66.27, 65.77, 62.68, 62.65, 40.90, 40.68,
40.63, 40.42, 40.21, 40.01, 36.81, 36.74, 36.73, 18.43, 18.40. ESI-MS (m/z) for
C17H23NO5S2 expected [M]+: 385.1, obtained: [M+Na]+: 408.09.
4.4.2.3 General synthesis of random copolymers
PEGMA,

methacrylate

activated

ester

monomer,

4-Cyano-4-

[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid (RAFT agent) were weighed in a 4
mL glass vial (amount of reagents taken are listed below) and dissolved in 200 μL dioxane.
Next, AIBN solution in dioxane was added to this solution. Total volume of solvent
(dioxane) was 0.3 mL. To prepare for polymerization, the glass vial was purged with argon
and stoppered. After that, the vial was subjected to four freeze-pump-thaw cycles, sealed
completely and transferred to an oil bath preheated at 80 °C. The polymerization was
continued for 48 h and then quenched by cooling down with cold water. The solvent was
evaporated, and the product was first precipitated in hexane. The final product was
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collected after redissolving in DCM and precipitating in diethyl ether two times. Finally,
the polymer was dried overnight under high vacuum.
NPC polymer:
S
10 S

CN
S
O

x
OO

y
O

O
9

S
S

OH
O

Amount of chemicals used as par the general synthetic
procedure described above: PEGMA: 258 mg (0.52 mmol),

O
O
O

NPC monomer: 50 mg (0.13 mmol), RAFT: 4.1 mg (0.0102
mmol), AIBN: 0.34 mg (0.0021 mmol). Yield: 88%. GPC

NO2

(THF), Mn: 21 kDa, Đ: 1.3. 1H NMR (400 MHz, CDCl3) (δ

ppm): 8.30, 8.28, 7.44, 7.42, 7.41, 4.57, 4.55, 4.54, 4.22, 4.07, 3.65, 3.64, 3.61, 3.55, 3.54,
3.54, 3.53, 3.37, 3.06, 3.04, 2.95, 1.94, 1.82, 1.01, 0.88, 0.87, 0.85. 13C NMR (100 MHz,
CDCl3) (δ ppm): 155.46, 152.30, 145.50, 125.41, 121.97, 71.95, 70.62, 70.58, 70.54, 68.60,
68.47, 66.83, 59.05, 36.65, 31.91, 29.65, 29.34, 22.69, 14.15. From 1H NMR, the molar
ratio of the repeating units was determined by integrating the methylene protons next to
the methacrylate ester groups in the activated carbonate and PEG monomeric units (x:y ≈
0.2:0.8).
PFP polymer:
Amount of chemicals used as par the general synthetic
procedure described above: PEGMA: 232 mg (0.46 mmol),
PFP monomer: 50 mg (0.12 mmol), RAFT: 3.7 mg (0.0092
mmol), AIBN: 0.30 mg (0.0018 mmol). Yield: 96%. GPC
(THF), Mn: 22 kDa, Đ: 1.2. 1H NMR (400 MHz, CDCl3) (δ
ppm): 4.60, 4.58, 4.23, 4.22, 4.08, 3.81, 3.71, 3.67, 3.67, 3.65, 3.64, 3.64, 3.63, 3.62, 3.59,
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3.55, 3.55, 3.54, 3.53, 3.37, 3.06, 2.95, 1.87, 1.76, 1.25, 1.02, 0.89, 0.87, 0.86, 0.86. 13C
NMR (100 MHz, CDCl3) (δ ppm): 177.25, 151.22, 72.08, 70.75, 70.72, 70.67, 70.58,
68.73, 68.60, 68.27, 63.94, 59.17, 45.29, 44.99, 36.48.

19

F NMR (376 MHz, CDCl3) (δ

ppm): -152.96, -157.12, -161.74. From 1H NMR, the molar ratio of the repeating units was
determined by integrating the methylene protons next to the methacrylate ester groups in
the activated carbonate and PEG monomeric units (x:y ≈ 0.2:0.8).
TCL polymer:
S
S
O

10 S

Amount of chemicals used as par the general synthetic

CN
x
OO

y
O

O
9

S
S

OH
O

procedure described above: PEGMA: 224 mg (0.45 mmol),
TCL monomer: 50 mg (0.11 mmol), RAFT: 3.6 mg (0.0089
mmol), AIBN: 0.29 mg (0.0018 mmol). Yield: 91%. GPC

O
O
O
Cl

(THF), Mn: 22 kDa, Đ: 1.3. 1H NMR (400 MHz, CDCl3) (δ
ppm): 7.60, 7.46, 7.44, 4.57, 4.56, 4.54, 4.23, 4.23, 4.08,

Cl
Cl

3.67, 3.66, 3.65, 3.65, 3.63, 3.62, 3.56, 3.55, 3.55, 3.54, 3.38, 3.06, 2.95, 1.82, 1.81, 1.26,
1.02, 0.89, 0.88, 0.88, 0.86, 0.85. 13C NMR (100 MHz, CDCl3) (δ ppm): 152.00, 145.98,
131.72, 131.36, 131.14, 126.24, 125.16, 72.08, 70.75, 70.71, 70.66, 68.73, 68.60, 67.35,
59.17, 36.69, 32.04, 29.76, 22.82. From 1H NMR, the molar ratio of the repeating units
was determined by integrating the methylene protons next to the methacrylate ester groups
in the activated carbonate and PEG monomeric units (x:y ≈ 0.2:0.8).
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CF3 polymer:
S

10 S

CN
S
O

x
OO

y
O

OH

Amount of chemicals used as par the general synthetic

O

procedure described above: PEGMA: 240 mg (0.48 mmol),
O
9

S
S
O

NPC monomer: 50 mg (0.12 mmol), RAFT: 3.8 mg (0.0095

O

mmol), AIBN: 0.31 mg (0.0019 mmol). Yield: 84%. GPC

CF3

(THF), Mn: 28 kDa, Đ: 1.2. 1H NMR (400 MHz, CDCl3) (δ

O
F3C

ppm): 5.66, 4.57, 4.21, 4.08, 3.65, 3.65, 3.38, 1.89, 1.79, 1.59, 1.26, 1.02, 0.88, 0.86. 13C
NMR (100 MHz, CDCl3) (δ ppm): 71.95, 70.61, 70.58, 70.53, 68.47, 68.06, 63.81, 59.04,
44.85, 30.94. 19F NMR (376 MHz, CDCl3) (δ ppm): -73.33. From 1H NMR, the molar ratio
of the repeating units was determined by integrating the methylene protons next to the
methacrylate ester groups in the activated carbonate and PEG monomeric units (x:y ≈
0.2:0.8).
NMe2 polymer:
Amount of chemicals used as par the general synthetic
procedure described above: PEGMA: 259 mg (0.52 mmol),
NPC monomer: 50 mg (0.13 mmol), RAFT: 4.2 mg (0.0103
mmol), AIBN: 0.34 mg (0.0021 mmol). Yield: 95%. GPC
(THF), Mn: 31 kDa, Đ: 1.2. 1H NMR (500 MHz, DMSO-d6)
δ 7.06, 7.04, 6.75, 6.73, 4.45, 4.20, 4.05, 3.64, 3.46, 3.28,
3.11, 3.03, 2.92, 1.83, 1.28, 1.19, 0.99, 0.89, 0.84.

13

C NMR (100 MHz, DMSO-d6) (δ

ppm): 152.90, 147.98, 140.86, 120.67, 111.98, 70.69, 69.20, 69.01, 65.22, 57.43. From 1H
NMR, the molar ratio of the repeating units was determined by integrating the methylene
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protons next to the methacrylate ester groups in the activated carbonate and PEG
monomeric units (x:y ≈ 0.2:0.8).
NMe3 polymer:

Scheme 4.1 Methylation of NMe2-polymer to form NMe3-polymer

For methylation reaction, NMe2 polymer (25 mg, 0.0524 mmol) was first weighed
in a 1.5 mL glass vial and dissolved in 400 μL DCM. Next, 296 mg (130 μL, 2.1 mmol) of
methyl iodide was added dropwise to the solution. After 12 h of reaction, solvent was
evaporated and the polymer was precipitated in diethyl ether three times. Finally, the
polymer was dried overnight under high vacuum. Yield: 92%. GPC (TFE), Mn: 32 kDa, Đ:
1.3. 1H NMR (400 MHz, DMSO-d6) (δ ppm): 8.10, 8.08, 7.58, 7.56, 4.51, 4.19, 4.06, 3.66,
3.63, 3.56, 3.55, 3.47, 3.47, 3.46, 3.45, 3.40, 3.28, 3.14, 2.68, 2.68, 2.67, 2.56, 2.56, 2.40,
2.40, 2.40, 1.28, 0.99, 0.89, 0.88, 0.84. 13C NMR (100 MHz, DMSO-d6) (δ ppm): 151.75,
150.45, 144.09, 122.04, 121.70, 70.68, 69.19, 69.00, 57.43, 56.01.
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Scheme 4.2 Synthesis of random copolymers of NHS
Co-polymer of PEGMA and hydroxyethylene disulfide, was synthesize based on a
previously reported procedure (see synthesis of p(PEGMA-co-EDSMA).16 To install the
NHS carbonate ester group, 300 mg of p(PEGMA-co-EDSMA) polymer was weighed in a
glass vial and dissolved in 2 mL DMF. Next, 606 mg (2.83 mmol) of proton-sponge (1,8Bis(dimethylamino)naphthalene) was added to the solution and stirred for 15 min to
dissolve. After that, 724 mg (2.83 mmol) N,N′-disuccinimidyl carbonate was added to the
reaction mixture portion-wise over 15 min. The reaction was stirred for 2 days. The product
was precipitated with diethyl ether twice and then dialyzed to purify in DCM:MeOH (1:1)
solvent system. Finally, the polymer was dried overnight under high vacuum. Yield: 92%.
GPC (THF), Mn: 17 kDa, Đ: 1.2.
1

H NMR (400 MHz, CDCl3) (δ ppm): 4.59, 4.40, 4.22, 3.67, 3.65, 3.65, 3.64, 3.63, 3.62,

3.56, 3.55, 3.54, 3.53, 3.37, 3.05, 2.96, 2.87, 1.88, 1.78, 1.72, 1.25, 1.02, 0.88, 0.88, 0.85.
13

C NMR (100 MHz, CDCl3) (δ ppm): 168.92, 151.60, 77.48, 72.09, 70.76, 70.72, 70.67,

68.60, 63.95, 59.18, 45.01, 25.68. From 1H NMR, the molar ratio of the repeating units
was determined by integrating the methylene protons next to the methacrylate ester groups
in the activated carbonate and PEG monomeric units (x:y ≈ 0.2:0.8).
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4.4.3

Kinetics study with activated ester polymers and small molecule lysine
analogue
O
NH
O
O

O

j

i
O

H2N

O
O

O
O

O
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i
O

Ar/R-OH
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S
S

S
S

O
9

O
O
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Scheme 4.3 Kinetics of aminolysis study with small molecule lysine analogue
To compare the kinetics of aminolysis vs. hydrolysis for different activated ester
containing polymers in the context of protein encapsulation, we have studied the reaction
of a protected small molecule lysine analogue, Nα-Acetyl-L-lysine methyl ester
hydrochloride (Lys, Sigma), with all reactive carbonate ester polymers. In a typical
procedure, ~1 mg of polymer was dissolved in 3.5 mL phosphate buffer (100 mM, pH 8.5).
The solution is transferred to three UV-Vis cuvettes and 10 μL Lys solution (10 mg/mL)
was added. The cuvettes were sealed, stirred with magnetic stirrers and UV-Vis
measurements were taken at different time points over a period of 12 h. Only polymer
solutions in phosphate buffer (100 mM, pH 8.5) without the addition of Lys reagent were
tested to evaluate the degree of hydrolysis. For NHS and CF3-polymers, 1H NMR
measurements were performed for kinetics analysis under identical conditions.
4.4.4

Conjugation of proteins with NPC, PFP and NHS-polymers
In a typical process, the self-immolative polymers were dissolved in phosphate

buffer (100 mM, pH 8.5) to make 10 mg/mL solution. Protein stocks (horseradish
peroxidase, HRP and cytochrome C, Cyt C) were also prepared at 400 μg/mL concentration
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(in phosphate buffer, 100 mM, pH 8.5). Finally, 25 μL of protein stock solution was added
dropwise to a stirred 50 μL of polymer solution. The reaction was continued for 12 h at
room temperature and subjected to SDS-PAGE analyses.
4.4.5

SDS-PAGE for protein-polymer conjugation
40 μL of protein-polymer conjugates were mixed with 10 μL of gel loading buffer

(DTT free) and incubated at 95 °C for 5 min. After that, 40 μL of each sample was loaded
into the acrylamide gel and electrophoresis was continued at constant voltage (130 V) for
45 min. To study the protein release, protein-polymer conjugate samples were treated with
10 mM GSH, incubated at 37 ºC for 4 h and subjected to acrylamide gel electrophoresis.
The amount of released protein from the nanoassembly was estimated via generating a
standard curve from the known amounts of pure proteins loaded into the gel lanes. All gel
image analysis and quantification were performed with Bio-Rad Image LabTM software.
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Figure 4.5 1H NMR spectrum (400 MHz) of methacrylate monomer of 2-hydroxyethyl
disulfide in CDCl3.
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Figure 4.6. 13C NMR spectrum (100 MHz) of methacrylate monomer of 2-hydroxyethyl
disulfide in CDCl3.

Figure 4.7 ESI-MS analysis of methacrylate monomer of 2-hydroxyethyl disulfide in
methanol.
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Figure 4.8. 1H NMR spectrum (400 MHz) of NPC-monomer in CDCl3.

Figure 4.9 13C NMR spectrum (100 MHz) of NPC-monomer in CDCl3.
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Figure 4.10 ESI-MS analysis of NPC-monomer in methanol.
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Figure 4.11 1H NMR spectrum (400 MHz) of PFP-monomer in CDCl3.
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Figure 4.12 13C NMR spectrum (100 MHz) of PFP-monomer in CDCl3.

Figure 4.13 19F NMR spectrum (376 MHz) of PFP-monomer in CDCl3.
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Figure 4.14 ESI-MS analysis of PFP-monomer in methanol.
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Figure 4.15 1H NMR spectrum (400 MHz) of TCL-monomer in CDCl3.
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Figure 4.16 13C NMR spectrum (100 MHz) of TCL-monomer in CDCl3.

Figure 4.17 ESI-MS analysis of TCL-monomer in methanol.
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Figure 4.18 1H NMR spectrum (400 MHz) of CF3-monomer in CDCl3.

Figure 4.19 13C NMR spectrum (100 MHz) of CF3-monomer in CDCl3.
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Figure 4.20 19F NMR spectrum (376 MHz) of CF3-monomer in CDCl3.

Figure 4.21 ESI-MS analysis of CF3-monomer in methanol.
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Figure 4.22 1H NMR spectrum (400 MHz) of NMe2-monomer in CDCl3.

Figure 4.23 13C NMR spectrum (100 MHz) of NMe2-monomer in CDCl3.
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Figure 4.24 ESI-MS analysis of NMe2-monomer in methanol.
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Figure 4.25 1H NMR spectrum (400 MHz) of NPC-polymer in CDCl3.

167

h,h’

e

e’
f

d

f’

c

g

h

b
a

g
*CDCl3

h

g
a

d

c,b

Figure 4.26 1H NMR spectrum (400 MHz) of PFP-polymer in CDCl3.

Figure 4.27 19F NMR spectrum (376 MHz) of PFP-polymer in CDCl3.
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Figure 4.28 1H NMR spectrum (400 MHz) of TCL-polymer in CDCl3.
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Figure 4.29 1H NMR spectrum (400 MHz) of CF3-polymer in CDCl3.
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Figure 4.30 19F NMR spectrum (376 MHz) of CF3-polymer in CDCl3.
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Figure 4.31 1H NMR spectrum (400 MHz) of NMe2-polymer in DMSO-d6.
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Figure 4.32 1H NMR spectrum (400 MHz) of NMe3-polymer in DMSO-d6.
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Figure 4.33 1H NMR spectrum (400 MHz) of NHS-polymer in CDCl3.
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CHAPTER 5
HARNESSING

ELECTROSTATIC

AND

COVALENT

CONJUGATION

STRATEGIES FOR EFFICIENT ENCAPSULATION AND INTRACELLULAR
DELIVERY OF ANTIBODY
Adapted in parts from the manuscript under review: Dutta, K; Kanjilal, P. Das, R.;
Thayumanavan, S. “Synergistic Interplay of Covalent and Non-Covalent Interactions in
Reactive Polymer Nanoassembly Facilitates Intracellular Delivery of Antibodies”

5.1 Introduction
Molecular self-assembly, inspired by recognition processes in nature, has formed
the basis for many functional supramolecular architectures.1 Although these selfassembled structures are mainly governed by weak non-covalent forces, the co-existence
of both covalent and non-covalent interactions is also prevalent in many biological
processes. For example, covalent modifications of histones through acetylation and
methylation of lysines dictate their electrostatic non-covalent binding interactions with
negatively charged DNA in the chromatin structure.2 Similarly, in synthetic chemistry the
concept of dynamic covalent bonds, coupled with non-covalent templating, has been
utilized to create supramolecular structures and identification of ligands for protein
targets.3-4 In this article, we report a covalent self-assembly strategy that is templated by
non-covalent interactions between the host and the guest molecules to address a key
challenge in achieving robust encapsulation of complex and sensitive biomacromolecules.
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Intracellular targeting of “undruggable” proteins is an unresolved challenge that
impacts many diseases with low life expectancy.5-6 Antibodies, long-standing diagnostic
candidates in the biologics toolkit, could now serve to address this therapeutic challenge
as it is possible to produce them at large scale for many protein targets.7-10 Unlike smallmolecule drugs, antibodies present very high specificity to its target antigens, thus offering
therapeutic benefits with minimal side-effects. Binding to a particular epitope via the Fab
region of antibody could turn-off the cellular activity of the protein of interest causing
deactivation of relevant biological signaling pathways. In fact, antibody-based
therapeutics occupy a large portion of the FDA-approved biologics.8,

11

But, these

biologics target only the extracellular epitopes. When it comes to intracellular targets, its
utility has been confined to diagnostics so far and for developing a fundamental
understanding of a limited number of cellular processes. This is mainly attributed to the
inability of antibodies to penetrate live cell membrane, owing to their large hydrophilic
nature and entrapment in endosomal compartment.12 Although conventional strategies,
such as electroporation and microinjection, are able to traffic antibodies inside cells, they
are limited because of their poor efficacy and the potential for imparting severe
cytotoxicity due to cell membrane damage.13
Acknowledging the therapeutics need, two key approaches targeting intracellular
delivery of antibody have been taken: (a) physical encapsulation, and (b) electrostatic
complexation strategies with the help of peptide, lipid, inorganic and polymer based
nanoparticles.14-22 However, given the enormous possibility of antibody therapeutics, the
dearth of literature for intracellular trafficking of functional antibody points to the
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significant challenges associated with such macromolecular cargo delivery without the
loss of biological activity.
In this chapter, we have utilized a down-selected activated carbonate polymer with
higher degree of aminolysis and low hydrolysis from our previous studies (Chapter 4) and
further improved the efficacy for protein and antibody encapsulation (Figure 5.1). With
the help of an electrostatics-aided covalent capture strategy, we demonstrate efficient

Figure 5.1 Schematic representation of an electrostatic-aided covalent self-assembly of
polymer network using protein (antibody) as the template and its transport into the cytosol
to deliver the cargo in functional form.

encapsulation of large proteins, such as antibodies. Finally, we investigate the cellular
trafficking of functional antibodies to probe cytosolic delivery and evaluated their
biological activities in targeting specific intracellular epitopes (Figure 5.1).
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5.2 Results and discussion
5.2.1

Electrostatics-aided covalent self-assembly strategy for the generation of

polymer-protein nanoassembly
In addition to identifying PFP-moiety as the optimal functionality for protein
conjugation (discussed in Chapter 4), we were interested in tuning the structural features
further to boost the encapsulation efficacy. Protein surfaces are composed of diverse
arrays of amino acids with different surface charges and hydrophobicity. Charged residues
on protein surfaces play an important role in dynamic reversible interactions with other
biomacromolecules (in protein-protein and protein-antibody complexes).23 For most
water-soluble proteins, charges are distributed on the surfaces as a patch with an average
size between 1-2 nm.24 We hypothesized that introducing a negatively charged group in
the activated ester polymer backbone could help recruit protein near the vicinity of
polymer via electrostatic interaction with positively charged patches, based on amino acid
residues such as lysines, arginines and histidines.24-26 We hypothesized that once
electrostatically drawn to polymer, the proximity-induced reactivity between lysine
functionalities from the protein and the activated carbonate esters on polymer backbone
should increase. To test this possibility, we synthesized a random copolymer consisting
three different monomeric units, bearing PFP carbonate ester, PEG and 3-sulfopropyl
functionalities with a compositional ratio of 2:6:2 (PAb, Figure 5.2a). Sulfonate moiety,
having pKa ≈ −0.5,27 would remain as negatively charged at the conjugation of pH 8.5, for
interactions with positively charged groups on protein surface. To test the effect of mere
electrostatic interactions in protein conjugation, we also synthesized a control polymer
consisting PEG and sulfopropyl moieties (SO3-polymer, Figure 5.2a).
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5.2.2 Polymer-protein nanoassembly formation and characterizations
Before pursuing the antibody conjugation, we tested the encapsulation efficacy
and the subsequent stimulus-mediated release of proteins with the designed random
copolymer, PAb. Two different proteins of very different molecular weights, HRP (~44
kDa) and β-gal (~465 kDa, with four subunits of 116.3 kDa), were chosen to form

Figure 5.2 (a) Design of self-immolative polymer, PAb, for protein and antibody
conjugation along with control polymers; Polymer-protein nanoassembly
characterizations: (b, c) Dynamic light scattering measurements; and (d,e)
Transmission electron microscopy images for NA-HRP and NA-β-gal,
respectively along with naked proteins, scale bar: 500 nm; (f,g) SDS-PAGE
analyses under reducing and non-reducing (with GSH) conditions to show
efficient encapsulation and redox-mediated release with the NA-HRP and NA-βgal nanoassemblies, respectively.
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polymer-protein nanoassembly. Whereas the ζ potential was measured to be similar to the
naked protein for NA-HRP (naked HRP: -8 mV; NA-HRP: -9 mV), it was reduced
significantly in the case of NA-β-gal (naked β-gal:-25 mV; NA-β-gal: -13 mV). Dynamic
light scattering (DLS) measurements showed uniform distribution of nanoassemblies with
119 and 162 nm hydrodynamic diameters for NA-HRP and NA-β-gal, respectively
(Figure 5.2b-c), suggesting efficient shrink-wrapping with polymer network. Further
analyses with transmission electron microscopy (TEM) revealed discrete nanoassemblies
with distribution patterns matching with the DLS studies (Figure 5.2d-e).
Gel electrophoresis (SDS-PAGE) studies under non-reducing conditions showed
no protein band, confirming that the proteins are effectively wrapped by the polymer
(Figure 5.2f-g). Note that the encapsulation efficacies were much higher, ~91% and ~82%
for HRP and β-gal respectively, for the PAb polymer, compared to the corresponding PFPpolymer without the sulfonate moieties (see Chapter 4). Interestingly, control SO3polymer without the PFP units also showed negligible protein encapsulation (<10%),
suggesting that electrostatics alone is not sufficient for efficient encapsulation of proteins
either. Thus, it is the combination of electrostatic and covalent self-assembly that offer
efficient wrapping of proteins by the polymer.
Next, we investigated whether the nanoassembly can release the proteins in a
stimuli-responsive manner. The protein bands reappeared in the gel electrophoresis
studies, when the nanoassembly was run in the gel under reducing conditions (10 mM
glutathione). This concentration corresponds to the typical intracellular GSH
concentrations of the cytosol. Retaining the structure and function of the released proteins
are critical in developing an effective encapsulation strategy. Towards this goal, we first
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investigated the secondary structure of the released HRP and β-gal from the
nanoassemblies. Circular dichroism spectra of the released proteins showed no apparent
changes suggesting conservation of secondary structure of proteins releasing from the

Figure 5.3 (a,b) Circular dichroism spectra of native HRP, NA-HRP and β-gal, NAβ-gal, respectively; (c,d) Comparison of protein activity for native, encapsulated and
released HRP and β-gal proteins (Encap and Release: NA-Protein nanoassemblies
without and with 10 mM GSH treatment, respectively); (e,f) Intracellular uptake of
rhodamine tagged HRP and β-gal delivered with NA-HRPRhod and NA-β-galRhod
indicating uniform cellular distribution in HeLa cells, respectively. Scale bar: 20 μm;
and (g,h) X-gal staining assay showing cytosolic activity of β-gal delivered through
NA-β-gal, whereas naked protein sample remained unstained due to cell membrane
impermeability.
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nanoassembly upon treatment of glutathione (Figure 5.3a-b). Similarly, in vitro activity
studies of the released proteins revealed that the proteins activities were greatly silenced
(6% and 5% for HRP and β-gal, respectively; Figure 5.3c-d).28-29 However, upon releasing
from the shrink-wrapped state, both proteins regained their enzymatic activities (84% and
87% for HRP and β-gal, respectively). Thus, both structure and functional assays show
efficacy of the polymer shell in efficiently wrapping the protein and the recovery of
activity of the protein upon encountering a specific environmental stimulus.
Finally, cellular internalization of the protein cargoes was tested for
nanoassemblies encapsulated with rhodamine-tagged HRP and β-gal via confocal laser
scanning microscopy (CLSM, Figure 5.3e-f). Uniform red fluorescence in HeLa and
MDA-MB-231 cell lines suggested that the nanoassemblies were efficiently internalized
by the cells. Furthermore, we were also interested in investigating whether the delivered
protein is active, i.e. if the protein was unwrapped to be activated inside the cells. To this
end, intracellular activity of delivered β-gal was tested using the x-gal assay. Generation
of intense blue color in the cells, compared to the controls, suggests that the protein was
not only transported across the cellular membrane to the cytosol, but that it is active inside
the cells (Figure 5.3g-h).
5.2.3

Extension of the encapsulation strategy to antibody and cellular delivery
Inspired by the results with globular proteins, we tested the ability of these

polymers to encapsulate and deliver antibodies inside cells. A typical immunoglobulin G
(IgG) antibody is about ~150 kDa in molecular weight and has ~82 surface lysines. The
developed encapsulation strategy with activated ester and negatively charged sulfonate
moieties could provide chemical and electrostatic handles for boosting the encapsulation
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of a such large antibody. Indeed, we were able to efficiently form polymer-IgG
nanoassemblies (NA-IgG), as evident from the absence of IgG band (at ~150 kDa) for

Figure 5.4 (a) SDS-PAGE study to show efficient encapsulation of IgG inside the NA-IgG
nanoassembly indicated by the absence of IgG band; (b) Transmission electron microscopy
images for NA-IgG, scale bar: 500 nm; and (c) Dynamic light scattering and (d) ζ potential
measurements for native IgG and NA-IgG nanoassembly; (e) Intracellular uptake of NAIgGRhod in HeLa cells, scale bar: 20 μm; (f) Mechanism of cellular uptake for NA-IgGRhod in
presence and absence of endocytic inhibitors; (g) Endosomal colocalization and escape studies
after incubation with NA-IgGRhod in HeLa cells at 4 and 24 h (green: lysotracker; red:
rhodamine B-IgG; blue: nuclear stain, scale bar: 10 μm.
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NA-IgG samples in the SDS-PAGE analysis (Figure 5.4a). TEM and DLS studies
revealed monomodal distribution of NA-IgG samples with an average size of 94 nm and
ζ potential was found to be -12 mV (Figure 5.4b-d).
Our ultimate aim is to traffic the antibody for intracellular targeting of specific
proteins. Prior to delivering a functional antibody, we were interested in testing the
cellular localization of a fluorophore-labelled antibody. A rhodamine labelled IgG was
first encapsulated in the polymer nanoassembly (NA-IgGRhod) and delivered in HeLa cells.
A uniform distribution of red fluorescence, as observed from CLSM studies, confirmed
the intracellular access of the delivered IgG (Figure 5.4e). When tested with other cell
lines, the transfection efficacies were found to be as follows: HeLa: 69%, MDA-MB-231:
80% and EMT6: 91%. Cellular uptake can be governed by various pathways.30 To probe
the cellular internalization mechanism for our nanoassemblies, we incubated cells with
different endocytosis pathway inhibitors and checked their influence in cellular uptake of
nanoparticle via flow cytometry.30-32 As evident from Figure 5.4f, the uptake is governed
by the clathrin-mediated endocytosis pathway for HeLa cells, since hyperosmolar sucrose
is a dominant uptake inhibitor. Upon being endocytosed inside the cells, the next
important step for cytosolic access is to escape from the endosome. Time dependent
CLSM studies with lysotracker green (an endosome/lysosome marker stain) showed
colocalization of red (from rhodamine-labelled IgG) and green (lysotracker) channels
after 4 h of incubation with the NA-IgG (Figure 5.4g). escape from endosome and
cytosolic accumulation of IgG after 24 h. Also, high cellular viability for NA-IgG samples
across three different cell lines suggest that the designed nanoassemblies are non-toxic
even at a high dosage of 2 mg/mL.
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5.2.4

Intracellular trafficking of functional antibodies: anti-pAkt and anti-NPC

antibody
In order to test the potential of polymeric nanoassemblies in trafficking antibody
inside cells, it is critical to show that the antibody is able to recognize the targeted epitope
inside the cells. To this end, we aimed to test the ability of these nanoassemblies in
delivering two functional monoclonal antibodies, viz. anti-nuclear pore complex (anti-

Figure 5.5 (a) Schematic of cytosolic delivery for anti-NPC and anti-pAkt antibodies
in functional forms through the polymer nanoassembly; (b) Immunostained HeLa
cells after NA-anti-NPC delivery showing highlighted nuclear pore complex
localized in nuclear membrane, scale: 10 μm; (c) Cellular viability study in MCF-7
cells after delivery of NA-anti-pAkt showing dose dependent decrease in cell
survival; (d) Detection of caspase 3/7 in MCF7 cells after NA-anti-pAkt delivery (6
h) using a green fluorescent dye labelled caspase substrate, scale bar: 20 μm; and (e)
Western blot analysis showing cleavage of PARP owing to the activation of caspase
pathway in MCF-7 cells.
185

NPC) and anti-phospho-Akt (Ser473) antibody (Figure 5.5a). The epitopes for both these
antibodies are present in the cytosol and thus analyzing these antibodies would also
confirm the endosomal escape that we observed in our fluorescence microscopy studies.
When delivered inside cells, anti-NPC antibody bind to the nuclear pore complex located
on the nuclear membrane.15-16 While naked anti-NPC antibody could not penetrate cellular
membrane efficiently and failed to locate on the nuclear membrane, NA-anti-NPC could
traffic the antibody and successfully highlighted the nuclear pore complex of the cells.
This is evident from the red-colored membrane of the nucleus (stained with a blue dye),
due to the binding of the anti-NPC antibody (Figure 5.5b).
Gratified by this observation, we further tested the intracellular activity with
another antibody, anti-pAkt. Protein kinase B, also known as Akt, is an intracellular signal
transduction protein responsible for activation of nuclear factor-κB (NF-κB) and several
other proteins in the Akt signaling pathway that are responsible for cellular growth.18, 33 It
inhibits the key apoptotic pathway in many cancer cells and therefore blocking this could
result in reinstating the apoptosis mechanism.33-34 With this goal in mind, we delivered
anti-pAkt antibody with our polymer nanoassembly and were gratified to see that the
cellular viability had reduced in a dose-dependent manner (Figure 5.5c). In addition to
utilizing viability as an assay, we were also interested in showing that this is indeed due
to the specific inhibition of the Akt pathway. If these results were indeed due to the
reactivation of the targeted apoptosis pathway, we should observe the presence of caspase
3/7 enzymes, one of the key controllers for cellular apoptosis pathways. To this end, we
examined the presence of caspase 3/7 via immunofluorescence technique. The assay
utilizes a caspase substrate attached to a nucleic acid binding dye that only fluoresces upon
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substrate cleavage by active cellular caspases after binding to nuclear DNA. A clear green
fluorescence from the detection assay localized on cellular nucleus confirmed the
activation of caspase pathways leading to cellular apoptosis (Figure 5d). To further probe
the apoptosis process, we studied the cleavage of poly(ADP-ribose) polymerase (PARP)
protein via intracellularly activated caspases through western blot analyses (Figure 5.5e).
The apoptotic activation led to cleavage of PARP (~116 kDa) into 89 and 24 kDa
fragments with the NA-anti-pAkt sample, while naked anti-pAkt control did not show any
discernible amount of activity. These studies demonstrate the ability of the developed
polymeric nanoassembly system in delivering antibody cargoes into the cytosol with the
retention of recognition function.
5.3 Conclusions
In summary, we demonstrated a versatile strategy for encapsulation of large
proteins and antibody therapeutics using an activated carbonate polymer platform. Based
on the kinetics studies and previous investigation in protein encapsulation experiments
(chapter 4), we chose PFP-carbonate as the preferred functionality for further
development in encapsulating large proteins, such as antibodies. To further boost the
conjugation efficiency, we engineered the polymer structures with electrostatic handles
that offered higher degree of encapsulation presumably through proximity-induced
reactivity enhancement. We show here that the electrostatics-aided covalent encapsulation
strategy provided a robust platform to (i) capture larger antibody molecules with high
fidelity that are found difficult to encapsulate otherwise; (ii) protect the structure and
silence the cargo activity while in encapsulated state; (iii) enable regaining the functional
activity of the payload upon release by the influence of an intracellular stimulus; (iv)
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efficiently deliver the encapsulated cargo into the cytosol; and (v) ensure that the desired
biological functions of the cargo are retained upon intracellular delivery and cytosolic
release. We believe that the developed polymer nanoassembly system would serve as a
generalized protein delivery platform, specifically for antibody-based intracellular drug
targets, which is so far considered as one of the most challenging goals for the
development of antibody therapeutics.
5.4 Experimental
5.4.1 Materials
Reagents used for polymerization- polyethylene glycol monomethyl ether
methacrylate (PEGMA; MW 500), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid,
4-Cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid (chain transfer
agents), D,L-dithiothreitol (DTT), bis(pentafluorophenyl) carbonate and N,N′disuccinimidyl carbonate were also procured from Sigma-Aldrich. 2,2′-azobis-(2methylpropionitrile) (AIBN) was purchased from Sigma-Aldrich, USA and purified by
recrystallization in methanol. All protein samples, e.g., peroxidase from horseradish and
β-galactosidase were purchased from Sigma-Aldrich. Anti-nuclear pore complex proteins
antibody (Anti-NPC) and phospho-AKT1 (ser473) recombinant rabbit monoclonal
antibody (Anti-pAkt) were purchased from abcam and Thermo Fisher Scientific,
respectively.
5.4.2

Synthesis of random copolymer consisting pentafluorophenyl carbonate,

PEG and sulfopropyl methacrylate monomers (PFP-SO3-polymer), PAb
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Scheme 5.1 Polymerization reaction scheme for synthesis of PAb polymer
PEGMA (180 mg, 0.36 mmol), PFP monomer (50 mg, 0.12 mmol), 3-sulfopropyl
methacrylate

potassium

salt

(29

mg,

0.12

mmol)

and

4-Cyano-4-

(phenylcarbonothioylthio)pentanoic acid (2.3 mg, 0.0083 mmol, RAFT agent) were
weighed in a 4 mL glass vial and dissolved in 1 mL DMF by stirring for 15 min. AIBN
solution in DMF was added to this solution. Total volume of solvent (DMF) was 1.2 mL.
To prepare for polymerization, the glass vial was purged with argon and stoppered. After
that, the vial was subjected to four freeze-pump-thaw cycles, sealed completely and
transferred to an oil bath preheated at 80 °C. The polymerization was continued for 48 h
and then quenched by cooling down with cold water. The solvent was evaporated, the
product was first precipitated in diethyl ether and purified by extensive dialysis in
acetone:methanol (1:1). Finally, the polymer was dried overnight under high vacuum.
Yield: 79%, GPC (TFE), Mn: 38 kDa, Đ: 1.1. From 1H NMR, the molar ratio of the
repeating units was determined by integrating the methylene protons next to the
methacrylate ester groups in the activated carbonate, methyl protons of PEG monomeric
unit and the methylene protons next to the sulfonate group in sulfopropyl units (i:j:k ≈
0.2:0.6:0.2). 1H NMR (400 MHz, DMSO-d6) (δ ppm): 4.59, 4.15, 4.01, 3.60, 3.51, 3.45,
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3.43, 3.43, 3.42, 3.41, 3.33, 3.24, 3.13, 2.99, 2.01, 1.99, 1.75, 1.24, 1.23, 0.95, 0.87, 0.86,
0.85, 0.85, 0.84, 0.80, 0.80, 0.78.
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C NMR (100 MHz, DMSO-d6) (δ ppm): 149.86,

139.20, 133.53, 129.24, 127.55, 125.32, 118.12, 114.61, 107.44, 77.28, 70.67, 69.16,
68.97, 57.43, 47.31, 36.46, 35.15.
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F NMR (376 MHz, DMSO-d6) (δ ppm): -154.01, -

157.47, -162.27.
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Figure 5.6 1H NMR spectrum (400 MHz) of PFP-SO3-polymer, PAb in DMSO-d6.

Figure 5.7 19F NMR spectrum (376 MHz) of PFP-SO3-polymer, PAb in DMSO-d6.
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5.4.3 Synthesis of control sulfonate polymer, SO3-polymer

Scheme 5.2 Polymerization reaction scheme for the synthesis of control SO3-polymer

PEGMA (750 mg, 1.5 mmol), 3-sulfopropyl methacrylate potassium salt (92 mg,
0.38 mmol) and 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid (7.8 mg, 0.028
mmol, RAFT agent) were weighed in a 20 mL glass vial and dissolved in 2 mL 2,2,2trifluoroethanol (TFE) by stirring for 15 min. AIBN solution in TFE was added to this
solution. Total volume of solvent was 2.5 mL. To prepare for polymerization, the glass
vial was purged with argon and stoppered. After that, the vial was subjected to four freezepump-thaw cycles, sealed completely and transferred to an oil bath preheated at 70 °C.
The polymerization was continued for 24 h and then quenched by cooling down with cold
water. The solvent was evaporated, the product was first precipitated in diethyl ether and
purified by extensive dialysis in water. Finally, the polymer was lyophilized, and dried
overnight under high vacuum. Yield: 92%, GPC (TFE), Mn: 28 kDa, Đ: 1.1. From 1H
NMR, the molar ratio of the repeating units was determined by integrating the methyl
protons of PEG monomeric units and methylene protons next to the sulfonate group in
sulfopropyl units (j:k ≈ 0.8:0.2). 1H NMR (400 MHz, D2O) (δ ppm): 4.20, 3.81, 3.72, 3.65,
3.65, 3.64, 3.63, 3.55, 3.41, 3.40, 2.95, 2.13, 1.95, 1.60, 1.28, 1.10, 0.93. 13C NMR (100
MHz, D2O) (δ ppm): 71.04, 69.79, 69.63, 69.48, 68.16, 58.10, 47.98, 45.05, 44.78, 23.60.

191

c
d

e
g

f

c’
d’

b

* D2O

b

a

a

b,e
g

f,d,d’

c,c’

Figure 5.8 1H NMR spectrum (400 MHz) of SO3-polymer in D2O.
5.4.4 Encapsulation of proteins and antibody with activated ester polymer, PAb

Scheme 5.3 Reaction scheme for covalent protein encapsulation aided by electrostatic
interactions
In a typical process, the self-immolative polymer, PAb, was dissolved in phosphate
buffer (100 mM, pH 8.5) to make 10 mg/mL solution. Protein stocks were also prepared
in phosphate buffer (100 mM, pH 8.5, [HRP] = 400 μg/mL, [β-gal] and [IgG]= 200
μg/mL). Finally, 25 μL of protein stock solution was added dropwise to a stirred 50 μL of
polymer solution. The reaction was continued for 12 h at room temperature. Next,
calculated amount of (PEO)4-bis-amine was added and stirred for another 12 h for
crosslinking. Finally, the reaction mixture was dialyzed to purify the nanoassemblies
encapsulated with proteins.
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5.4.5 Measurement of DLS and Zeta-potentials
Dynamic light scattering (DLS) and zeta potential measurements were performed
using a Malvern Nanozetasizer-ZS instrument. All nanoassemblies and protein samples
were diluted with PBS (pH 7.4) to adjust final concentration to 1 mg/mL.

(a)

(b)

Figure 5.9 ζ potential measurements for NA-HRP and NA-β-gal samples along with the
native proteins.

5.4.6 TEM measurements
Bright Field TEM images were captured on a JEOL JEM- 2000FX TEM operating
at 200kV acceleration voltage. 0.5 uL of prepared Polymer-protein assemblies were drop
casted on a carbon coated TEM grid and dried overnight at room temperature. The sample
was subjected to TEM analyses without any additional staining.
5.4.7 SDS-PAGE for polymer-protein conjugation and release studies
40 μL of protein-polymer conjugates were mixed with 10 μL of gel loading buffer
(DTT free) and incubated at 95 °C for 5 min. After that, 40 μL of each sample was loaded
into the acrylamide gel and electrophoresis was continued at constant voltage (130 V) for
45 min. To study the protein release, protein-polymer conjugate samples were treated with
10 mM GSH, incubated at 37 ºC for 4 h and subjected to acrylamide gel electrophoresis.
The amount of released protein from the nanoassembly was estimated via generating a
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standard curve from the known amounts of pure proteins loaded into the gel lanes. All gel
image analysis and quantification were performed with Bio-Rad Image LabTM software.

Figure 5.10 SDS-PAGE of control SO3-polymer showing inefficient protein (HRP)
conjugation.

5.4.8 Activity assays for HRP and β-gal
To measure the activity of released proteins from the nanoassembly, polymerprotein conjugates were treated with 10 mM glutathione (GSH) for 4 h.
HRP (ABTS assay):
The enzymatic activity of HRP and Cyt C can be studied by examining the
catalytic conversion of 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS).
Proteins with peroxidase activity (e.g., HRP, Cyt C) catalyze the reduction of H2O2 to
water in presence of ABTS forming oxidized ABTS radical cation which imparts a
brilliant blue-green color. The kinetics of the activity assay can be studied by monitoring
the absorbance of the ABTS radical cation at 418 nm. After releasing proteins from the
nanoassembly, samples were washed with PBS to remove traces of glutathione and other
byproducts that might interfere with the assay reagent. Test solution was prepared in a 96
well plate by mixing 2 μL of sample solution with 80 μL H2O2 (25 mM) and 100 μL ABTS
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(1 mg/mL). Absorbance spectra were recorded using a SpectraMax® iD5 multiplate
reader at 418 nm for a period of 6 min.
β-gal (ONPG assay)
The activity of released β-gal protein was measured via the β-Gal Assay Kit
reagent (Thermo Fisher Scientific). β-gal catalyzes the hydrolyses of ortho-nitrophenylβ-D-galactopyranoside (ONPG) substrate producing ONP anion with a bright yellow
color (absorbance 420 nm). Test solution was prepared in a 96 well plate by adding 2 μL
released protein sample solution, 98 μL PBS buffer and 40 μL ONPG assay reagent. The
assay kinetics was immediately recorded over 45 min using a SpectraMax® iD5
multiplate reader at 420 nm.
(b)

(a)

Figure 5.11 Kinetic plots for activity assay studies with NA-HRP and NA-β-gal samples
along with naked proteins and controls. Encap and Release: NA-Protein nanoassemblies
without and with GSH treatment, respectively.
β-gal (in HeLa cells)
To check the cellular activity of the β-gal trafficked inside the cytosol via the
nanoassemblies, an intracellular activity assay (x-gal assay) was performed. HeLa cells
were seeded (1×105 cells) in a 24 well tissue culture plate and incubated for 24 h at 37°C
and 5% CO2 atmosphere to ensure complete adhesion. Next, cells were washed three times
with PBS buffer and incubated with NA-β-gal nanoassemblies (protein concentration 10
μg/mL) at 37 °C for 6 h in complete media. Afterwards, media was removed, cells were
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washed with PBS three times and stained with the Senescence β-Galactosidase Staining
Kit (Cell Signaling) according to the manufacturer’s protocol. Cell were imaged with a
light microscope to capture the development of blue color which was indicative of β-gal
activity delivered inside cells.

Figure 5.12 X-gal cellular assay for untreated and treated HeLa cells with polymer, β-gal
and NA-β-gal showing nanoassembly mediated delivery of β-gal in cells in its active form.

5.4.9 Circular dichroism (CD) spectra measurements
Polymer-protein conjugates were incubated with 10 mM glutathione (GSH) for 6
h to release proteins from the nanoassembly. After that samples were centrifuged in
Amicon Ultra Centrifugal Filter (MWCO 50 kDa for HRP, MWCO 200 kDa for β-gal) to
remove residual polymers from the proteins. After that protein samples were concentrated
in Amicon filters with MWCO 10 kDa and protein concentrations were measured with
Pierce 660 nm Protein Assay Reagent (Thermo Fisher Scientific). Next, the protein
samples (200 μL) were transferred to a quartz cuvette (path length: 1 mm) and measured
the CD spectra with a JASCO J-1500 spectrophotometer (scan rate: 20 nm/min, interval:
0.2 nm).
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5.4.10 Cell culture-general information
All cell lines were cultured in 100 mm cell culture petri-dish with Dulbecco’s
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) in a humidified incubator
with 5% CO2 at 37 °C. DMEM/F12 media was supplemented with 10% fetal bovine serum
(FBS), 1% L-glutamine and 1% antibiotic-antimycotic (100 units/mL of penicillin, 100
μg/mL of streptomycin, and 0.25 μg/mL of Amphotericin B).
5.4.11 Cellular uptake of rhodamine tagged HRP and β-gal
HeLa and MDA-MB-231 cells were seeded at 1×105 cells/mL density (1 mL) in
35 mm glass-bottomed petri-dishes. Cells were cultured for 3 days at 37°C and 5% CO2
atmosphere to ensure complete adhesion. Next, cells were washed three times with PBS
buffer and incubated with NA-HRPRhod and NA-β-galRhod nanoassemblies (rhodamine
conjugated proteins, concentration 10 μg/mL) at 37 °C for 6 h in complete media.
Afterwards, media was removed, washed with PBS three times and incubated with
NucBlue™ Live ReadyProbes™ reagent (Thermo Fisher Scientific) in complete media
for 1 h to stain the cell nucleus. Live cell imaging was performed using Nikon Spectral
A1+ confocal microscope and images were analyzed with Nikon NIS-Elements 4.0
software.
5.4.12 Measurement of DLS and Zeta-potentials for polymer-IgG nanoassembly
(NA-IgG)
Dynamic light scattering (DLS) and zeta potential measurements were performed
using a Malvern Nanozetasizer-ZS instrument. All nanoassemblies and protein samples
were diluted with PBS (pH 7.4) to adjust final concentration to 1 mg/mL.
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5.4.13 TEM measurements of NA-IgG
Bright Field TEM images were captured on a JEOL JEM- 2000FX TEM operating at
200kV acceleration voltage. 0.5 uL of prepared Polymer-IgG assemblies were drop casted
on a carbon coated TEM grid and dried overnight at room temperature. The sample was
subjected to TEM analyses without any additional staining.
5.4.14 SDS-PAGE for IgG conjugation and release studies
40 μL of protein-polymer conjugates were mixed with 10 μL of gel loading buffer
(DTT free) and incubated at 95 °C for 5 min. After that, 40 μL of each sample was loaded
into the acrylamide gel and electrophoresis was continued at constant voltage (130 V) for
45 min. To study the protein release, protein-polymer conjugate samples were treated with
10 mM GSH, incubated at 37 ºC for 4 h and subjected to acrylamide gel electrophoresis.
The amount of released protein from the nanoassembly was estimated via generating a
standard curve from the known amounts of pure proteins loaded into the gel lanes. All gel
image analysis and quantification were performed with Bio-Rad Image LabTM software.
5.4.15 Cellular uptake studies for polymer-IgG nano assembly (NA-IgG)
HeLa, MDA-MB-231 and EMT6 cells were seeded at 1×105 cells/mL density (1
mL) in 35 mm glass-bottomed petri-dishes. Cells were cultured for 3 days at 37°C and 5%
CO2 incubator to ensure complete adhesion. Next, cells were washed three times with PBS
buffer and incubated with polymer-IgG nanoassemblies (rhodamine conjugated IgG,
concentration 10 μg/mL) at 37 °C for 6 h in complete media. Afterwards, media was
removed, washed with PBS three times and incubated with NucBlue™ Live
ReadyProbes™ reagent (Thermo Fisher Scientific) in complete media for 1 h to stain the

198

cell nucleus. Live cell imaging was performed using Nikon Spectral A1+ confocal
microscope and images were analyzed with Nikon NIS-Elements 4.0 software.
5.4.16 Endocytosis mechanism studies
HeLa, MDA-MB-231 and EMT6 cells were seeded at 1.2×105 cells/mL density (1
mL) in a 24 well tissue culture plate and incubated for 24 h at 37 °C. Afterwards, cells
were washed with PBS three times and pre-incubated with EIPA (100 μM, macropinocytosis pathway), Nystatin (30 μM, caveolin pathway) and hyper-osmolar sucrose (45
mM, clathrine pathway) in serum-free media for 1 h at 37°C. Next, media was removed
and cells were co-incubated for another 1 h in presence of polymer-IgG nanoassemblies
(with rhodamine conjugated IgG, concentration 10 μg/mL, in 1 mL serum-free media) and
different inhibitors (concentrations same as above). Untreated and polymer-rhodamineIgG treated cells without any inhibitor were used as negative and positive controls,
respectively. Afterwards, cells were harvested by washing with cold PBS followed by
trypsinization (0.25% trypsin-EDTA solution) for 5 min. Detached cells were collected in
Eppendorf tubes, pelleted by centrifugation, washed two times with cold PBS and finally
re-suspended in 400 μL cold PBS. Samples were immediately analyzed in a BD
LSRFortessa™ flow cytometer instrument. Data analyses were performed with FlowJo
software (version 10) to obtain fluorescence intensities of cell samples.
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(a)

(b)

Figure 5.13 Studies of cellular uptake mechanism (endocytosis) through flow cytometry
after NA-IgGRhod incubation in presence and absence of endocytic inhibitors (a) MDAMB-231 and (b) EMT6 cell lines.
5.4.17 Endosomal escape study
HeLa, MDA-MB-231 and EMT6 cells were seeded at 1×105 cells/mL density (1
mL) in 35 mm glass-bottomed petri-dishes. Cells were cultured for 3 days at 37°C and 5%
CO2 incubator to ensure complete adhesion. Next, cells were washed three times with PBS
buffer and incubated with polymer-IgG nanoassemblies (rhodamine conjugated IgG,
concentration 10 μg/mL) at 37 °C for 4 h in complete media. To study the endosomal
escape, one set of samples was subjected to endosomal staining with Lysotracker Green
(Thermo Fisher Scientific) for confocal microscopy. The other set was further incubated
in complete media for 24 h before subjecting to endosome staining and confocal
microscopy. Cell nucleus was stained with NucBlue™ Live ReadyProbes™ reagent
(Thermo Fisher Scientific) and live cell imaging was performed using Nikon Spectral A1+
confocal microscope. All images were analyzed with Nikon NIS-Elements 4.0 software.
5.4.18 Cell viability with alamarBlue® assay
HeLa, MDA-MB-231 and EMT6 cells were seeded in a 96 well tissue culture plate
(7500 cells/100 μL) and incubated for 24 h at 37 °C. After that, media was replaced, and

200

cells were treated with polymer-antibody conjugates and empty crosslinked polymers at
different concentrations. Samples were incubated for another 24 h at 37 °C. Next, media
was removed, cells were washed with PBS and were treated with 100 μL 10% alamarBlue
in complete media. The well plate was incubated for 1 h at 37 °C. Finally, the reagent was
transferred to a black 96 well flat-bottomed plate and subjected to fluorescence
measurement in a SpectraMax® iD5 microplate reader (excitation/emission: 560/590

NA-IgG nanoassembly

Polymer only

nm).

Figure 5.14 Cytotoxicity studies in HeLa, MDA-MB-231 and EMT6 cells after
incubation with only polymer and NA-IgG complexes, respectively.
5.4.19 Intracellular delivery of anti-NPC antibody
1×105 HeLa cells were plated in a 35 mm glass-bottom tissue culture plate and
incubated at 37 °C-5% CO2 atmosphere for 24 h. After that media was removed and cells
were transfected with polymer-antibody (Anti-NPC) conjugate (Anti-NPC concentration
20 μg/mL) and naked Anti-NPC antibody for 24 h in complete media. After that, media
was removed and cells were washed with PBS three times. 4% paraformaldehyde
(Biotium) was used to fix the cells (at room temperature, 10 min). After fixation, celles
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were washed again two times with PBS and permeabilized with permeabilization buffer
(1 mL, Biotium) for 10 min at room temperature. Next, cells were washed two times with
PBS and blocked with 2% BSA solution for 1 h. After washing once with PBS, cells were
incubated with secondary antibody (Anti-Mouse IgG H&L, Alexa Fluor® 647
conjugated, abcam) and nuclear stain (NucBlue™ Live ReadyProbes™ reagent, Thermo
Fisher Scientific) for 1 h at room temperature. Finally, cells were washed two times with
PBS and subjected to confocal laser scanning microscopy using Nikon Spectral A1+
confocal microscope. All images were analyzed with Nikon NIS-Elements 4.0 software.

Figure 5.15 (a) Additional images for NA-anti-NPC nanoassembly treated HeLa cells
showing staining of nuclear pore complex in red; and (b) Naked Anti-NPC antibody
treated HeLa cells showing no apparent nuclear pore complex staining. Scale bar: 10 μm.
5.4.20 Cellular viability after delivery of pAkt antibody
MCF-7 cells were seeded in a 96 well tissue culture plate (7500 cells/100 μL) and
incubated for 24 h at 37 °C. After that, media was replaced, and cells were treated with
polymer-pAkt antibody conjugates, empty crosslinked polymers, and pAkt antibody and
polymer-igG antibody conjugates at different concentrations. Further, cells were
incubated for 24 h at 37 °C. Afterwards, media was removed, cells were washed with PBS

202

and treated with 100 μL 10% alamarBlue in complete media. The well plate was incubated
for 1 h at 37 °C. Finally, the reagent was transferred to a black 96 well flat-bottomed plate
and subjected to fluorescence measurement in a SpectraMax® iD5 microplate reader
(excitation/emission: 560/590 nm).
5.4.21 Study of apoptosis with polymer-antibody nanoassembly
1×105 MCF-7 cells were plated in a 24 well tissue culture plate and incubated at
37 °C-5% CO2 atmosphere for 24 h. After that media was removed and cells were
transfected with polymer-antibody (pAkt) conjugate (pAkt concentration 10 μg/mL),
empty crosslinked polymer and naked pAkt antibody for 6 h in complete media. After that
media was replaced and cells were treated with CellEvent™ Caspase-3/7 Green Detection
Reagent (based on the manufacturer’s protocol) to identify apoptotic cells.

Figure 5.16 Detection of caspase 3/7 for untreated and only crosslinked polymer treated
MCF-7 cells. No green fluorescence was observed indicating absence of any apoptosis
pathway. Scale bar: 10 μm.

5.4.22 Western blot analysis for detection of PARP cleavage via activation of
apoptosis
2×105 MCF-7 cells were plated in a 6 well tissue culture plate and incubated at 37
°C-5% CO2 atmosphere for 24 h. After that media was removed and cells were transfected
with polymer-antibody (pAkt) conjugate (pAkt concentration 10 and 20 μg/mL), empty
203

crosslinked polymer and naked pAkt antibody for 24 h in complete media. Positive control
samples were transfected with staurosporine (at 1 and 2 μM concentrations) and incubated
for 24 h. After transfection, media was removed, and cells were washed with ice cold PBS
two times to prepare for isolation of total protein. Next, cells were scraped to remove from
the plate, transferred with cold PBS in an eppendorf tube and centrifuged to pelletize. Two
cold PBS washings were performed to remove any proteins from media. Next, RIPA lysis
buffer (Thermo Fisher Scientific) containing protease/phosphatase inhibitor mix (Cell
Signaling) was added to the centrifuge tubes containing cell pellets and incubated for 15
min at room temperature. To ensure complete lysis, tubes were sonicated (3×30 s) and
incubated at room temperature for another 15 min. Finally, lysed cells were centrifuged at
14000 rpm at 4 °C for 30 min and collected the soluble protein fraction from the
supernatant. The protein content was quantified with BCA assay. Western blot analysis
was performed to quantify the amount of PARP and its cleavage due to activation of
caspase enzymes. Target proteins and loading control were detected with rabbit
monoclonal antibodies (PARP & β-Actin mAbs, Cell Signaling). AP-linked anti-rabbit
IgG was used as secondary antibody and proteins bands were detected via chromogenic
technique with 1-Step™ NBT/BCIP substrate (Thermo Fisher Scientific).
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CHAPTER 6
SUMMARY AND FUTURE DIRECTIONS
6.1. Summary of the dissertation
Biologics are considered to be a safer therapeutic option that can not only minimize
toxicity and off-target effects of small molecule drugs, but those can also drug many
‘undruggable’ targets. However, due to hydrophilicity and fragile nature of the biologic
drugs, it is difficult to achieve efficient intracellular trafficking of those with retention of
structural properties and functional attributes. Acknowledging the challenges, this
dissertation discusses design strategies of stimuli-responsive polymeric delivery systems
for the encapsulation of biologics.
In chapter 1, we have discussed the opportunities of biologic drugs and challenges
associated with their intracellular delivery. Next, we describe specific hurdles associated
with three kinds of biomacromolecules, viz., protein, nucleic acid and antibody, and state
of the art techniques to address those. By highlighting the promises and pitfalls, we have
established the benefits of such existing methodologies as well as the need for new
molecular designs to address the drawbacks.
To this end, in chapter 2, we have introduced the design of a self-immolative
polymer, containing activated carbonate and disulfide linkages, for covalent conjugation
of proteins through their surface exposed lysines. The polymer-protein nanoassemblies are
not only able to encapsulate proteins, but those can also efficiently protect the sensitive
biomacromolecules from enzymatic degradation and release the cargoes only in presence
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of reducing environment. Further, cellular studies have revealed the efficient tracking of
proteins into the cytosol with retention of their biological activities.
As nucleic acids are highly negatively charged, a non-covalent self-assembly
strategy is employed in chapter 3 comprising protein, siRNA and zwitterionic lipids acting
symbiotically to form a stable self-assembled structure guided by electrostatic and
hydrophobic interactions. While a synthetic cationic polymer is designed to
electrostatically complex siRNA, we hypothesize to employ a crosslinking reaction in the
second step to neutralize the cationic charge without any loss of siRNA from the
nanoassembly. We have utilized these Lipid-siRNA-Polymer (L-siP) nanoassemblies to
deliver multiple siRNAs and have assessed their efficacies in silencing multiple target
genes.
In chapter 4, we have studied the structure-property relationship to improve the
efficacy of our previously designed polymer for protein delivery, as discussed in chapter
2. By studying a series of activated carbonate polymers for reactivity and protein
conjugation efficiency, we have identified a candidate that shows significantly higher
aminolysis with lysines of protein compared to undesired competitive hydrolysis. In
chapter 5, the down-selected activated carbonate containing polymer is structurally tuned
further to boost conjugation efficiency with larger proteins. By employing an electrostaticsaided covalent conjugation strategy, we have showed efficient encapsulation and redoxtriggered cytosolic delivery of proteins with retention of cellular activity. We have
extended the strategy for encapsulation of antibody drugs and have shown successful
cytosolic delivery to recognize the target epitopes that resulted in the perturbation of
cellular signaling pathways.
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6.2. Future directions
6.2.1. Self-immolative ‘pro-drug’ strategy for antibody-drug-polymer conjugates
The ultimate goal of drug delivery is to package and transport drug without leakage
and degradation en route to its target site. However, delivery of hydrophobic drug is
challenging due to the aqueous insolubility, short half-life and spill-off from the delivery
vehicles. A pro-drug concept, where the actual drug is generated in situ after getting
released from a covalently attached molecule or delivery vehicle, can be beneficial to
address these issues.
To this end, we hypothesize a covalent self-assembly strategy to encapsulate a
suitable hydrophobic drug within a crosslinked polymer network. The self-immolative
polymer platform that we have developed for encapsulation of protein and antibody could

Scheme 6.1 A pro-drug approach for encapsulation of hydrophobic drug having a
nucleophilic reactive handle for attachment with the polymer and its extension in antibody-drug conjugate strategy.
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be utilized to encapsulate and release the drug on demand with the help of redox stimulus
(Scheme 6.1). Furthermore, this polymeric nanoparticle can also be decorated with an
antibody for targeting purposes. The drug loading capacity can be desirably tuned with this
approach which, in turn, can address the current bottleneck of antibody-drug conjugates
(ADC) suffering from lower antibody drug ratio (ADR).

6.2.2. Tuning HLB of host-guest assemblies for enhancing encapsulation efficiency
Designing a universal molecular container that can encapsulate small molecule
actives with a wide range of logP values is one of the most challenging objectives with
significant academic and industrial importance. If achieved, it can create enormous
opportunities in formulation development across many technological sectors.

Scheme 6.2 Modulation of hydrophilic-lipophilic balance to generate stable nanoparticles
with high encapsulation efficacy of small molecules with a wide range of logP.
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Inspired by previous studies from our lab and ongoing research activities, we hypothesize
to create polymeric nanogel systems with tunable hydrophilic-lipophilic balance (HLB)
that will be able to predictively capture small molecule actives, e.g., therapeutic drugs,
actives for home and personal care (skin care products, detergents and beverages) and
agricultural crop protection (herbicide, fungicide and insecticide) formulations.
To this end, the homo, random and block copolymer based nanogel systems,
developed in our lab, can be further optimized. Based on our previous observations with
polymer nanogel based encapsulation approaches, we hypothesize that both
microenvironmental and bulk hydrophobicity of the nanogels affect the encapsulation of
molecules with varying logP. To test this, we can create polymer nanogels with systematic
variation of amphiphilicity by choosing appropriate crosslinker. For example, a
homopolymer nanogel system can be stabilized in aqueous media via crosslinking with an
oligoethylene glycol based crosslinker (see Scheme 6.2 for details). Thus, by choosing an
appropriate combination of polymer (homopolymer, random or block copolymer) and
crosslinker (with varying hydrophobicity, e.g., PEG, aromatic, alkyl dithiols) systems, it
might be possible to capture actives with a wide range of logP and stabilize in the
crosslinked nanogels. A fundamental study, such as this, might help to design custom-made
nanogels with high encapsulation efficacy.

6.2.3. AND-gated approach for nucleic acid delivery based on ‘L-siP’ strategy
Delivery of therapeutics to specific diseased cells requires the drug encapsulated
vehicle to cross several barriers before it is delivered to the actual place of action of the
therapeutic molecule. However, physiological conditions differ drastically across the
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gateways in the complex biological milieu. Thus, it is often difficult to design a unique
delivery strategy that can adapt the ongoing changes throughout the course of journey of
the drug delivery vehicle. This can be addressed via incorporating a stimuli-responsive unit
that can response to a specific environmental cue to release the encapsulated drug on target
site. However, due to differential physiological conditions in the delivery pathway, a better
strategy could be to engineer a delivery vehicle responsive towards dual stimuli where the
resulting response from each stimulus would synergize to facilitate the desired therapeutic
action.
Building on the symbiotic self-assembly strategy discussed in chapter 3, we
hypothesize the design of a 2nd generation ‘L-siP’ nanoassembly with built-in ‘AND’ gated

Scheme 6.3 Concept of 2nd generation ‘L-siP’ nanoassembly based on AND gate stimuliresponse units.
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stimuli-responsive units, wherein two stimuli incorporated in the polymer and lipid
structures will be sequentially processed to release the nucleic acid cargo. To this end, a
pH responsive unit can be incorporated in the lipid structure and a redox-responsive unit
will be present in the polymer backbone (Scheme 6.3). In the final tri-component selfassembled nanostructure, both pH and redox-stimuli-responsive units are needed to be
processed for an efficient cargo release. In addition, the initial electrostatic complexation
efficacy between the polymer and the nucleic acid can also be tested with different cationic
moieties incorporated in the polymer.
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